

## Harms and Benefits of Subcutaneous Hydration in Older Patients

### *Systematic Review and Meta-Analysis*

Danielsen, Mathias Brix; Andersen, Stig; Worthington, Elisa; Jorgensen, Martin Gronbech

*Published in:*

Journal of the American Geriatrics Society

*DOI (link to publication from Publisher):*

[10.1111/jgs.16707](https://doi.org/10.1111/jgs.16707)

*Publication date:*

2020

*Document Version*

Early version, also known as pre-print

[Link to publication from Aalborg University](#)

*Citation for published version (APA):*

Danielsen, M. B., Andersen, S., Worthington, E., & Jorgensen, M. G. (2020). Harms and Benefits of Subcutaneous Hydration in Older Patients: Systematic Review and Meta-Analysis. *Journal of the American Geriatrics Society*, 68(12), 2937-2946. <https://doi.org/10.1111/jgs.16707>

#### General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

#### Take down policy

If you believe that this document breaches copyright please contact us at [vbn@aub.aau.dk](mailto:vbn@aub.aau.dk) providing details, and we will remove access to the work immediately and investigate your claim.

# TITLE

## Harms and Benefits of Subcutaneous Hydration in Older Patients: Systematic Review and Meta-analysis

### Running title: Subcutaneous Hydration in Older Patients

Mathias Brix Danielsen<sup>a</sup>, MD; Stig Andersen, MD, PhD<sup>a,b</sup>; Elisa Worthington, MD<sup>c</sup>; Martin  
Gronbech Jorgensen, PhD<sup>a</sup>

<sup>a</sup>Department of Geriatric Medicine, Aalborg University Hospital, Aalborg, Denmark

<sup>b</sup>Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

<sup>c</sup>Department of Emergency Medicine, Aalborg University Hospital, Aalborg, Denmark

Corresponding author:

Mathias Brix Danielsen

Mail: Department of Geriatric Medicine, Aalborg University Hospital, Gl. Rød bygn. 6, 2.  
etage, Hobrovej 18-22, 9000 Aalborg, Denmark

E-mail: [maad@rn.dk](mailto:maad@rn.dk), Twitter handle: @MB\_Danielsen

### IMPACT STATEMENT

We certify that this work is novel and specifically adds a high-quality and thorough review of  
all available literature on the harms and benefits of subcutaneous hydration. Furthermore,  
this review adds valuable information relevant in the clinical care of older persons, and it  
could potentially insure the most fitting method for parenteral hydration is chosen.

Manuscript word count: 3445, 3 figures and 2 tables

## ABSTRACT

Abstract word count: 292

**Objective:** To systematically review all available original publications on the harms and effects of subcutaneous (SC) hydration in older patients.

**Data Sources:** MEDLINE, EMBASE, CINAHL, CENTRAL, Web of Science and trial registries were searched from inception to 5 November 2019 for any type of study on SC hydration without language restrictions.

**Study Selection:** Studies of any design were eligible if they used SC hydration in older patients.

**Data Extraction:** Two reviewers independently extracted the data and assessed the risk of bias of individual outcome.

**Data Synthesis:** Thirty-one publications from 29 studies met the eligibility criteria. Six randomized controlled trials provided data for the meta-analyses. The subgroup analysis including only studies with the lowest risk of bias showed fewer adverse effects associated with SC compared with intravenous (IV) (RR 0.69, 95% CI 0.53-0.88,  $p=0.003$ ,  $n=4$ ,  $I^2=0.0\%$ , 545 infusions in each group). In absolute numbers, high-quality studies showed an incidence rate of 90 adverse effects per 1000 infusions with SC hydration and 130 (95% CI 102-169) adverse effects per 1000 infusions with IV hydration. The confidence in this estimate is moderate. Secondary outcomes showed that SC hydration is less efficient compared to IV as estimated by the surrogate markers of reductions in s-osmolality and volume of fluid infused; however, markedly reduces the risk of agitation (RR 0.42, 95% CI 0.22-0.79,  $p=0.007$ ,  $I^2=65\%$ ,  $n=3$ ), and is 3.2 minutes faster to setup. Nonetheless, the quality of evidence of all secondary outcomes is low or very low.

**Conclusions:** SC hydration is safer than IV and potentially reduces the risk of agitation, but is less effective. SC hydration should be available as an alternative to IV when older patients are treated for mild to moderate dehydration. More studies are needed to increase the confidence in the estimates.

**Primary funding source:** Department of Clinical Medicine, Aalborg University and Department of Geriatric Medicine, Aalborg University Hospital. (PROSPERO: [CRD42017071912](https://doi.org/10.1111/jgs.16707))

**Key Words:** Hypodermoclysis, Older patients, Hydration treatment, systematic review, meta-analysis

## INTRODUCTION

Dehydration is a common and potentially dangerous condition in older patients.<sup>1</sup> A hallmark of aging is a reduced sensation of thirst. The consequences are augmented by the reduced ability of the aging kidneys to concentrate urine.<sup>2</sup> The infusion of fluid is required when oral rehydration is insufficient. Intravenous (IV) hydration is the common choice because large volumes can be infused and intravenous medication can be simultaneously administered. However, an alternative choice is subcutaneous (SC) hydration, in which fluid is infused into the subcutaneous space and absorbed into the bloodstream.<sup>3</sup> This often forgotten method has been reported in recent decades as an easy and safe method for parenteral hydration of geriatric patients with mild to moderate dehydration.<sup>4-6</sup> Despite these studies, SC is still reported to be underused.<sup>7-9</sup>

Fluid infused subcutaneously reaches the circulation within an hour, according to the results of a radioisotope study<sup>3</sup>. Hence, the hydration effect should be similar between SC- and IV-infused fluid, although a small delay may occur with SC infusion. A clinically relevant difference between IV and SC hydration might be in the risk of adverse effects. Furthermore, from our clinical experience, it seems that the risk of adverse effects is the main reason for the limited use of SC hydration.

Previous reviews on SC hydration in older patients had important methodological shortcomings. They did not include a transparent and comprehensive systematic search of the literature, *a priori* registration or adequate evaluation of risk of bias.<sup>4-6</sup> These limitations led us to conduct a systematic review and meta-analysis following the PRISMA guidelines.<sup>10</sup> The primary aim was to compare the risk of adverse effects using SC vs IV hydration in older

patients and to estimate the incidence and profile of adverse effects. Additional aims were to compare the clinical effect of SC hydration vs IV. Thus, the overall aim was to assess if SC hydration is a safe and clinically relevant alternative to IV hydration.

## METHODS

We followed the recommendations of the Preferred Reporting Items for Systematic reviews and Meta-Analyses when reporting harms (PRISMA-Harms)<sup>10</sup> and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) to rate the quality of evidence and present the results.<sup>11</sup> The study was *a priori* registered in PROSPERO ([CRD42017071912](https://doi.org/10.1111/jgs.16707))

### Eligibility criteria

To achieve a comprehensive overview and following the recommendations of the Cochrane Handbook<sup>12</sup> on reviews of adverse effects, we included relevant studies of all designs (randomized controlled trials (RCTs), observational studies and case reports) and types (e.g., conference abstracts, letters to the editor). We attempted to contact authors for additional information or full-text publications in cases of short reports, such as conference abstracts. No restriction on language, publication date or settings was imposed, but restricted inclusion to studies on older patients (age >65 years or mean age >60 years). Furthermore, studies had to include SC hydration as an intervention with hydration as an indication for infusion. We included studies with IV hydration as a comparator or no comparator in observational studies. Studies on the SC infusion of drugs, parenteral nutrition, the relevance of hyaluronidase or those without patient information were excluded. Cross-sectional studies and case reports

without any information on adverse effects were excluded, as the reason for including these type of studies was to estimate the incidence and profile of adverse effects.

## Information sources and search

The search strategy was developed in collaboration with a health sciences librarian. We systematically searched the following databases: MEDLINE, EMBASE, CINAHL, Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science. In addition, we searched ClinicalTrials.gov and [www.who.int/ictrp](http://www.who.int/ictrp) for unpublished studies and ongoing trials. Furthermore, we cross-referenced both included studies and relevant reviews for eligible studies. All databases were searched from inception to the date of the final search, 5 November 2019. Authors of unpublished and ongoing trials were asked if data were available to be included in this review. The full search string for the included databases can be found in Supplementary Text S1.

## Study selection

Two reviewers (MBD and SA) independently assessed eligibility, initially by title and abstract and subsequently by full text. We settled disagreements by consensus or by involving a coauthor (MGJ).

## Data items and collection process

We first translated all non-English publications using a translate engine<sup>13</sup>, and when insufficient a translator provided a written translation. Two reviewers (MDB and SA) independently extracted the data using piloted forms. The following data were extracted: study and patient characteristics, type of fluid infused, the use of hyaluronidase and the duration of treatment. In all studies with missing data, we attempted to contact authors by

e-mail to obtain this pertinent information. To estimate exposure, we extracted the total number of infusions. If not reported, we calculated it by multiplying the number of participants by the mean number of days of infusion.

An adverse effect, in general, is defined as “an unfavorable outcome that occurs during or after the use of a drug or other intervention and for which the causal relation between the intervention and the event is at least a reasonable possibility”.<sup>12</sup> Additionally, we divided adverse effects into serious and minor and adhered to the WHO definition of serious adverse effects as any consequence of infusion requiring treatment.<sup>14</sup> All outcome data is extracted as intention to treat.

#### Risk of bias in individual studies

We used the Cochrane Risk of Bias 2.0 (RoB 2.0) to assess the risk of bias in RCTs<sup>15</sup>; furthermore, we assessed the risk of bias in observational studies based on the key criteria listed by GRADE<sup>16</sup>. Two reviewers (MD & SA) independently assessed the risk of bias at the outcome-level.

#### Data synthesis and analysis

To assess whether the RCTs were sufficiently homogeneous and could be combined in a meta-analysis, we compared the studies with respect to the participants, interventions and outcomes measures. We did not combine RCTs and observational studies in the meta-analyses. For the meta-analysis, we applied an inverse variance random-effects model (DerSimonian-Laird<sup>17</sup>). Statistical heterogeneity was explored using the  $I^2$  statistic. We report dichotomous outcomes in risk ratio (RR) and continuous outcomes in mean difference (MD).



When the same outcome was reported using different scales, we used the standardized mean difference (SMD). Stata version 15 (StataCorp LLC TX College Station. 2017) and ADMETAN<sup>18</sup> was used to perform the analyses. Comparisons were 2-tailed with a statistical significance indicated at 5%, and with 95% confidence intervals. The data analysis only included studies reporting both the number of adverse effects and the number of infusions. As hydration treatment can last several days, a single patient can experience multiple adverse effects. Thus, we analyzed the outcome of adverse effects by the number of infusions.

As recommended by Cochrane RoB 2 meta-analyses were stratified by the overall risk of bias.<sup>15</sup> Prespecified subgroup analyses of the primary outcome with regard to the addition of hyaluronidase and the setting of the studies was also conducted. Furthermore, we performed a separate meta-analysis on major and minor adverse effects as an explanatory analysis.

To estimate the incidence of adverse effects associated with SC hydration we combined data from all included studies by adding the number of reported adverse effects and the number of infusions from all studies and calculated an overall incidence rate. In addition, we estimated the incidence by combining data from studies at the lowest risk of bias only. We used this incidence and the RR from our lowest risk of bias subgroup to calculate the absolute risk difference according to the GRADE guidelines<sup>19</sup>.

#### Additional analyses

As dehydration cannot be defined by a single symptom, sign or laboratory value<sup>2,20</sup> we conducted meta-analyses of all available surrogate markers of dehydration and clinical effect of hydration treatment if they were reported by at least two RCTs. Furthermore, we compared time spent on catheter insertion.

## RESULTS

### Study selection

A total of 5064 references were screened by title and abstract, of which 242 qualified for full-text screening (figure 1. PRISMA flow chart<sup>21</sup>). Most publications excluded during full-text screening were reviews or descriptions of subcutaneous hydration. In addition, 9 publications were cross-sectional studies and 4 were case reports with no information on adverse effects. Furthermore, we found two relevant study protocols, of which one had no data yet<sup>22</sup> and the author of the other e-mailed us a poster but had no full-text report. The poster had insufficient data to be included in the meta-analysis<sup>23</sup>. The individual reasons for exclusion of publications read in full-text form can be found in Supplementary Text S2.

### Study characteristics

Thirty-one publications representing 29 different studies met our eligibility criteria. The designs of the included publications were: 7 RCTs<sup>24–30</sup>, 1 case-control study<sup>31</sup>, 11 prospective cross-sectional studies<sup>32,33,42,34–41</sup>, 6 retrospective cross-sectional studies<sup>43–50</sup> and 4 case reports<sup>51–54</sup>. Fourteen studies were performed in a hospital setting, 6 in short-/long-term care facilities and nine included a combination of hospital and short-/long-term care or home-based treatment, while 1 did not report the setting. The median age in the included studies was 82 years (range 61-85). The median number of patients included was 57 (range 8-634), and the median number of SC infusions was 252 (range 17-4500), excluding case reports. Nine studies reported sources of funding, and none were industry-sponsored. Of the 23 authors contacted for additional information, 7 responded and most provided only a partial response.

185 Information on which studies replied and what information was delivered is available in  
186 Supplementary Text S3.

187 Table 1 provides a summary of the study characteristics of included RCTs and Supplementary  
188 Table S1. provides a summary of the outcomes available for extraction. Extracted study  
189 characteristics for all included studies can be found in Supplementary Text S3. One RCT, four  
190 prospective studies and one retrospective cross-sectional study did not report data  
191 sufficiently to allow an estimate of the number of infusions or they did not report the number  
192 of adverse effects. We attempted to contact the authors to obtain these data, but none  
193 responded. Hence, these studies were not included in the data synthesis.

194

#### 195 [Risk of bias within studies](#)

196 For the outcome of adverse effects, four out of six RCTs had an Overall RoB 2 of *Some*  
197 *Concern*<sup>24,28–30</sup> and the remaining two had a *High risk of bias*<sup>25,26</sup>. Across all outcomes, no  
198 studies reported an *a priori* protocol or statistical analysis plan. In addition, description and  
199 measuring of outcomes were often lacking. The RoB 2 of individual RCTs on all outcomes with  
200 response to signaling questions can be found in Supplementary Text S4. A table of risk of bias  
201 in the observational studies can be found in Supplementary Table S2.

## Synthesis of results

### Adverse effects

Combining data from the six RCTs<sup>24–26,28–30</sup> in a meta-analysis, the studies with the lowest overall risk of bias (*Some concern*) showed a statistically significant 31% lower risk of adverse effects with SC hydration compared with IV (RR 0.69, 95% CI 0.53 to 0.88, test for effect  $p=0.003$ ,  $I^2=0.0\%$   $n=4$ , Figure 2 and Table 2). One RCT did not report the number of adverse effects observed and was therefore omitted from the meta-analysis; however, the authors did report no difference in observed complications.<sup>27</sup> A subgroup meta-analysis on the setting and use of hyaluronidase can be found in Supplementary Figures S1 and S2.

To estimate the incidence rate of adverse effects, we combined all included studies with suitable data (five RCTs and fourteen observational studies)<sup>24,25,37,39,40,42,44–49,26,50,28–31,33–35</sup>. The data showed an incidence rate of 53 adverse effects per 1000 infusions (95% CI 48 to 57,  $n=19$ , 10,970 infusions) for SC hydration. Combining only studies with the lowest risk of bias (four RCTs and four observational studies)<sup>24,28–31,33,37,39</sup> an incidence rate of 90 adverse effects per 1000 SC infusions (95% CI 80 to 101,  $n=8$ , 2876 infusions) was found. In absolute numbers, patients experienced 130 adverse effects with IV hydration per 1000 infusions (95% CI 102 to 169, table 2). This absolute number is based on a calculation mentioned in the methods section under data synthesis and analysis.

Serious adverse effects of SC from all studies and the lowest risk of bias studies showed incidence rates of 2.2 adverse effects (95% CI 1.3 to 3.1,  $n=19$ , 10,970 infusions) and 3.7 adverse effects per 1000 SC infusions (95% CI 1.5 to 5.9,  $n=8$ , 2876 infusions), respectively. Incidences of the different minor adverse effects (the lowest risk of bias studies only) can be

seen in Figure 3. Furthermore, meta-analyses on serious adverse effects and the different types of adverse effects can be found in Supplementary Figures S3 and S4 respectively.

The included case reports describe 1 case with caecal perforation from SC hydration in a lean 86-year-old female<sup>51</sup> and 1 case with erythema progressing to necrosis from SC hydration<sup>52</sup>. The remaining case reports describe common adverse effects reported in other publications.

### **Clinical effects of the hydration treatment**

The included studies used an array of surrogate markers of dehydration in an attempt to evaluate how well the SC and IV hydration treated the problem. However, most of these markers were reported in a non-uniform manner making them unfit to include in a meta-analysis. Only s-osmolality was reported sufficient homogeneously to be combined in a meta-analysis, and this analysis showed IV hydration lowering serum osmolality statistical significantly more than SC hydration (MD 5.75 mmol/kg in favor of IV, 95% CI 0.13 to 11.4,  $p=0.045$ ,  $I^2=0.0\%$ ,  $n=2$ , Table 2 and Supplementary Figure S5)<sup>24,30</sup>. The other surrogate markers of dehydration examined by different studies were creatinine levels<sup>28–30</sup>, urea levels<sup>28,30</sup>, patient discomfort<sup>29</sup> and Barthel Score<sup>29</sup>. Worth noting is that none of the studies reported a statistically significant difference between the two groups in any of the variables.

We examined the effects of the hydration treatment by the surrogate markers of death, the volume of fluid infused and agitation as these variables were reported by more than one study. Three studies reported deaths<sup>24,28,30</sup> and three did not<sup>26,29,55</sup>. No difference between SC and IV was found (RR 1.26 in favor of IV, 95% CI 0.25 to 6.34,  $p=0.78$ ,  $I^2=0.0\%$ ,  $n=3$ , Table 2 and Supplementary Figure S6)<sup>24,28,30</sup>. Three studies reported volume of fluid infused<sup>28–30</sup> and

the meta-analysis showed a statically significant difference in favor of IV hydration between the groups (SMD 0.62, 95% CI 0.24 to 1.01,  $p=0.0027$ ,  $I^2=50\%$ ,  $n=3$ , Table 2 and Supplementary Figure S7)<sup>28-30</sup>. Three studies reported agitation as an outcome<sup>26,28,30</sup>. There was a statistically significant difference in favor of SC hydration in the risk of agitation between the groups (RR 0.42 in favor of SC, 95% CI 0.24 to 0.78,  $p=0.007$ ,  $I^2=65\%$ ,  $n=3$ , Table 2 and Supplementary Figure S8)<sup>26,28,30</sup>. It should be noted, however, that the included studies in this analysis all included patients with cognitive impairment.

Data from 2 studies<sup>26,29</sup> showed a statistically significant difference in catheters insertion time between SC and IV (mean difference 3.2 minutes faster to insert SC, 95% CI 1.5 min. faster to 4.9 min. faster,  $p<0.001$ ,  $I^2=46.2\%$ ,  $n=2$ , Table 2 and Supplementary Figure S9)<sup>26,29</sup>. The reported mean time spent on IV catheter insertion was 5.2 minutes<sup>26,29</sup>.

#### Risk of bias across studies

Evaluating the risk of publication bias, we identified one unpublished RCT comparing IV with SC. A poster from this study describes fewer complications with SC hydration than with IV. Based on a funnel plot, there is no suspicion of publication bias, but cautious interpretation is important with only 6 studies (Supplementary Figure S10).

We found no overall risk of selective reporting bias on adverse effects, as we found no RCT on SC hydration vs IV without this outcome. However, there is a potential risk of altering the definition of adverse effects following data collection, as none of the included studies had an a priori registration. This also accounts for markers of hydration status.

## DISCUSSION

### Summary of evidence

Most older patients require fluid therapy due to an increased risk of dehydration.<sup>56</sup> Hydration treatment is a cornerstone in the treatment of older patients, but gaining IV access can be time-consuming in multimorbid patients.<sup>57</sup> Subcutaneous hydration is an alternative method and the data presented in this study show that SC hydration is a safer alternative than IV hydration. In absolute numbers, based on data from the studies with the lowest risk of bias, patients receiving SC hydration experienced 90 adverse effects per 1000 infusions vs. IV hydration with 130 adverse effects per 1000 infusions. The level of heterogeneity was very low, which increases the confidence in the estimate. However, none of the studies had a low risk of bias and in the four studies that contributed to the estimate all had an overall RoB2 of *Some Concern*.<sup>24–26,28,30</sup> This contributes to a reduction in the credibility of the estimate, and our overall confidence in the estimate is moderate (Table 2). Therefore, the results provide a good indication of the likely estimate.

Both IV and SC infusions are associated with a low incidence rate (~ 10%) of adverse effects. The majority of these are minor adverse effects causing mild discomfort to the patient and requiring reinsertion of the needle. Only 1 in 270 infusions for both IV and SC will lead to a major adverse effect that will increase the duration of hospital stay or require additional treatment. However, care should be taken when the SC needle is inserted into the abdomen, as there is a risk of perforation of the large intestines when treating very thin or cachectic patients. Furthermore, the main component helping absorb fluid from subcutaneous space

into the blood is albumin.<sup>58</sup> Theoretically, patients with a low level of albumin could have difficulties absorbing SC hydration, and caution is advised despite the lack of evidence.

The main drawback of SC hydration is the restriction on the volume of fluid that can be infused. Guidelines describe a maximum of 1.5 L of fluid per needle per day.<sup>2,6</sup> The listed indication for SC hydration is treatment of mild to moderate dehydration or fluid supplementation in patients with reduced oral intake at risk of dehydration.<sup>2</sup> These indications are supported by our finding of a lower volume of fluid infused with SC compared to the IV route and the reduced lowering of serum osmolarity. Overall, the quality of evidence regarding the effect of hydration treatment comparing the two methods is very low, making it very likely that the true effect is substantially different (Table 2). There were very few deaths reported and the meta-analysis failed to provide any meaningful estimate due to a very large confidence interval. Finally, the 58% lower risk of agitation with SC hydration is potentially very interesting as this condition is associated with increased morbidity and mortality.<sup>59</sup>

However, the studies included in this meta-analysis all had some concern of risk of bias and the outcome was reported as agitation and not delirium. The confidence in this estimate is low, and the likelihood that the true estimate will be substantially different is high (Table 2). Giving the importance of this outcome further research is much needed to investigate this.

With a mean time spent on IV catheter insertion of 5.2 minutes, the 3.2 fewer minutes required to insert the SC catheter may be relevant to the limited staff resources in modern healthcare. Nevertheless, this result should be interpreted with caution because most data were obtained from a single study with a high risk of bias combined with a high level of



statistical heterogeneity. The confidence in this estimate is very low, and the likelihood that the true estimate will be substantially different is high (Table 2).

The strengths of the current review include (1) a comprehensive search; (2) inclusions of all study designs and reports regardless of publication languages; (3) high methodological quality; and (4) all outcomes reported in absolute numbers to support clinical interpretation.

## Limitations

### Review level

Our description of the statistical method for the analysis of secondary outcomes in the preregistered protocols was insufficient, and the results should, therefore, be interpreted with caution.

### Outcome level

A major limitation of the results in this review is the limited number of RCTs. Furthermore, most of our analyses were conducted with data from studies with at least Some Concern of bias. The incidence of adverse effects would likely be higher than what is reported if all studies adhered to the full list of events. Finally, we were only able to retrieve additional data from a few of the studies.

In conclusion, there is acceptable evidence that SC hydration is a safer alternative method of parenteral hydration compared to IV. The recommendations that only mild to moderately dehydrated patients should be treated with SC hydration is reasonable based on the results on the effectiveness presented here; however, the quality of the evidence is very low. Finally, the reduced risk of agitation found in patients with cognitive impairment when treated with

330 SC hydration is intriguing. Overall, more high quality studies are needed to establish the true  
331 benefits and harms of SC hydration.

## Acknowledgment

The authors would like to thank authors of included studies who responded to the contact for additional information.

**Conflict of Interest Disclosure:** No authors have any conflicts of interest.

**Authors' Contributions:** *Concept and design:* Danielsen, Andersen, Jorgensen

*Acquisition, analysis, or interpretation of data:* Danielsen, Andersen, Worthington, Jorgensen

*Drafting of the manuscript:* Danielsen, Andersen, Jorgensen

*Critical revision of the manuscript for important intellectual content:* Danielsen, Andersen, Worthington, Jorgensen

**Funding/Support:** This review was funded by the Department of Clinical Medicine, Aalborg University and Department of Geriatric Medicine, Aalborg University Hospital.

**Role of the Funder/Sponsor:** None

**Additional Contributions:** We thank Laura Marie Aalkjær Danielsen for help translating from French, MLISc Pernille Skou Gaardsted, Medical library, Aalborg University Hospital for help developing the search strategy, and Msc Niels Henrik Bruun, Unit of Clinical Biostatistics, Aalborg University Hospital for statistical support. All who contributed significantly to this work have been mentioned.

350 **Reproducible Research Statement:** Study protocol Available at PROSPERO: [CRD42017071912](https://doi.org/10.1111/jgs.16707).

351 Statistical code and data set: Available from M. Danielsen MD, Department of Geriatric

352 Medicine, Aalborg University Hospital, Denmark Email: Maad@rn.dk

353

## 354 References

- 355 1. El-Sharkawy AM, Watson P, Neal KR, et al. Hydration and outcome in older patients  
356 admitted to hospital (The HOOP prospective cohort study). *Age Ageing*.  
357 2015;44(6):943-947. doi:10.1093/ageing/afv119
- 358 2. Thomas DR, Cote TR, Lawhorne L, et al. Understanding Clinical Dehydration and Its  
359 Treatment. *J Am Med Dir Assoc*. 2008;9(5):292-301. doi:10.1016/j.jamda.2008.03.006
- 360 3. Lipschitz S, Campbell AJ, Roberts MS, et al. Subcutaneous fluid administration in  
361 elderly subjects: validation of an under-used technique. *J Am Geriatr Soc*.  
362 1991;39(1):6-9.
- 363 4. Turner T, Cassano A-M. Subcutaneous dextrose for rehydration of elderly patients--an  
364 evidence-based review. *BMC Geriatr*. 2004;4:2. doi:10.1186/1471-2318-4-2
- 365 5. Remington R, Hultman T. Hypodermoclysis to treat dehydration: A review of the  
366 evidence. *J Am Geriatr Soc*. 2007;55(12):2051-2055. doi:10.1111/j.1532-  
367 5415.2007.01437.x
- 368 6. Caccialanza R, Constans T, Cotogni P, Zaloga GP, Pontes-Arruda A. Subcutaneous  
369 Infusion of Fluids for Hydration or Nutrition: A Review. *J Parenter Enter Nutr*.  
370 2018;42(2):296-307. doi:10.1177/0148607116676593
- 371 7. Lowe E, Gillon S. ARE SUBCUTANEOUS FLUIDS UNDERUSED IN THE HOSPICE SETTING?

- 372 *BMJ Support Palliat Care*. 2014;4(Suppl 1):A101.3-A102. doi:10.1136/bmjspcare-  
373 2014-000654.292
- 374 8. Yurkofsky M, Ouslander JG. Medical care in skilled nursing facilities (SNFs) in the  
375 United States. <https://www.uptodate.com>. Published 2019. Accessed May 9, 2019.
- 376 9. Barua P, Bhowmick BK. Hypodermoclysis - A victim of historical prejudice. *Age*  
377 *Ageing*. 2005;34(3):215-217. doi:10.1093/ageing/afi077
- 378 10. Zorzela L, Loke YK, Ioannidis JP, et al. PRISMA harms checklist: Improving harms  
379 reporting in systematic reviews. *BMJ*. 2016;352:i157. doi:10.1136/bmj.i157
- 380 11. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction—GRADE  
381 evidence profiles and summary of findings tables. *J Clin Epidemiol*. 2011;64(4):383-  
382 394. doi:10.1016/J.JCLINEPI.2010.04.026
- 383 12. Higgins J, Green S, (editors), eds. *Cochrane Handbook for Systematic Reviews of*  
384 *Interventions*. Version 5. The Cochrane Collaboration, 2011. Available from  
385 [www.handbook.cochrane.org](http://www.handbook.cochrane.org).
- 386 13. Google Translate. <https://translate.google.com/> Accessed May, 2019.
- 387 14. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and  
388 management. *Lancet (London, England)*. 2000;356(9237):1255-1259.  
389 doi:10.1016/S0140-6736(00)02799-9
- 390 15. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in  
391 randomised trials. *BMJ*. 2019;366:l4898. doi:10.1136/bmj.l4898
- 392 16. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of  
393 evidence—study limitations (risk of bias). *J Clin Epidemiol*. 2011;64(4):407-415.  
394 doi:10.1016/J.JCLINEPI.2010.07.017

- 395 17. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*.  
396 1986;7(3):177-188. doi:10.1016/0197-2456(86)90046-2
- 397 18. Fisher D. ADMETAN: Stata module to provide comprehensive meta-analysis.  
398 2018;(S458561). doi:DOI:
- 399 19. Guyatt GH, Oxman AD, Santesso N, et al. GRADE guidelines: 12. Preparing Summary  
400 of Findings tables—binary outcomes. *J Clin Epidemiol*. 2013;66(2):158-172.  
401 doi:10.1016/J.JCLINEPI.2012.01.012
- 402 20. El-Sharkawy AM, Sahota O, Maughan RJ, Lobo DN. The pathophysiology of fluid and  
403 electrolyte balance in the older adult surgical patient. *Clin Nutr*. 2014;33(1):6-13.  
404 doi:10.1016/j.clnu.2013.11.010
- 405 21. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred Reporting Items  
406 for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *Ann Intern Med*.  
407 2009;151(4):264. doi:10.7326/0003-4819-151-4-200908180-00135
- 408 22. NCT03710408. Adverse Effects of Subcutaneous vs Intravenous Hydration on Older  
409 Acutely Admitted Patients: an Assessor-blinded, Non-inferiority RCT.  
410 <https://clinicaltrials.gov/show/nct03710408>. doi:10.1002/CENTRAL/CN-01664216
- 411 23. TCTR20140506002. Satisfaction in Hypodermoclysis and Intravenous Hydration in  
412 Palliative Care Patients.  
413 <http://apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20140506002>.  
414 doi:10.1002/CENTRAL/CN-01825225
- 415 24. Challiner YC, Jarrett D, Hayward MJ, Al-Jubouri MA, Julious SA. A comparison of  
416 intravenous and subcutaneous hydration in elderly acute stroke patients. *Postgrad*  
417 *Med J*. 1994;70(821):195-197. doi:10.1136/pgmj.70.821.195

- 418 25. Delamaire D, Meigne B, Lecoq A, Cattenoz C, Michel M, Michel O. Un essai contrôlé  
419 d'hydratation en faveur d'une actualisation de l'hypodermoclyse chez le sujet âgé. *La*  
420 *Rev Médecine Interne*. 1992;13(7):S321. doi:10.1016/S0248-8663%2805%2980908-7
- 421 26. Esmeray G, Şenturan L, Döventaş A. A Study on Efficacy of Hydration Administered by  
422 Subcutaneous Infusion in Geriatric Patients. *Turkish J Geriatr Geriatr Derg*.  
423 2018;21(3):438-445. doi:10.31086/tjgeri.2018344059
- 424 27. Luk J, Chan F, Chu L. Is hypodermoclysis suitable for frail Chinese elderly. *Asian J*  
425 *Gerontol Geriatr*. 2008;3(1):49-50.
- 426 28. O'Keeffe ST, Lavan JN. Subcutaneous fluids in elderly hospital patients with cognitive  
427 impairment. *Gerontology*. 1996;42(1):36-39.  
428 <http://www.ncbi.nlm.nih.gov/pubmed/8641599>. Accessed April 26, 2016.
- 429 29. Slesak G, Schnürle JW, Kinzel E, Jakob J, Dietz K. Comparison of subcutaneous and  
430 intravenous rehydration in geriatric patients: A randomized trial. *J Am Geriatr Soc*.  
431 2003;51(2):155-160. doi:10.1046/j.1532-5415.2003.51052.x
- 432 30. Noriega OD, Blasco SA. Eficacia de la vía subcutánea frente a la hidratación  
433 intravenosa en el paciente anciano hospitalizado: estudio controlado aleatorizado.  
434 *Rev Esp Geriatr Gerontol*. 2014;49(3):103-107. doi:10.1016/j.regg.2013.12.003
- 435 31. Dasgupta M, Binns MA, Rochon PA. Subcutaneous fluid infusion in a long-term care  
436 setting. *J Am Geriatr Soc*. 2000;48(7):795-799.
- 437 32. Bigot A, Boccanfuso L, Rouch L, Lebaudy C, Gérard S, Cestac P. Investigation into the  
438 usage of hypodermoclysis in the geriatric units. *Int J Clin Pharm*. 2013;35(6):1298.
- 439 33. Arinzon Z, Feldman J, Fidelman Z, Gepstein R, Berner YN. Hypodermoclysis  
440 (subcutaneous infusion) effective mode of treatment of dehydration in long-term

- care patients. *Arch Gerontol Geriatr*. 2004;38(2):167-173.  
doi:10.1016/j.archger.2003.09.003
34. Centeno C, Bruera E. Subcutaneous hydration with no hyaluronidase in patients with advanced cancer. *J Pain Symptom Manag*. 1999;17(5):305-306.
35. Fainsinger RL, MacEachern T, Miller MJ, et al. The use of hypodermoclysis for rehydration in terminally ill cancer patients. *J Pain Symptom Manage*. 1994;9(5):298-302.
36. Justino ET, Tuoto FS, Kalinke LP, Mantovani M de F. HYPODERMOCLYSIS IN ONCOLOGY PATIENTS RECEIVING PALLIATIVE CARE. *Cogitare Enferm*. 2013;18(1):84-89.
37. Lamande M, Dardaine-Giraud V, Ripault H, Chavanne D, Constans T. Utilisation de l'hypodermoclyse en gériatrie : Étude prospective sur 6 mois. *L'Année gérontologique*. 2004;18(1):121-130.
38. Martínez-Riquelme A, Rawlings J, Morley S, Kendall J, Hosking D, Allison S. Self-administered subcutaneous fluid infusion at home in the management of fluid depletion and hypomagnesaemia in gastro-intestinal disease. *Clin Nutr*. 2005;24(1):158-163. doi:10.1016/J.CLNU.2004.09.016
39. Torsheim AK, Falkmer U, Kaasa S. [Hydration of patients with advanced cancer--is subcutaneous infusion a good solution?]. *Tidsskr den Nor lægeforening*. 1999;119(19):2815-2817.
40. Vidal M, Hui D, Williams J, Bruera E. A Prospective Study of Hypodermoclysis Performed by Caregivers in the Home Setting. *J Pain Symptom Manage*. 2016;52(4):570-574.e9. doi:10.1016/j.jpainsymman.2016.04.009



- 464 41. Worobec G, Brown MK. Hypodermoclysis therapy. In a chronic care hospital setting. *J*  
465 *Gerontol Nurs*. 1997;23(6):23-28.
- 466 42. ŠŤASTNÁ V, SOUKUPOVÁ K, KUČEROVÁ H. NAŠE ZKUŠENOSTI SE SUBKUTÁNNÍ  
467 REHYDRATACÍ. *Ces Geriatr Rev*. 2009;7(1):46-48.
- 468 43. Bruera E, Belzile M, Watanabe S, Fainsinger RL. Volume of hydration in terminal  
469 cancer patients. *Support Care Cancer*. 1996;4(2):147-150.
- 470 44. Bruera E, Legris MA, Kuehn N, Miller MJ. Hypodermoclysis for the administration of  
471 fluids and narcotic analgesics in patients with advanced cancer. *J Pain Symptom*  
472 *Manag*. 1990;5(4):218-220.
- 473 45. Chalany J. [Subcutaneous rehydration in patients in terminal phase of dementia].  
474 *Casopis lékařů českých*. 2015;154(1):14-18.
- 475 46. Hussain NA, Warshaw G. Utility of clysis for hydration in nursing home residents. *J Am*  
476 *Geriatr Soc*. 1996;44(8):969-973.
- 477 47. Schen RJ, Singer-Edelstein M. Subcutaneous infusions in the elderly. *J Am Geriatr Soc*.  
478 1981;29(12):583-585. doi:10.1111/j.1532-5415.1981.tb01265.x
- 479 48. Schen RJ, Singer-Edelstein M. Hypodermoclysis. *Jama*. 1983;250(13):1694-1694.  
480 doi:10.1001/jama.1983.03340130024016
- 481 49. Yap LK, Tan SH, Koo WH. Hypodermoclysis or subcutaneous infusion revisited.  
482 *Singapore Med J*. 2001;42(11):526-529.
- 483 50. Schen RJ, Ariely S. Administration of potassium by subcutaneous infusion in elderly  
484 patient. *Br Med J*. 1982;285(6349):1167-1168. doi:10.1136/bmj.285.6349.1167
- 485 51. Mongardon N, Le Manach Y, Tresallet C, Lescot T, Langeron O. Subcutaneous  
486 hydration: a potentially hazardous route. *Eur J Anaesthesiol*. 2008;25(9):771-772.

- doi:10.1017/S0265021508004158 [doi]
52. Kackielo H, Carney M. Hypodermoclysis associated with rhabdomyolysis leading to acute renal failure and death. *J Am Geriatr Soc*. 2000;48(8):S129-S129.
53. Sato K, Karino M, Nishi T, et al. Three elderly patient cases maintained by home hypodermoclysis--a practical hydrating method performed by family members. *Gan To Kagaku Ryoho*. 2008;35:85-87.
54. Lemeray J, Kluger N, Girard C. Adverse effect of hypodermoclysis: an unusual clinical presentation. *Ann Dermatol Venereol*. 2012;139(1):77-78.  
doi:10.1016/j.annder.2011.06.001 [doi]
55. Delamaire D, Meigne B, Lecoq A, Cattenoz C, Michel M, Michel O. A rehydration randomized trial favoring the subcutaneous route in the elderly. *Rev Med interne*. 1992;13(7):S321. doi:10.1016/S0248-8663(05)80908-7
56. Lima Ribeiro SM, Morley JE. Dehydration is Difficult to Detect and Prevent in Nursing Homes. *J Am Med Dir Assoc*. 2015;16(3):175-176. doi:10.1016/j.jamda.2014.12.012
57. Dychter SS, Gold DA, Carson D, Haller M. Intravenous therapy: a review of complications and economic considerations of peripheral access. *J Infus Nurs*. 2012;35(2):84-91. doi:10.1097/NAN.0b013e31824237ce
58. Gumińska I, Lisiak W, Gembicki M. Rate of distribution of Na<sup>131</sup>I and of <sup>131</sup>I labelled albumin injected subcutaneously. *Pol Med J*. 1967;6(2):303-310.
59. Witlox J, Eurelings LSM, de Jonghe JFM, Kalisvaart KJ, Eikelenboom P, van Gool WA. Delirium in Elderly Patients and the Risk of Postdischarge Mortality, Institutionalization, and Dementia. *JAMA*. 2010;304(4):443-451.  
doi:10.1001/jama.2010.1013

## Supporting information

Additional Supporting Information may be found in the online version of this article.

## Figure legend

### Figure 1. PRISMA flowchart

**Figure 2.** Meta-analysis on the number of adverse effects comparing subcutaneous hydration vs intravenous hydration stratified by overall risk of bias.

Footnote: Abbreviations: RoB 2.0: Cochrane Risk of Bias 2.0, n/N: Number of adverse effects / Number of infusions, CI: Confidence Interval, SC: Subcutaneous, IV: Intravenous. Meta-analysis pooling of Risk Ratios using the random-effects inverse-variance model with DerSimonian-Laird estimate of  $\tau^2$ .

The dashed line represents the overall pooled estimate.

### Figure 3. Incidence of minor adverse effects per 1000 infusions

Footnote: Data from the lowest risk of bias studies (in total n = 7, with 2171 infusions)<sup>24,28–30,33,37,39</sup>. I-bars represent 95% confidence interval. One study reported data on serious and total number of minor adverse effects but not on specific minor adverse effects<sup>31</sup>. This is the

530 reason for the discrepancy between the number of included studies and infusions in figure 3  
531 and the reported incidence of 90 per 1000 infusions.

**Table 1** Characteristics of included RCT studies

<b>Study &amp; year</b>	<b>Sample size</b>				
Country	(number of		<b>Patient population</b>	<b>Intervention (I) and</b>	<b>Duration of</b>
Language	infusions)	<b>Setting</b>	<b>characteristics</b>	<b>comparator (C) details</b>	<b>intervention/</b>
					<b>comparator</b>
<b>Delamaire 1992</b> <sup>25</sup> France French	<b>30</b> (105 infusions in each group <sup>a</sup> )	No description of setting	Geriatric patients. Described as elderly patients. No information on participants' hydration status. Mean age: 83 years No information on sex	<b>I:</b> SC infusion. (no further description) <b>O:</b> IV infusion. (no further description)	Mean: 7 days, SD: No data
<b>Challiner 1994</b> <sup>24</sup> United Kingdom English	<b>34</b> (68 infusions in each group <sup>b</sup> )	Hospital, Elderly Care Unit	Geriatric patients with acute stroke. Dehydrated (mean s-osmolality 296 mmol/kg at baseline) Mean age 83.5 years Male: 23, Female: 11	<b>I:</b> SC infusion. Two liters of fluid per 24 hours delivered through a 19 G butterfly <b>O:</b> IV infusion. Two liters of fluid per 24 hours delivered through an IV access (no further information)	48 hours (predetermined)
<b>O'Keeffe 1996</b> <sup>28</sup> United Kingdom English	<b>60</b> (90 infusions in each group <sup>c</sup> )	Hospital, acute geriatric unit.	Geriatric patients with cognitive impairment. Mild dehydration or poor oral intake (mean s-urea 28 mg/dl, mean s-creatinine 1.2 mg/dl at baseline) Mean age 82.5 years Male: 23, Female: 37	<b>I:</b> SC infusion. Up to 2 liters of fluid per 24 hours. 21 G butterfly needle in infraclavicular, scapular, abdominal or thigh areas. <b>O:</b> IV infusion. Up to two liters of fluid per 24 hours. 18-20 G cannula in forearm veins	48 hours (predetermined)
<b>Slesak 2003</b> <sup>29</sup> Germany English	<b>96</b> (288 infusions in each group <sup>a</sup> )	Hospital, geriatric wards in the Geriatric Department	Geriatric patients with signs of mild to moderate dehydration (median s-creatinine 1.0 mg/dl at baseline) Mean age 85.3 years Male: 29, Female: 67	<b>I:</b> SC infusion. Up to 1.5 liters of fluid per 24 hours. Butterfly needle 21 G, in SC tissue of thigh, abdomen, or thorax. <b>O:</b> IV infusion. Up to 1.5 liters of fluid per 24 hours. Peripheral IV catheters 18-22 G	Median 6 days, range 1-36 days
<b>Luk 2008</b> <sup>27</sup> China English	<b>57</b> (Unable to calculate number of infusions)	Hospital	Geriatric patients with mild to moderate dehydration. (mean urea/creatinine ratio 0.11 (iv group) 0.14 (sc group) at baseline) Mean age: 85 years Male: 34, Female: 23	<b>I:</b> SC infusion. Up to 1.5 liters of fluid per 24 hours. 22 G butterfly needle in the SC tissue of the lateral abdomen. <b>O:</b> IV infusion. Up to 1.5 liters of fluid per 24 hours. 18-22 G angiocaths.	Up to 3 days (Predetermined)
<b>Noriega 2014</b> <sup>30</sup> Spain Spanish	<b>70</b> (102 infusions in SC group, 99 infusions in IV group <sup>a</sup> )	Hospital, Acute Geriatrics unit	Geriatric patients, dehydrated (mean s-osmolality 327 mmol/kg, mean s-urea 108 mg/dl, mean s-creatinine 1.9 mg/dl at baseline) Mean age: 85.4 years Male: 35, Female: 32	<b>I:</b> SC infusion. Up to 1.5 liters of fluid per 24 hours. Butterfly needle 21-25 G, in SC tissue of thigh, abdomen or scapular. <b>O:</b> IV infusion. Up to 1.5 liters of fluid per 24 hours. Peripheral IV catheters 20-24 G in forearm or hand.	3 days, (Predetermined)
<b>Esmeray 2018</b> <sup>26</sup> Turkey English	<b>30</b> Cross-over RCT (90 infusions in each group.)	Long-term care. "Private long-stay geriatric care unit"	Geriatric patients with dementia. 60% were dependent on support for fluid intake. Mild/ moderate dehydrated or risk of dehydration. No further information on participants' hydration status. Mean age: 82 years Male: 3, Female: 27	<b>I:</b> SC infusion. 21–23 G butterfly needle <b>O:</b> IV infusion. (No further information)	Three SC infusions and three IV infusion. No data on how long many days this took.

Abbreviations: RCT: Randomized controlled trial, SC: Subcutaneous, IV: Intravenous, G: Gauge.

<sup>a</sup> Calculated based on the number of participants per group x mean duration of intervention.

<sup>b</sup> Calculated based on the number of participants per group x two infusions per day x two days of infusions.

<sup>c</sup> Number of infusions calculated by the number of participants x 1.5 per day per group.

**Table 2.** GRADE Summary of findings: subcutaneous hydration

No of studies (design)	n/N of infusions		Relative effect measure (95% CI)	Absolute effect	Quality of the evidence
	SC	IV			
Risk of adverse effects					
Lowest risk of bias subgroup (4 RCTs)	82/548	119/545	RR 0.69 (0.53: 0.88)	The incidence of adverse effects with SC is 90 per 1000 infusions compared to 130 per 1000 infusions with IV (95% CI 102-169). <sup>a</sup>	⊕⊕⊕O Moderate <sup>b,c</sup>
Effect of treating the problem (dehydration), inferred from the surrogate outcome “Effect on serum osmolality”					
(2 RCTs)	51 <sup>f</sup>	50 <sup>f</sup>	MD 5.75 (0.13: 11.37)	IV hydration will lower serum osmolality by 5.75 mmol/kg (95% CI 0.13 more to 11.4 more) compared with SC hydration.	⊕OOO Very low <sup>b,c,d</sup>
Effect of hydration treatment, “Death”					
(3 RCTs)	3/84	2/82	RR 1.3 (0.25: 6.34)	Unable to calculate meaningful absolute values due to a very large confidence interval.	⊕OOO Very low <sup>c,d,e</sup>
Effect of the hydration treatment, inferred from the surrogate outcome “Volume of fluid infused”					
(3 RCTs)	110 <sup>f</sup>	111 <sup>f</sup>	SMD: 0.62 (0.24: 1.01) <sup>g</sup>	IV hydration will infuse 155 ml more fluid per day (95% CI 60 ml more to 253 ml more) compared to SC hydration when infusing 1000 ml/day. <sup>h</sup>	⊕OOO Very low <sup>b,d</sup>
Effect of the hydration treatment, inferred from the surrogate outcome “Agitation”					
(3 RCTs) <sup>i</sup>	26/93	63/93	RR 0.42 (0.22: 0.79)	68% patients treated with IV hydration with cognitive impairment will experience agitation vs 28% treated with SC hydration (95% CI 15%-54%).	⊕⊕OO Low <sup>b,d</sup>
Time spent on catheter insertion					
(2 RCTs)	138 <sup>f</sup>	138 <sup>f</sup>	MD 3.2 (1.48: 4.87)	Setting up SC hydration takes 3.2 fewer minutes (1.5 to 4.9 less) than setting up IV hydration.	⊕OOO Very low <sup>b,e</sup>

Abbreviations: RCT: Randomized controlled trial, SC: Subcutaneous, IV: Intravenous, CI: Confidence interval, RR: risk ratio, MD: Mean difference, SDM, Standardized Mean Difference.

<sup>a</sup> Based on incidence of adverse effects from SC hydration from the studies with the lowest risk of bias (4 RCTs and 4 observational studies.)

<sup>b</sup> Downgraded due to risk of bias of included studies

<sup>c</sup> Downgraded due to imprecision

<sup>d</sup> Downgraded due to indirectness

<sup>e</sup> Downgraded due to inconsistency


GRADE Evidence profile table can be found in Supplementary Table S3


<sup>f</sup> Number of patients evaluated for this outcome

<sup>g</sup> We have use standard mean difference (SMD) as included studies reported either volume per day or volume overall.


<sup>h</sup> Based on numbers from Slesak 2003<sup>29</sup> with 1000 ml ± 250 being infused per day in IV group.

<sup>i</sup> All studies included mostly patients with cognitive impairment.









# Supplementary of

## Harms and Benefits of Subcutaneous Hydration in Older Patients: Systematic Review and Meta-analysis

### Table of Contents

Supplementary Text S1. Search string for included databases. ....	3
MEDLINE search – PubMed interface .....	3
Cochrane library .....	3
Web of Science.....	3
CINAHL.....	3
EMBASE.....	4
Supplementary Text S2. Exclusions reason for papers read in full text.....	5
Table 1 Characteristics of included RCT studies (a landscape copy of Table 1).....	16
Supplementary Table S1. Outcomes of included RCT with information on method of measuring, ascertainment and individual Overall Risk of Bias.....	17
Supplementary Table S1 continue .....	18
Supplementary Text S3. Extracted study characteristics .....	19
3.1 Randomized studies.....	19
Challiner 1994 (24).....	19
Delamaire 1992 (25).....	20
Esmeray 2018 (26).....	20
Luk 2008 (27) .....	21
Noriega 2014 (30).....	22
O'Keeffe 1996 (28) .....	23
Slesak 2003 (29) .....	24
3.2 Non-randomized studies .....	25
Arinzon 2004 (33).....	25
Bigot 2013 (32).....	26
Bruera 1990 (44).....	26
Bruera 1996 (43).....	27
Centeno 1999 (35) .....	28
Chalany 2015 (45) .....	28
Dasgupta 2000 (31).....	29
Fainsinger 1994 (36).....	30
Hussain 1996 (46).....	30
Justino 2013 (37) .....	31
Kackielo 2000 (52) .....	31
LAMANDÉ 2004 (38).....	32
Lemeray 2012 (54).....	33
Martinez-Riquelme 2005 (39).....	33

Mongardon 2008 (51) .....	34
Sato 2008 (53).....	34
Schen 1981 (47).....	35
Schen 1982 (50).....	35
Schen 1983 (48).....	36
Torsheim 1999 (40) .....	36
Vidal 2016 (41).....	37
Worobec 1997 (42).....	38
Yap 2001(49) .....	38
ŠŤASTNÁ 2009 (34).....	39
Supplementary Text S4. Risk of Bias 2. Judgement of individual domains. ....	40
4.1 Outcome: Adverse effects .....	40
4.2 Outcome: Death.....	41
4.3 Outcome: Catheter insertion time .....	42
4.4 Outcome: Osmolality .....	43
4.5 Outcome: Volume of fluid infused .....	44
4.6 Outcome: Agitation .....	45
4.7 Signaling questions for the outcome: Adverse effects.....	46
4.8 Signalling questions for the outcome: Death.....	61
4.9 Signalling questions for the outcome: Catheter insertion time .....	72
4.10 Signalling questions for the outcome: Osmolality .....	77
4.11 Signalling questions for the outcome: Volume of fluid infused .....	83
4.12 Signalling questions for the outcome: Agitation .....	90
Supplementary Table S2. Risk of bias of cross-sectional studies for the outcome of adverse effects .....	97
Supplementary Figure S1. Subgroup meta-analysis by setting of study on number adverse effects comparing subcutaneous vs intravenous hydration .....	98
Supplementary Figure S2. Subgroup meta-analysis by use of hyaluronidase on number adverse effects comparing subcutaneous vs intravenous hydration .....	99
Supplementary Figure S3. Meta-analysis on serious adverse effects comparing subcutaneous vs intravenous hydration.....	100
Supplementary Figure S4. Meta-analysis on all the different types of adverse effects comparing subcutaneous vs intravenous hydration .....	101
Supplementary Figure S5. Meta-analysis on reduction of serum osmolality comparing subcutaneous vs intravenous hydration.....	102
Supplementary Figure S6. Meta-analysis on death comparing subcutaneous vs intravenous hydration .....	103
Supplementary Figure S7. Meta-analysis on volume of fluid infused comparing subcutaneous vs intravenous hydration .....	104
Supplementary Figure S8. Meta-analysis on agitation comparing subcutaneous vs intravenous hydration.....	105
Supplementary Figure S9. Meta-analyses on time spend on catheter insertion comparing subcutaneous vs intravenous hydration.....	106
Supplementary Figure S10. Funnel plot for adverse effects from 6 RCTs of subcutaneous vs intravenous hydration ....	107
Supplementary Table S3. GRADE Evidence profile: subcutaneous hydration .....	108
Reference .....	109

## Supplementary Text S1. Search string for included databases.

### MEDLINE search – PubMed interface

("Hypodermoclysis"[Mesh] OR hypodermoclysis\*[tw]) OR  
 ("Solutions, Rehydration"[MeSH] OR fluid therap\*[tw] OR "Fluid Therapy"[Mesh] OR  
 "Dehydration"[Mesh] OR dehydrat\*[tw] OR  
 hypovolaemi\*[tw] OR hypovolemi\*[tw] OR "Hypovolemia"[Mesh] OR  
 rehydrat\*[tw] OR  
 Fluid Administrat\*[tw]) AND  
 (subcutaneou\*[tw] OR "Infusions, Subcutaneous"[MeSH])

### Cochrane library

ID	Search
#1	MeSH descriptor: [Hypodermoclysis] explode all trees
#2	hypodermoclysis*:ti,ab,kw (Word variations have been searched)
#3	#1 or #2
#4	MeSH descriptor: [Rehydration Solutions] explode all trees
#5	MeSH descriptor: [Fluid Therapy] explode all trees
#6	MeSH descriptor: [Dehydration] explode all trees
#7	MeSH descriptor: [Hypovolemia] explode all trees
#8	"fluid therap*":ti,ab,kw (Word variations have been searched)
#9	dehydrat*:ti,ab,kw (Word variations have been searched)
#10	hypovolaemi*:ti,ab,kw (Word variations have been searched)
#11	hypovolemi*:ti,ab,kw (Word variations have been searched)
#12	rehydrat*:ti,ab,kw (Word variations have been searched)
#13	"Fluid Administrat*":ti,ab,kw (Word variations have been searched)
#14	#4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13
#15	MeSH descriptor: [Infusions, Subcutaneous] explode all trees
#16	subcutaneou*:ti,ab,kw (Word variations have been searched)
#17	#15 or #16
#18	#14 and #17
#19	#18 or #3

### Web of Science

#1 TS=hypodermoclysis\*  
 #2 TS=("fluid therap\*" OR dehydrat\* OR hypovolaemi\* OR hypovolemi\* rehydrat\* OR "Fluid Administrat\*")  
 #3 TS=subcutaneou\*  
 #4 #3 AND #2  
 #5 #4 OR #1

### CINAHL

S1 (MH "Hypodermoclysis")  
 S2 hypodermoclysis\*  
 S3 S1 OR S2  
 S4 (MH "Infusions, Subcutaneous+")  
 S5 subcutaneou\*  
 S6 S4 OR S5  
 S7 fluid therap\*  
 S8 dehydrat\*  
 S9 hypovolaemi\*

S10 hypovolemi\*  
 S11 rehydrat\*  
 S12 Fluid Administrat\*  
 S13 (MH "Rehydration Solutions")  
 S14 (MH "Fluid Therapy+")  
 S15 (MH "Dehydration") OR (MH "Hyponatremia")  
 S16 S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15  
 S17 S6 AND S16  
 S18 S3 OR S17

## EMBASE

1. hypodermoclysis/  
 2. hypodermoclys\*.mp.  
 3. 1 or 2  
 4. subcutaneous drug administration/  
 5. subcutaneou\*.mp.  
 6. 4 or 5  
 7. fluid therapy/ or fluid resuscitation/ or exp parenteral nutrition/ or exp rehydration/  
 8. dehydration/  
 9. hypovolemia/  
 10. fluid therap\*.mp.  
 11. dehydrat\*.mp.  
 12. hypovolaemi\*.mp.  
 13. rehydrat\*.mp.  
 14. Fluid Administrat\*.mp.  
 15. or/7-14  
 16. 6 and 15  
 17. 3 or 16  
 18. remove duplicates from 17

## Supplementary Text S2. Exclusions reason for papers read in full text

Listed alphabetical by title of paper.

1. Gabriel J. A guide to Subcutaneous Infusion. British Journal of Nursing 2019;28(sup14c):1-7 2019  
*Exclusion reason:* Review, description or comment on subcutaneous hydration;
2. Candon HL, Amirov C, Toen J V. A multifaceted intervention to address a case cluster of cellulitis associated with hypodermoclysis in a geriatric complex continuing care unit. Can J Infect Control. 2010;25(2 PG-101-106):101-106. *Exclusion reason:* Wrong intervention;
3. M. V, D. H, J.L. W, G.B. C, J. A. A prospective study: Hypodermoclysis performed by caregivers in the home setting. J Clin Oncol. 2014;32(31 SUPPL. 1):no pagination. *Exclusion reason:* Duplicate;
4. Bruera E, Neumann CM, Pituskin E, Calder K, Hanson J. A randomized controlled trial of local injections of hyaluronidase versus placebo in cancer patients receiving subcutaneous hydration. Ann Oncol. 1999;10(10):1255-1258. *Exclusion reason:* Wrong intervention;
5. Bruera E, Neumann CM, Pituskin E, Calder K, Hanson J. A randomized controlled trial of local injections of hyaluronidase versus placebo in cancer patients receiving subcutaneous hydration. Annals of oncology. 1999;10(10):1255-1258 *Exclusion reason:* Wrong intervention;
6. E. B, K.O. A, J.L. P, et al. A randomized, controlled trial of parenteral hydration in patients with advanced cancer. J Clin Oncol. 2010;28(15 SUPPL. 1):no pagination. *Exclusion reason:* Wrong intervention
7. Cohen JS. A summary of complications of fluid therapy. Vet Clin North Am. 1982;12(3):545-558. *Exclusion reason:* Animal study
8. POLACEK E, JECH C. Absorption of 0.9 o/o sodium chloride injected subcutaneously in dehydration shock. Cesk Pediatr. 1956;11(6 PG-406-411):406-411. *Exclusion reason:* Animal study;
9. ABBOTT WE, KRIEGER H, BABB LI, SAVOIE E, LEVEY S. Administration of dextran by hypodermoclysis. Surg Gynecol Obstet. 1954;99(2 PG-147-150):147-150. *Exclusion reason:* Indication not hydration;
10. Schen R. Administration of fluid by subcutaneous infusion: revival of a forgotten method. Harefuah. 1997;132(10 PG-716-717):716-717. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
11. ADMINISTRATION of fluids by hypodermoclysis. J Am Med Assoc. 1952;150(9):942-943. *Exclusion reason:* Not geriatric population
12. Gluck SM. Advantages of hypodermoclysis. J Am Geriatr Soc. 1984;32(9 PG-691-692):691-692. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
13. J. L, N. K. Adverse effect of hypodermoclysis: An unusual clinical presentation. Ann Dermatol Venereol.:no pagination. *Exclusion reason:* Duplicate;
14. Woodall HE. Alternatives to rehydration during hypodermoclysis. Am Fam Physician. 2002;66(1 PG-28; author reply 28, 30):28; author reply 28, 30. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
15. Cline M, Gershon K. An alternative to IV fluids - Hypodermoclysis. Oncol Nurs Forum. 2005;32(2 PG-450-450):450. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
16. Burgoyne G. Appropriate use of hypodermoclysis. Can Fam Physician. 1993;39(Journal Article PG-24, 26):24,26. *Exclusion reason:* No patients data;
17. Bear AJ, Bukowy EA, Patel JJ. Artificial Hydration at the End of Life. Nutr Clin Pract. 2017;32(5 PG-628-632):628-632. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
18. Boland E, Johnson M, Boland J. Artificial hydration in the terminally ill patient. Br J Hosp Med. 2013;74(7 PG-397-401):397-401. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
19. Smith L, Amelia EJ, Mueller M. Artificial Nutrition and Hydration at End of Life. Home Healthc Now. 2015;33(1 PG-38-43):38-43. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
20. Ying I. Artificial nutrition and hydration in advanced dementia. Can Fam Physician. 2015;61(3 PG-245-8, e125):245-248, e125. *Exclusion reason:* Review, description or comment on subcutaneous hydration;

21. Thomas JR, Yocum RC, Haller MF, von Gunten CF. Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study. J Palliat Med. 2007;10(6 PG-1312-1320):1312-1320. *Exclusion reason:* Not geriatric population;
22. Tine S., Phung-Nguyen A.-T., Abdo Wahed Y., Martel C., Ratiney R., Perillat I. Évaluation de la pertinence des perfusions sous-cutanées en unité de soins de longue durée. Pharm Hosp. 2009;44(177):70-74. *Exclusion reason:* Cross-sectional study without adverse effects
23. Soremekun OA, Shear ML, Connolly J, Stewart CE, Thomas SH. Basic-level emergency medical technician administration of fluids and glucose via enzyme-assisted subcutaneous infusion access. Prehosp Disaster Med. 2012;27(3 PG-220-225):220-225. *Exclusion reason:* Not geriatric population;
24. BERMAN JK, PIERCE GS, BEST MM. Burn shock; its treatment with continuous hypodermoclysis of isotonic solution of sodium chloride into the burned areas; clinical studies in 2 cases. Arch Surg. 1946;53(5):577-587. *Exclusion reason:* Not geriatric population
25. Finn M. Canadian perspective. Hypodermoclysis: an old solution revisited. J Gynecol Oncol Nurs. 1996;6(3 PG-32-33):32-33. *Exclusion reason:* Not able to find full text;
26. de la RE, Zamora Monge G. Canalization of a subcutaneous route as a valid alternative for geriatric patients in hospital stay with moderate dehydration. Agora Enferm. 2015;19(1 PG-5-8):5-8. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
27. A.K. D, P. Y, A.K. A, B.B. R. Clinical approach to altered serum sodium levels. Journal, Indian Acad Clin Med. 2006;7(2 PG-91-103):91-103. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
28. LINDSEY D. Clinical Contribution of Hypodermoclysis. Can Fam Physician. 1992;38(Journal Article PG-2801-2801):2801. *Exclusion reason:* Duplicate;
29. Clinical management. J Intraven Nurs. 1998;21(1S):S26-68. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
30. Smith LS. CLINICAL QUERIES. Hypodermoclysis with older adults. Nursing (Lond). 2014;44(12 PG-66-66):66. *Exclusion reason:* Duplicate;
31. Cerchietti L, Navigante A, Sauri A, Palazzo F. Clinical trial. Hypodermoclysis for control of dehydration in terminal-stage cancer. Int J Palliat Nurs. 2000;6(8 PG-370-374):370-374. *Exclusion reason:* Duplicate;
32. C.D. B, J.A. B. Comfort care for patients dying in the hospital. N Engl J Med. 2015;373(26 PG-2549-2561):2549-2561. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
33. Barbosa G, Laís Samara M, Oliceira S, Barbosa J. Complicações da via subcutânea na infusão de medicamentos e soluções em cuidados paliativos. Rev Rene 2019;20(1):1-9 2019 *Exclusion reason:* Wrong intervention.
34. Hall B. Complications of hypodermoclysis (re-emphasis with a case presentation). J Ky Med Assoc. 1968;66(7):626-627. *Exclusion reason:* Not geriatric population;
35. Kala M. Complications of the subcutaneous administration of fluids and possibilities of their solutions. Interni Med pro Praxi. 2013;15(1):36-37. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
36. Menahem S, Shvartzman P. Continuous subcutaneous delivery of medications for home care palliative patients-using an infusion set or a pump? Support Care Cancer. 2010;18(9 PG-1165-1170):1165-1170. *Exclusion reason:* Wrong intervention;
37. Smulders YM. Continuous subcutaneous infusion in palliative care, an undervalued method. Ned Tijdschr Geneesk. 2003;147(7 PG-319; author reply 319):319. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
38. Ansari SA, Rivera E, Modawal A. Correction of sodium electrolyte abnormalities with hypodermoclysis in the long-term care setting. J Am Geriatr Soc. 2004;52(4 PG-21-22):S21-S22. *Exclusion reason:* Case report without adverse effects;
39. DANGERS of hypodermoclysis. Nutr Rev. 1953;11(8):232-234. *Exclusion reason:* Review, description or comment on subcutaneous hydration
40. Pierrat D. Deep subcutaneous perfusion: a little-known method for rehydrating the elderly. Servir. 1990;38(6 PG-308-309):308-309. *Exclusion reason:* Review, description or comment on subcutaneous hydration;

41. J. K. Dehydration and subcutaneous infusion (hypodermoclysis) in the elderly. MMW-Fortschritte der Medizin. 2014;156(4):45-47. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
42. Zeeshan J, Poltz S. Dehydration in geriatric patients. Fluid substitution--also subcutaneous! MMW Fortschr Med. 2000;142(44 PG-40-42):40-42. *Exclusion reason:* Duplicate;
43. McAulay D. Dehydration in the terminally ill patient. Nurs Stand. 2001;16:33-37. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
44. Lima RS, J.E. M. Dehydration is difficult to detect and prevent in nursing homes. J Am Med Dir Assoc. 2015;16(3 PG-175-176):175-176. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
45. Kilgore C. Dehydration isn't simple to diagnose and treat. Caring Ages. 2010;11(2):6-7. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
46. Noble-Adams R. Dehydration: subcutaneous fluid administration. Br J Nurs. 1995;4(9 PG-488, 490, 492-4):488,490,492-494. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
47. Gandhi JS, Patel V. Delivery of fluids by the subcutaneous route. Postgrad Med J. 2000;76(897 PG-453):453. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
48. Walsh G. Difficult peripheral venous access: Recognizing and managing the patient at risk. JAMA - J Assoc Vasc Access. 2008;13(4):198-203. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
49. WEBB WR. Effect of hyaluronidase on rate of absorption of subcutaneous fluids. AMA Arch Surg. 1952;65(5):770-773. *Exclusion reason:* Studie on the relevance of hyaluronidase
50. E. B, R. S, MA. R, et al. Effects of parenteral hydration in terminally ill cancer patients: a preliminary study. J Clin Oncol. 2005;23(10 PG-2366-71):2366-2371. *Exclusion reason:* Wrong intervention
51. Crowley M, Brim C, Proehl J, et al. Emergency Nursing Resource: Difficult Intravenous Access. J Emerg Nurs. 2012;38(4):335-343. *Exclusion reason:* Review, description or comment on subcutaneous hydration
52. NCT00320866. Evaluation of Symptoms, Complications and Side Effects of Adding Medications Continuously To Subcutaneous Infusion (Hypodermoclysis) In Home Care Hospice Patients. <https://clinicaltrials.gov/show/nct00320866>. 2006. *Exclusion reason:* Trial protocol
53. J. Z, S. P. Exsiccation in geriatric patients: Replacement of fluid via subcutaneous infusion. MMW-Fortschritte der Medizin. 2000;142(44 PG-40-42):40-42. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
54. Fainsinger R. Fast facts and concepts. Nonoral hydration techniques in palliative care #134. J Palliat Med. 2006;9(1 PG-207-208):207-208. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
55. Batirel, H. Fluid administration during lung resection: what is the optimum. Journal of Thoracic Disease 2019;11(5):1746-1748 2019 *Exclusion reason:* Wrong intervention
56. Shahla S, Gregersen M. Hospital-at-home by a multidisciplinary geriatric team reduces mortality after discharge from an emergency medical department. Eur Geriatr Med. 2013;4:S173. *Exclusion reason:* Wrong intervention
57. Cote TR. How to perform subcutaneous hydration. J Am Med Dir Assoc. 2008;9(5 PG-291):291. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
58. SOLDI A. Hyaluronidase and hypodermoclysis. Farm Sci e Tec. 1949;4(5 PG-589-593):589-593. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
59. HYALURONIDASE and hypodermoclysis. J Am Med Assoc. 1953;151(8):644-645. *Exclusion reason:* Not geriatric population;
60. HUGUENARD P, DELIGNE P. Hyaluronidase and postoperative hypodermoclysis in the adult. Therapie. 1952;7(3 PG-244-248):244-248. *Exclusion reason:* Not geriatric population;
61. Simpson RG. Hyaluronidase in geriatric therapy. Practitioner. 1977;219(1311 PG-361-363):361-363. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
62. Broadhurst D. Hydrating Your Patient the Easy Way: Hypodermoclysis. Vasc Access. 2012;6(2 PG-7-19):7-19. *Exclusion reason:* Review, description or comment on subcutaneous hydration;



63. N. V, A. C, V. C. Hydration and nutrition issues in old people cared for at home: A retrospective survey. Eur Geriatr Med. 2010;1:S132. *Exclusion reason:* Cross sectional study without adverse effects;
64. Fenton P. Hydration consultation hypodermoclysis: another way to replace fluids (May 2000). Nursing (Lond). 2000;30(9 PG-12-12):12. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
65. Ardiz MDP, Bruera E. Hydration in palliative care: when, how and why. Med Paliativa. 2007;14(2 PG-104-120):104-120. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
66. Lanuke K, Fainsinger RL, DeMoissac D. Hydration management at the end of life. J Palliat Med. 2004;7(2 PG-257-263):257-263. *Exclusion reason:* Cross sectional study without adverse effects;
67. Brugnolli A, Bevilacqua A, Clodig M, Danielis M. Hydration with hypodermoclysis in elderly patients. Assist Inferm E Ric. 2012;31(3 PG-145-150):145-150. *Exclusion reason:* Duplicate;
68. Russell S. Hypodermic clysis: A viable rehydration option? Geriatr Nurs (Minneap). 2018;39(2):247-249. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
69. BERMAN LB. Hypodermoclysis is Not Recommended for Parenteral Fluid and Electrolyte Therapy. Jama-Journal Am Med Assoc. 1977;237(7 PG-687-687):687. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
70. Hypodermoclysis. Am Fam Physician. 1993;47(1):255. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
71. Scholz P, Schottky H. Hypodermoclysis. Z Gerontol Geriatr. 2013;46:85-86. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
72. GLUCK SM. Hypodermoclysis - Reply. Jama-Journal Am Med Assoc. 1983;250(13 PG-1694-1695):1694-1695. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
73. Lima PR V, Simões SCA. Hypodermoclysis -- technique with a future]. Nurs Rev Form Contin em Enferm. 2007;17(223):44-49. *Exclusion reason:* Not able to find full text
74. FAINSINGER RL, MILLER M, BRUERA E. Hypodermoclysis and Dehydration. Can Fam Physician. 1992;38(Journal Article PG-2803-2803):2803. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
75. Smith T, Basa E, Nguyen T. Hypodermoclysis and intermittent subcutaneous medication administration for hydration, analgesia and palliative sedation in the acute palliative care setting. Oncol Nurs Forum. 2005;32(2 PG-430-430):430. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
76. Hypodermoclysis and Saline Infusion in the Presbyterian Hospital, New York. Am J Nurs. 1904;4(5):354-357. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
77. Bruera E, Legris MA, Kuehn N, Miller MJ. Hypodermoclysis for the administration of fluids and narcotic analgesics in patients with advanced cancer. J Pain Symptom Manag. 1990;5(4):218-220. *Exclusion reason:* Duplicate
78. Cerchietti L, Navigante A, Sauri A, Palazzo F. Hypodermoclysis for control of dehydration in terminal-stage cancer. International journal of palliative nursing 2000;6(8):370-374. *Exclusion reason:* Not geriatric population;
79. Brugnolli A, Bevilacqua A, Clodig M, Danielis M. Hypodermoclysis hydration in the elderly. Assist Inferm Ric. 2012;31(3 PG-145-150):145-150. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
80. Constans T, Dutertre JP, Frogé E. Hypodermoclysis in dehydrated elderly patients: local effects with and without hyaluronidase. J Palliat Care. 1991;7(2):10-12. *Exclusion reason:* Wrong intervention
81. T. C, B. D. Hypodermoclysis in geriatrics settings. Rev Geriatr. 2003;28(5 PG-13-14):B13-B14. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
82. DAWSON HR. Hypodermoclysis in Palliative Care. Can Fam Physician. 1992;38(Journal Article PG-2801-):2801-. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
83. MOLLOY DW, CUNJE A. Hypodermoclysis in the Care of Older Adults - an Old Solution for New Problems. Can Fam Physician. 1992;38(Journal Article PG-2038-2043):2038-2043. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
84. Wisinger MM. Hypodermoclysis in the elderly: a means of hydration. Nurs Homes Sr Citiz Care. 1987;36(3 PG-32-33):32-33. *Exclusion reason:* Case report without adverse effects;

85. Schen RJ, Edelstein-Singer M. Hypodermoclysis in the home. J Am Geriatr Soc. 1984;32(12 PG-944):944. *Exclusion reason:* Case report without adverse effects;
86. Gill S, Dasgupta M, Rochon P. Hypodermoclysis in the treatment of dehydration. Am Fam Physician. 2001;64(9 PG-1516, 1518-9):1516,1518-1519. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
87. Gluck SM. Hypodermoclysis revisited. Jama. 1982;248(11 PG-1310-1311):1310-1311. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
88. Hypodermoclysis seen as alternative to IV fluids for palliative care. Oncol News Int. 2005;14(8 PG-42-55):42-55. *Exclusion reason:* Not able to find full text;
89. North HB. Hypodermoclysis Technic at Harper Hospital Detroit. Am J Nurs. 1925;25(3 PG-178-179):178-179. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
90. Remington R, Hultman T. Hypodermoclysis to treat dehydration: a review of the evidence. J Am Geriatr Soc. 2007;55(12 PG-2051-2055):2051-2055. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
91. L.S. S. Hypodermoclysis with older adults. Nursing (Lond). 2014;44(12):66. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
92. DE SIMONE F. Hypodermoclysis with sistosan in persistent hemorrhage. Gazz Med Ital. 1953;112(8 PG-225):225. *Exclusion reason:* Wrong intervention;
93. Olde Rikkert MG, Bogaers MA, Bruijns E. Hypodermoclysis, an undervalued rehydration method in geriatrics. Tijdschr Gerontol Geriatr. 1994;25(5 PG-197-204):197-204. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
94. Dutertre JP, Constans T. Hypodermoclysis: a forgotten technique. La Rev Med interne. 1991;12(2 PG-153-155):153-155. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
95. Walsh G. Hypodermoclysis: an alternate method for rehydration in long-term care. J Infus Nurs. 2005;28(2 PG-123-129):123-129. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
96. Humphrey P. Hypodermoclysis: an alternative to I.V. infusion therapy. Nursing (Lond). 2011;41(11 PG-16-17):16-17. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
97. Brown MK, Worobec F. Hypodermoclysis: another way to replace fluids corrected] published erratum appears in NURSING 2000 Jul; 30(7): 8]. Nursing (Lond). 2000;30(5 PG-58-59):58-59. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
98. Schoenbeck SL, McBride K. Hypodermoclysis: easy, safe, cost-effective. J Pract Nurs. 2010;60(1 PG-7-8):7-8. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
99. Mei A, Auerhahn C. Hypodermoclysis: maintaining hydration in the frail older adult. Ann Long Term Care. 2009;17(5 PG-28-30):28-30. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
100. Martin CM. Hypodermoclysis: renewed interest in an old technique. Consult Pharm. 2010;25(4 PG-204-6, 209):204-206,209. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
101. Hypodermoclysis: resurrecting an effective, simple and more humane intervention in the care of elderly residents. Can Nurs Home. 2001;12(1 PG-16-17):16-17. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
102. Barua P, Bhowmick BK. Hypodermoclysis--a victim of historical prejudice. Age Ageing. 2005;34(3 PG-215-217):215-217. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
103. Humphrey P. I.V. ROUNDS. Hypodermoclysis: An alternative to I.V. infusion therapy. Nursing (Lond). 2011;41(11 PG-16-17):16-17. *Exclusion reason:* Duplicate;
104. CORELLI F. Importance of the pyrogen in medical practice and in transfusions (prevention of reactions of transfusion, of hypodermoclysis, phlebotoclysis, intravenous calcium, etc). Policlin Sez Prat. 1950;57(11):345-347. *Exclusion reason:* Review, description or comment on subcutaneous hydration
105. Chattopadhyay I, Shandilya S, Sajjad K, Oomeer S. Improvement in Practice of Hypodermoclysis in Older Inpatients in a Community Hospital. Age Ageing. 2012;41(Journal Article PG-4-4):4. *Exclusion reason:* Wrong intervention;

106. B. K-K. Infusion therapy under ambulatory conditions - What homecare undertaking can achieve. J fur Anesth und Intensivbehandlung. 2004;11(3 PG-61-62):61-62. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
107. Pirrello RD, Ting Chen C, Thomas SH. Initial experiences with subcutaneous recombinant human hyaluronidase. J Palliat Med. 2007;10(4):861-864. *Exclusion reason:* Wrong intervention
108. Grez M, Perez-Cruz P, Rodriguez-Nunez A, Villouta F, Jaña C, Maldonado A, Bruera E. Is it possible for caregivers to administer subcutaneous hydration to patients with advanced cancer at home? Feasibility and perceptions. Journal of Clinical Oncology 2017;35(31):82. *Exclusion reason:* Cross-sectional study without adverse effects
109. Challiner Y, Hayward M, Al-Jubouri M, Julious S. Is subcutaneous rehydration as effective as intravenous in elderly stroke patients? Age Ageing. 1992;21 (Suppl(Journal Article PG-17)):17. *Exclusion reason:* Duplicate;
110. Takahashi T, Murayama R, Oe M, et al. Is Thrombus With Subcutaneous Edema Detected by Ultrasonography Related to Short Peripheral Catheter Failure? A Prospective Observational Study. J Infus Nurs. 2017;40(5 PG-313-322):313-322. *Exclusion reason:* Wrong intervention;
111. Burke MG. Journal club. Subcutaneous rehydration trial has promising results. Contemp Pediatr. 2010;27(1 PG-25-26):25-26. *Exclusion reason:* Not geriatric population;
112. Fernandez VY. Manejo de la vÃ-a subcutÃ;nea en cuidados paliativos. Metas Enferm. 2015;18(8):49-53. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
113. Dardaine V, Garrigue MA, Rapin CH, Constans T. Metabolic and hormonal changes induced by hypodermoclysis of glucose-saline solution in elderly patients. J Gerontol A Biol Sci Med Sci. 1995;50(6):M334-6. *Exclusion reason:* Wrong intervention;
114. Roberts MS, Lipschitz S, Campbell AJ, Wanwimolruk S, McQueen EG, McQueen M. Modeling of subcutaneous absorption kinetics of infusion solutions in the elderly using technetium. J Pharmacokinet Biopharm. 1997;25(1 PG-1-21):1-21. *Exclusion reason:* Wrong intervention;
115. K.C. J. Nutrition and hydration problems in palliative care patients. J Pharm Care Pain Symptom Control. 2000;8(1 PG-183-197):183-197. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
116. Berger EY. Nutrition by hypodermoclysis. J Am Geriatr Soc. 1984;32(3 PG-199-203):199-203. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
117. P&T Portfolio: Vitrase (hyaluronidase for injection). Drug Topics. <http://www.drugtopics.com/drugtopics/Miscellaneous/PT-Portfolio-Vitraser-hyaluronidase-for-injection/ArticleStandard/Article/detail/109917>. Published 2004. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
118. Bartlett W. Painless Hypodermoclysis. Ann Surg. 1921;73(2 PG-161-164):161-164. *Exclusion reason:* Not geriatric population;
119. DANOWSKI TS. Parenteral Fluids by Hypodermoclysis to Elderly Patients may be Hazardous. Jama-Journal Am Med Assoc. 1973;226(9 PG-1127-1127):1127. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
120. Dalal S, Hui D, Isabel T-V, et al. Parenteral hydration (PH) in advanced cancer patients: A multi-center, double-blind, placebo-controlled randomized trial. J Clin Oncol. 2012;30(15 PG-). *Exclusion reason:* Wrong intervention;
121. Reitschuler-Cross E, Arnold B. Parenteral hydration did not improve dehydration or quality of life in advanced cancer. Ann Intern Med. 2013;158(6 PG-10-10):JC10-JC10. *Exclusion reason:* Duplicate;
122. B. O, C. O, D. MD, P. UD, L. L. Parenteral hydration: Review of prevalence and rationale in hospice inpatients. Support Care Cancer. 2015;23(1 SUPPL. 1):S210. *Exclusion reason:* Cross-sectional study without adverse effects;
123. Mercadante S, Ferrera P, Girelli D, Casuccio A. Patients' and relatives' perceptions about intravenous and subcutaneous hydration. J Pain Symptom Manage. 2005;30(4 PG-354-358):354-358. *Exclusion reason:* Cross-sectional study without adverse effects;
124. M.J. C-M, M.L. V-A, J.D. R-P, Ruiz MM, Priego VM, J. C-G. Perceptions of health professionals on subcutaneous hydration in palliative care: A qualitative study. Palliat Med. 2015;30(6 PG-549-557):549-557. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
125. Cabanero-Martinez M, Velasco-Alvarez M, Ramos-Pichardo J, Ruiz Miralles ML, Priego Valladares M, Cabrero-Garcia J. Perceptions of health professionals on subcutaneous hydration in

- palliative care: A qualitative study. Palliat Med. 2016;30(6 PG-549-557):549-557. *Exclusion reason:* Duplicate;
126. GUGLIELMO B. Physiopathological reflections on hypodermoclysis. Experimental contribution. Minerva Nipiol. 1960;10(6)Suppl(Journal Article PG-238-245):238-245. *Exclusion reason:* Animal study;
127. DELIGNE P, HUGUENARD P. Postoperative hypodermoclysis with hyaluronidase. Anesth Anal. 1952;9(2 PG-268-288):268-288. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
128. Cunningham RDM, Darrow DC. Preparation of a solution of sodium bicarbonate and sodium chloride for hypodermoclysis. Am J Dis Child. 1931;41(6 PG-1347-1352):1347-1352. *Exclusion reason:* Review, description or comment on subcutaneous hydration
129. Zimmerman GW. Prescribing subcutaneous infusions. MMW Fortschr Med. 2013;155(17 PG-12):12. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
130. Wotton K, Crannitch K, Munt R. Prevalence, risk factors and strategies to prevent dehydration in older adults. Contemp Nurse A J Aust Nurs Prof. 2008;31(1 PG-44-56):44-56. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
131. Remington R, Hulman T. Progress in geriatrics hypodermoclysis to treat dehydration: a review of the evidence. Ann Long Term Care. 2009;17(1 PG-32-32):32. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
132. Soremekun OA, Shear ML, Patel S, et al. Rapid vascular glucose uptake via enzyme-assisted subcutaneous infusion: enzyme-assisted subcutaneous infusion access study. Am J Emerg Med. 2009;27(9 PG-1072-1080):1072-1080. *Exclusion reason:* Not geriatric population;
133. Regnard CFB, Viola R, Scott J. Re: comparison of concentrations of hyaluronidase... "Comparison of two different concentrations of hyaluronidase in patients receiving one-hour infusions of hypodermoclysis" (J Pain Symptom Manage 10(7): 505-509, 1995)... with commentary by Bruera E. J Pain Symptom Manag. 1996;12(3 PG-147-148):147-148. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
134. Cook L. Reduce hospitalizations with an Alternative Method of Hydration. J Am Med Dir Assoc. 2012;13(3 PG-17-17):B17-B17. *Exclusion reason:* Cross-sectional study without adverse effects;
135. Schen R. Response to: Hypodermoclysis - a victim of historical prejudice. Age Ageing. 2005;34(6 PG-656-657):656-657. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
136. Farrand S, Campbell AJ. Safe, simple subcutaneous fluid administration. Br J Hosp Med. 1996;55(11 PG-690-692):690-692. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
137. Zaloga GP, Pontes-Arruda A, Dardaine-Giraud V, Constans T, Clinimix Subcutaneous SG. Safety and Efficacy of Subcutaneous Parenteral Nutrition in Older Patients: A Prospective Randomized Multicenter Clinical Trial. 2016;(Journal Article PG-). *Exclusion reason:* Duplicate;
138. O'Hanlon S, Sheahan P, McEneaney R. Severe hemorrhage from a hypodermoclysis site. Am J Hosp Palliat Med. 2009;26(2):135-136. *Exclusion reason:* Not geriatric population
139. Kane EO. Simple device for rapid hypodermoclysis in combating shock. J Am Med Assoc. 1900;34(Journal Article PG-520-521):520-521. *Exclusion reason:* Review, description or comment on subcutaneous hydration
140. van Wigcheren PT, Onwuteaka-Philipsen BD, Pasman HRW, Ooms ME, Ribbe MW, van der Wal G. Starting artificial nutrition and hydration in patients with dementia in The Netherlands: frequencies, patient characteristics and decision-making process. Aging Clin Exp Res. 2007;19(1):26-33. *Exclusion reason:* Review, description or comment on subcutaneous hydration
141. NCT01116102. Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A). <https://clinicaltrials.gov/show/nct01116102>. 2010. *Exclusion reason:* Trial protocol
142. Templier F, Lagron MP. Subcutaneous administration of a therapeutic solution and/or a rehydration solution. Rev Infirm. 1998;(40)(40 PG-33-39):33-39. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
143. Fonzo-Christe C, Vukasovic C, Wasilewski-Rasca A, Bonnabry P. Subcutaneous administration of drugs in the elderly: survey of practice and systematic literature review. Palliat Med. 2005;19(3 PG-208-219):208-219. *Exclusion reason:* Review, description or comment on subcutaneous hydration;

144. Mansfield S, Monaghan H, Hall J. Subcutaneous fluid administration and site maintenance. Nurs Stand. 1998;13(12 PG-56, 59-62):56,59-62. *Exclusion reason:* Duplicate;
145. S. L., A.J. C., M.S. R., et al. Subcutaneous fluid administration in elderly subjects: Validation of an under-used technique. J Age Relat Disord. 1992;4(3 PG-9-12):9-12. *Exclusion reason:* Duplicate;
146. Lipschitz S, Campbell AJ, Roberts MS, et al. Subcutaneous fluid administration in elderly subjects: validation of an under-used technique. J Am Geriatr Soc. 1991;39(1):6-9. *Exclusion reason:* Duplicate;
147. Arthur AO, Goodloe JM, Thomas SH. Subcutaneous fluid administration: a potentially useful tool in prehospital care. Emerg Med Int. 2012;2012(Journal Article PG-904521):904521. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
148. Jain S, Mansfield B, Wilcox MH. Subcutaneous fluid administration--better than the intravenous approach? J Hosp Infect. 1999;41(4 PG-269-272):269-272. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
149. Schen RJ. Subcutaneous fluid infusion (hypodermoclysis) in palliative care. Med J Aust. 1993;158(11 PG-796):796. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
150. ASHBY M. Subcutaneous Fluid Infusion (Hypodermoclysis) in Palliative Care - Reply. Med J Aust. 1993;158(11 PG-796-796):796. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
151. M. A., B.G. F., E. K., S. L. Subcutaneous fluid infusion (hypodermoclysis) in palliative care: New role for an old trick 11]. Med J Aust. 1992;156(9 PG-669):669. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
152. Freeman M. Subcutaneous fluid infusions. Aust Fam Physician. 1991;20(9 PG-1357):1357. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
153. Dainty P, Elizabeth J. Subcutaneous fluids--a blast from the past or a rosy future? GM Midlife Beyond. 2009;39(3 PG-135-139):135-139. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
154. Paterson J. Subcutaneous hydration. Med J Aust. 1989;151(11-12 PG-727):727. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
155. Lopez JH, Reyes-Ortiz CA. Subcutaneous hydration by hypodermoclysis. Rev Clin Gerontol. 2010;20(2 PG-105-113):105-113. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
156. O'Keeffe S, Geoghegan M. Subcutaneous hydration in the elderly. Ir Med J. 2000;93(7 PG-197-198):197-198. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
157. Jones D, McGeorge S. Subcutaneous infusion. Nurs Older People. 2007;19(4):18. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
158. B. H. Subcutaneous infusion in exsiccosis: Is that not off-label use? MMW-Fortschritte der Medizin. 2014;156(6 PG-22):22. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
159. Zeeth J, Poltz S, Arras U. Subcutaneous infusion of fluids in geriatric care. Krankenpfl J. 2000;38(1-2 PG-16-19):16-19. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
160. L. P., D. B. Subcutaneous infusion or hypodermoclysis. Rev Geriatr. 1995;20(4 PG-237-239):237-239. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
161. Ferry M, Dardaine V, Constans T. Subcutaneous infusion or hypodermoclysis: a practical approach. J Am Geriatr Soc. 1999;47(1 PG-93-95):93-95. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
162. K. A. Subcutaneous infusion to prevent dehydration. MMW-Fortschritte der Medizin. 2008;150(23 PG-19):19. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
163. Hirsch B. Subcutaneous infusion to prevent dehydration: That is bodily harm! MMW-Fortschritte der Medizin. 2008;150(25):7. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
164. Subcutaneous infusions for geriatric patients. Rediscovery of an "old" technique. Z Gerontol Geriatr. 2012;45(7):665-672. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
165. J. Z. Subcutaneous infusions in geriatric patients. Internist Prax. 2009;49(4 PG-820-822):820-822. *Exclusion reason:* Review, description or comment on subcutaneous hydration;

166. Schen RJ, Singer-Edelstein M. Subcutaneous infusions in the elderly. J Am Geriatr Soc. 1981;29(12):583-585. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
167. O'Neill WM. Subcutaneous infusions--a medical last rite. Palliat Med. 1994;8(2 PG-91-93):91-93. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
168. Cheng K-C, Huang P-T, Liu C-S, Lin W-Y. Subcutaneous injection-induced cellulites. Biomedicine-Taiwan. 2017;7(2):43-45. *Exclusion reason:* Wrong intervention
169. Dardaine V, Ferry M, Constans T. Subcutaneous perfusion of hypodermoclysis: a useful rehydration method in geriatrics. Presse Med. 1999;28(40 PG-2246-2250):2246-2250. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
170. J. S. Subcutaneous rehydration for efficient treatment of elderly people during heat-waves. Dtsch medizinische Wochenschrift. 2015;140(11):827-830. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
171. Hernandez PB, Lopez LC, Garcia RM. Subcutaneous route. Usefulness in symptom control of terminally ill patients. MEDIFAM. 2002;12(2):104-110. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
172. Subcutaneous versus intravenous rehydration therapy in older patients. Dtsch Med Wochenschr. 1997;122(49):1540-1541. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
173. Suggestions for Hypodermoclyses And Intravenous Procedures. Am J Nurs. 1934;34(10):957-960. *Exclusion reason:* Review, description or comment on subcutaneous hydration
174. Novak F, Kralova P, Meisnerova E. SUN-P201: Comparison of Catheter-Related Complications with Hickman™ Catheters, Subcutaneous Ports and Peripherally Inserted Central Catheters in patients with Intestinal Failure Receiving Home Parenteral Nutrition. Clin Nutr. 2016;35:S119-S119. *Exclusion reason:* Wrong intervention
175. Saca ML, Feng A. Symptomatic hyponatraemia in home-based palliative care patients treated with subcutaneous infusions: case reports. Eur J Palliat Care. 2018;25(2):78-81. *Exclusion reason:* Case report without adverse effects;
176. N.I. C. Taking care of the terminally ill cancer patient: Management of gastrointestinal symptoms in patients with advanced cancer. Ann Oncol. 2004;15(Web Page PG-). *Exclusion reason:* Review, description or comment on subcutaneous hydration;
177. Connolly S, Korzempa H, Harb G, Lebel F, Syltevik C. Techniques for hyaluronidase-facilitated subcutaneous fluid administration with recombinant human hyaluronidase: the increased flow utilizing subcutaneously enabled administration technique (INFUSE AT) study. J Infus Nurs. 2011;34(5 PG-300-307):300-307. *Exclusion reason:* Not geriatric population;
178. Dardaine-Giraud V. Techniques of and indications for subcutaneous injections in geriatrics. La Rev Med interne. 2004;25 Suppl 4(Journal Article PG-S353-4):S353-4. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
179. G. D. Testing of the efficacy of hypodermoclysis as a treatment of Asiatic cholera during the 1886 epidemic in Venice. Riv Ital della Med di Lab. 2009;5(3 PG-227-232):227-232. *Exclusion reason:* Not geriatric population;
180. Donnelly M. The benefits of hypodermoclysis. Nurs Stand. 13(52 PG-44-45):44-45. *Exclusion reason:* Duplicate;
181. HECHTER O, DOPKEEN SK, YUDELL MH. The clinical use of hyaluronidase in hypodermoclysis. J Pediatr. 1947;30(6 PG-645-656):645-656. *Exclusion reason:* Not geriatric population
182. ABBOTT WE, LEVEY S, FOREMAN RC, KRIEGER H, HOLDEN WD. The danger of administering parenteral fluids by hypodermoclysis. Surgery. 1952;32(2):305-315. *Exclusion reason:* Wrong intervention;
183. Israels S. The Dangerous Hypodermoclysis. Can Med Assoc J. 1959;80(5 PG-395):395. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
184. Holman GH. The Dangerous Hypodermoclysis. Can Med Assoc J. 1959;80(4):313-314. *Exclusion reason:* Review, description or comment on subcutaneous hydration
185. Caron AM. The Development of a Clinical Decision Tool to Improve the Utilization of Hypodermoclysis in Long-Term Care Elders. Nurs Res. 2015;64(2 PG-38-40):E38-E40. *Exclusion reason:* Review, description or comment on subcutaneous hydration;

186. Di Giulio P, Finetti S, Giunco F, et al. The Impact of Nursing Homes Staff Education on End-of-Life Care in Residents With Advanced Dementia: A Quality Improvement Study. *Journal of Pain and Symptom Management* 2019;57(1):93-99. *Exclusion reason:* Cross-sectional study without adverse effects
187. Fainsinger R, Bruera E. The management of dehydration in terminally ill patients. *J Palliat Care*. 1994;10(3 PG-55-59):55-59. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
188. Keirle B, Taurand S, Cliquenois M. The subcutaneous approach. Its use in geriatric nursing. *Soins G rontologie*. 1996;3(3):19-22. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
189. V. D, M. F, T. C. The technical aspects of hypodermoclysis. *Rev Med Tours*. 1994;28(10 PG-347-349):347-349. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
190. Claisse L, Grosshans C, Passadori Y. The use of hypodermoclysis in palliative care. *Eur J Palliat Care*. 2005;12(6 PG-243-246):243-246. *Exclusion reason:* Cross-sectional study without adverse effects;
191. Dolamore MJ. The use of hypodermoclysis without hyaluronidase...Thomas DR, Cote TR, Lawthorne L, Levenson SA, et al. Understanding clinical dehydration and its treatment. *J Am Med Dir Assoc* 2008;9:292-301. *J Am Med Dir Assoc*. 2009;10(1 PG-75-75):75. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
192. I.D. K, I.U. S, A.D. W. The use of subcutaneous fluids in elderly patients. *Rev Clin Gerontol*. 1996;6(1 PG-115-116):115-116. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
193. Mansfield S, Monaghan H, Hall J. Tissue viability supplement. Subcutaneous fluid administration and site maintenance. *Nurs Stand*. 13(12 PG-56-62):56-62. *Exclusion reason:* Review, description or comment on subcutaneous hydration
194. Bruera E, MacDonald N, Loprinzi CL. To hydrate or not to hydrate: how should it be? *J Clin Oncol*. 2003;21(9 PG-84S-6S):84S-6S. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
195. Bausewein C. Under what conditions is subcutaneous administration of fluid indicated. *Internist (Berl)*. 2007;48(4 PG-439-441):439-441. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
196. Kobal Straus K. Uporaba hipodermoklize pri zdravstveni obravnavi uporabnikov institucionalnega varstva starejših. *Obz Zdr Nege*. 2014;48(1 PG-58-65):58-65. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
197. Kobal Straus K. Uporaba hipodermoklize pri zdravstveni obravnavi uporabnikov institucionalnega varstva starejših. *Obz Zdr Nege*. 2014;48(1 PG-58-65):58-65. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
198. OTAIZA E, MUNOZ F. Use of hyaluronidase in rapid hypodermoclysis. *Rev Bras Cir*. 1955;29(6 PG-501-511):501-511. *Exclusion reason:* Not geriatric population;
199. A. G, V. D-G, M. L, T. C. Use of hypodermoclysis in community dwelling elderly patients aged over 70 years: A survey near French general practitioners in the Centre region. *Rev Geriatr*. 2007;32(5 PG-333-342):333-342. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
200. Garrett D. Use of hypodermoclysis to manage dehydration. How can subcutaneous fluids be used in the care of older people who are dehydrated? *Nurs Older People*. 2013;25(4):12. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
201. De JE, R. M, A. D, A. E, Ma CA, C. R. Usefulness of hypodermoclysis for hydration of elderly patient. *Rev Multidiscip Gerontol*. 2007;17(1 PG-21-26):21-26. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
202. Using subcutaneous fluids in end-of-life care. *Nurs Times*. 2014;110(40):12-14. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
203. Barton A, Fuller R, Dudley N. Using subcutaneous fluids to rehydrate older people: current practices and future challenges. *QJM*. 2004;97(11):765-768. *Exclusion reason:* Review, description or comment on subcutaneous hydration;
204. Wood H, Trueman, G.; Culp, K.; Locke, J.; Lindes, V. A.; Holmes, A. M.; Dressler, N.; Acheson, D.; Edwards, L. L.; Curry N. What has been your experience with hypodermoclysis? What have

- been the burdens and benefits to your clients for whom it was used? J Gerontol Nurs. 2000;26(5 PG-48-50):48-50. *Exclusion reason:* Duplicate;
205. Roth D. When drinking is no longer sufficient: Subcutaneous fluid substitution in conditions of dehydration in geriatrics. Dtsch Apotheker Zeitung. 2016;156(25):82783. *Exclusion reason:* Review, description or comment on subcutaneous hydration
206. Arnheim K. With subcutaneous infusions for control of exsiccation. Preventing dehydration in elderly patients. MMW Fortschr Med. 2008;150(23 PG-19):19. *Exclusion reason:* Duplicate;
207. Wood H, Trueman G, Culp K, et al. Your turn. What has been your experience with hypodermoclysis? What have been the burdens and benefits to your clients for whom it was used? J Gerontol Nurs. 2000;26(5 PG-48-50):48-50. *Exclusion reason:* Duplicate;



**Table 1 Characteristics of included RCT studies (a landscape copy of Table 1)**

Study & year Country Language	Study design	Sample size	Setting	Patient population characteristics	Intervention details	Comparator details	Duration of intervention /comparator	Numbers of infusions	Funding sources of trials
<b>Delamaire 1992</b> <sup>25</sup> France French	RCT – Open label*	30	No description of setting	Geriatric patients Described as elderly patients. No information on participants hydration status. Mean age: 83 years No information on sex	SC infusion. (no further description)	IV infusion. (no further description)	Mean: 7 days, SD: No data	105 in each group† (7 infusions per participant¶)	No data
<b>Challiner 1994</b> <sup>24</sup> United Kingdom English	RCT – Open label*	34	Hospital, Elderly Care Unit	Geriatric patients with acute stroke. Dehydrated (mean s-osmolality 296 mOsm/kg baseline) Mean age 83.5 years Male: 23, Female: 11	SC infusion. Two liters of fluid per 24 hours delivered through a 19 G butterfly	IV infusion. Two liters of fluid per 24 hours delivered through an IV access (no further information)	48 hours (predetermined)	68 in each group‡ (4 infusions per participant¶)	No data
<b>O’Keeffe 1996</b> <sup>28</sup> United Kingdom English	RCT – Open Label*	60	Hospital, acute geriatric unit.	Geriatric patient with cognitive impairment. Mild dehydration or poor oral intake (mean s-urea 28 mg/dl, mean s-creatinine 1.2 mg/dl at baseline) Mean age 82.5 years Male: 23, Female: 37	SC infusion. Up to 2 liters of fluid per 24 hours. 21 G butterfly needle in infraclavicular, scapular, abdominal or thigh areas	IV infusion. Up to two liters of fluid per 24 hours. 18-20 G cannula in forearm veins	48 hours (predetermined)	90 in each group§ (3 infusions per participant¶)	No data
<b>Slesak 2003</b> <sup>29</sup> Germany English	RCT – Open label	96	Hospital, geriatric wards in the Geriatric Department	Geriatric patients with signs of mild to moderate dehydration (median s-creatinine 1.0 mg/dl; 88) Mean age 85.3 years Male: 29, Female: 67	SC infusion. Up to 1.5 liters of fluid per 24 hours. Butterfly needle 21 G, in SC tissue of thigh, abdomen, or thorax.	IV infusion. Up to 1.5 liters of fluid per 24 hours. Peripheral IV catheters 18-22 G	Median 6 days range 1-36 days	288 in each group† (6 infusions per participant¶)	No external funding
<b>Luk 2008</b> <sup>27</sup> China English	RCT – Open label	57	Hospital	Geriatric patient with mild to moderate dehydration. (mean urea/creatinine ratio 0.11 (iv group) 0.14 (sc group) at baseline) Mean age: 85 years Male: 34, Female: 23	SC infusion. Up to 1.5 liters of fluid per 24 hours. 22 G butterfly needle in the sc tissue of the lateral abdomen.	IV infusion. Up to 1.5 liters of fluid per 24 hours. 18-22 G angiocaths.	Up to 3 days (Predetermined)	Unable to calculate.	Tung Wah Group Hospitals Research Fund
<b>Noriega 2014</b> <sup>30</sup> Spain Spanish	RCT – Open label*	70	Hospital, Acute Geriatrics unit	Geriatric patients, dehydrated (mean s-osmolality 327 mOsm/kg, mean s-urea 108 mg/dl, mean s-creatinine 1.9 mg/dl at baseline) Mean age: 85.4 years Male: 35, Female: 32	SC infusion. Up to 1.5 liters of fluid per 24 hours. Butterfly needle 21-25 G, in SC tissue of thigh, abdomen or scapular.	IV infusion. Up to 1.5 liters of fluid per 24 hours. Peripheral IV catheters 20-24 G in forearm or hand.	3 days, (Predetermined)	102 in SC group, 99 in IV group† (3 infusions per participant¶)	No external funding
<b>Esmeray 2018</b> <sup>26</sup> Turkey English	RCT cross-over – open label*	30	Long-term care. “Private long-stay geriatric care unit”	Geriatric patients with dementia. 60% were dependent for support for fluid intake. Mild/moderate dehydrated or risk of dehydration. No further information on participants hydration status. Mean age: 82 years Male: 3, Female: 27	SC infusion. 21–23 G butterfly needle	IV infusion. (No further information described in the paper)	Three SC infusions and three IV infusion. No data on how long many days this took.	90 in each group. (6 infusions per participant¶)	No data

\* No description of blinding / concealment

† Calculated based on number of participants per group x mean duration of intervention.

‡ Calculated based on number of participants per group x two infusion per day x two days of infusions.

§ Number of infusions calculated by number of participants x 1.5 per day per group.

¶ Calculated based on number of infusions divided by number of participants

Abbreviations: RCT: Randomized controlled trial, SC: Subcutaneous, IV: Intravenous, G: Gauge

# Supplementary Table S1. Outcomes of included RCT with information on method of measuring, ascertainment and individual Overall Risk of Bias

	Adverse effects			Death			Catheter insertion time		
Study & year Country	Method of measuring the outcome	Methods of ascertainment	Overall RoB 2*	Method of measuring the outcome	Methods of ascertainment	Overall RoB 2†	Method of measuring the outcome	Methods of ascertainment	Overall RoB 2‡
<b>Delamaire 1992</b> France	No description of which adverse effects were observed	No information	—	No description	No information	!			
<b>Challiner 1994</b> United Kingdom	No description of which adverse effects were observed.	No information	!	No description	No information	+			
<b>O'Keeffe 1996</b> United Kingdom	No description of which adverse effects were observed.	Assessed by nursing staff.	!	No description	No information	+			
<b>Slesak 2003</b> Germany	Clear description of which adverse effects were observed.	Assessed by nursing staff and doctors.	!	No description	No information	+	Measured in minutes. No further description.	No information	!
<b>Luk 2008</b> China	Clear description of which adverse effects were observed.	No information	—						
<b>Noriega 2014</b> Spain	Insufficient description of which adverse effects were observed.	Study assessor.	!	No description	No information	!			
<b>Esmeray 2018</b> Turkey	Insufficient description of which adverse effects were observed.	Nurse from a different institute	—	No description	No information	!	Described as time spend for catheter insertion in minutes. No further description.	No information	!

Overall RoB 2: Cochrane Risk of Bias 2 overall risk-of-bias judgement for the outcome.<sup>15</sup>









\* For judgement of the individual domains see Supplementary Text 4.1. For answer to signiling questions see Supplementary Text 4.7.

† For judgement of the individual domains see Supplementary Text 4.2. For answer to signiling questions see Supplementary Text 4.8.

‡ For judgement of the individual domains see Supplementary Text 4.3. For answer to signiling questions see Supplementary Text 4.9.

Supplementary Table S1 continues on next page

## Supplementary Table S1 continue

	Osmolality			Volume of fluid infused			Agitation		
Study & year Country	Method of measuring the outcome	Methods of ascertainment	Overall RoB 2§	Method of measuring the outcome	Methods of ascertainment	Overall RoB 2¶	Method of measuring the outcome	Methods of ascertainment	Overall RoB 2**
Delamaire 1992 France									
Challiner 1994 United Kingdom	mOsm/kg, Freezing point measurement	Blood samples							
O'Keeffe 1996 United Kingdom				ml of fluid infused over 48 hours	Assessed by nursing staff		Presence yes or no	Doctors using Modified Cohen-Mansfield Agitation inventory	
Luk 2008 China									
Slesak 2003 Germany				ml of fluid infused per day	No information				
Noriega 2014 Spain	mOsm/kg	Blood samples		ml of fluid infused per day	Assessed daily by researchers		Presence yes or no	Need for physical / pharmacological restraint. No information on who assessed this.	
Esmeray 2018 Turkey							Presence yes or no	Described as presence of agitation. Assessed by a nurse.	

Overall RoB 2: Cochrane Risk of Bias 2 overall risk-of-bias judgement for the outcome.<sup>15</sup>

§ For judgement of the individual domains see Supplementary Text 4.4. For answer to signiling questions see Supplementary Text 4.10

¶ For judgement of the individual domains see Supplementary Text 4.5. For answer to signiling questions see Supplementary Text 4.11.

\*\* For judgement of the individual domains see Supplementary Text 4.6. For answer to signiling questions see Supplementary Text 4.12.

## Supplementary Text S3. Extracted study characteristics

### 3.1 Randomized studies

Challiner 1994 (24)

#### Methods

**Publication type:** Journal article

**Study design:** Randomized controlled trial - Open label

**Country of study:** England

**Language of publication:** English

**Year of study:** No data

**Source of funding:** No data

**Aim of study:** Efficacy of hypodermoclysis ("The aim of our study was to find out if subcutaneous fluids are effective in restoring hydration in elderly stroke patients when used in routine clinical practice. Serum osmolality was chosen as the biochemical marker of hydration.")

**Aim of intervention:** Predetermined volume ("Patients were randomly allocated to receive 2 litres of isotonic dextrose- saline solution (each litre contains 30 mmol of sodium chloride and 40 g of glucose) per 24 hours via the subcutaneous or the intravenous routes.")

**Sample size calculation:** Yes, based on serum osmolality

#### Participants

**Recruitment:** Consecutive patients from Elderly care unit

**Inclusion/exclusion criteria:** Inclusion: Unable to take oral fluids because of impaired conscious level or dysphagia. Exclusion: acute myocardial infarction, any condition for which the study fluid regime would be inappropriate, unable to give consent.

**Type of patient:** Geriatric patients with acute stroke. Dehydrated (mean s-osmolality 296 mOsm/kg baseline). ("Thirty-four acute stroke patients admitted consecutively to the Elderly Care Unit and unable to take oral fluids because of impaired conscious level and/or dysphagia.")

**Age:** SC: Mean: 82.8, range: 69-93, IV: Mean: 84.2, range: 71-95

**Setting:** Hospital ("Elderly Care Unit")

**Sex:** Male: 23, Female: 11

**Number of participants:** SC: 17, IV: 17

#### Interventions

Two liters of fluid per 24 hours.

**Intervention:** Subcutaneous hydration ("Subcutaneous fluids were delivered through a 19 gauge 'butterfly' cannula sited by a nurse on the trunk, axillary, scapular or thigh areas.")

**Comparator:** Intravenous hydration (No further description in the paper)

**Fluid type infused:** A combination of NaCl and dextrose

**Duration of intervention:** 48 hours (as per protocol)

**Number of infusions:** 68 per group\*\*

**Infusion site duration:** 48 hours

**Use of hyaluronidase:** Hyaluronidase when necessary ("As far as possible, medical and nursing staff ensured the fluids ran to time. Hyaluronidase was not used routinely but if the subcutaneous infusion ran behind time, 1,500 units of hyaluronidase were added to each litre bag of fluid.")

#### Outcomes

##### Adverse effects

**Outcome definition:** No list of adverse effects observed for. ("Any complications of the fluid therapy were noted.")

**How was the outcome assessed:** No data

##### Serum Osmolality

**Outcome definition:** Clearly defined

**Unit of measurement:** mOsm/kg. Reported as mean and standard deviation.

**How was the outcome assessed:** Blood sample analysis "Osmolality was measured using the Osmomat 030 (Clandon, UK)."

Baseline data was potentially relevantly different (299 mOsm/kg in SC group vs 293 mOsm/kg in IV group). In the paper they perform an analysis of covariance to allow for

	the difference in the baseline values. The data included in our meta-analysis is adjusted based on this analysis of covariance.
	<b><u>Death</u></b>
	<b>Outcome definition:</b> Clearly defined
	<b>How was the outcome assessed:</b> Death was not listed as a secondary outcome, but only listed as a reason for lost to follow up.
<b>Notes</b>	**Calculated based on number of participants per group x two infusion per day x 2 days of infusions. Unable to find active email of corresponding author.
Delamaire 1992 (25)	
<b>Methods</b>	<b>Publication type:</b> Abstract <b>Study design:</b> Randomized controlled trial - Open label <b>Country of study:</b> France <b>Language of publication:</b> French <b>Year of study:</b> No data <b>Source of funding:</b> No data <b>Aim of study:</b> Safety and efficacy of subcutaneous hydration. (Translation from French: “We compared these two techniques ( <i>SC and IV</i> ) in a randomized protocol by evaluating the feasibility, efficacy, safety and comfort of each”) <b>Aim of intervention:</b> Predetermined volume <b>Sample size calculation:</b> No data
<b>Participants</b>	<b>Recruitment:</b> No data <b>Inclusion/exclusion criteria:</b> Elderly patients unable to drink and / or dehydrated with renal impairment. <b>Type of patient:</b> Geriatric patients (Described as elderly patients, No information on participants hydration status) <b>Age:</b> Mean: 83, SD: No data <b>Setting:</b> No data <b>Sex:</b> No data <b>Number of participants:</b> 30
<b>Interventions</b>	<b>Intervention:</b> SC hydration (no further description) <b>Comparator:</b> IV hydration (no further description) <b>Fluid type infused:</b> A combination of NaCl and glucose (Translation from French: “2.5% NaCl + 4.5 g glucose”) <b>Duration of intervention:</b> Mean: 7 days, SD: No data <b>Number of infusions:</b> 105** per group <b>Infusion site duration:</b> No data <b>Use of hyaluronidase:</b> No data
<b>Outcomes</b>	<b><u>Adverse effects</u></b> <b>Outcome definition:</b> No list of adverse effects observed for. <b>How was the outcome assessed:</b> No data <b><u>Death</u></b> <b>How was the outcome assessed:</b> Death was not listed as an outcome in the paper.
<b>Notes</b>	**Calculated based on number of participants per group x mean duration of intervention Unable to find active email of corresponding author.
Esmeray 2018 (26)	
<b>Methods</b>	<b>Publication type:</b> Journal article <b>Study design:</b> Randomized controlled trial, crossover design - Open label <b>Country of study:</b> Turkey <b>Language of publication:</b> English <b>Year of study:</b> No data <b>Source of funding:</b> No data <b>Aim of study:</b> Safety and efficacy of subcutaneous hydration.

	<p><b>Aim of intervention:</b> Clinical indication (“For each administration, 1000 ml of 0.9% saline solution was used after prescription by doctor.”)</p> <p><b>Sample size calculation:</b> No data</p>
<b>Participants</b>	<p><b>Recruitment:</b> Patients were recruited from a private long-stay geriatric unit</p> <p><b>Inclusion/exclusion criteria:</b> Inclusion: Age &gt;65 years, daily fluid intake &lt;1000 ml, mild/moderate dehydrated or risk of dehydration, insufficient fluid intake. Exclusion: infection, acute dehydration, skin problems, IV medication or nutrition.</p> <p><b>Type of patient:</b> Geriatric patients (“Patients have Alzheimer’s or other types of dementia”, “60% were dependent for fluid intake support.”, No further information on participants hydration status)</p> <p><b>Age:</b> Mean: 81.97, SD: 8.81</p> <p><b>Setting:</b> Long-term care. (“private long-stay geriatric care unit”)</p> <p><b>Sex:</b> Male: 3, Female: 27</p> <p><b>Number of participants:</b> 30</p>
<b>Interventions</b>	<p><b>Intervention:</b> SC hydration (“21–23-gauge SC infusion butterfly needles.”)</p> <p><b>Comparator:</b> IV hydration (No further information described in the paper.)</p> <p><b>Fluid type infused:</b> NaCl</p> <p><b>Duration of intervention:</b> 3 SC infusions and 3 IV infusion. No data on how long many days this took.</p> <p><b>Number of infusions:</b> SC: 90, IV: 90</p> <p><b>Infusion site duration:</b> SC mean: 32 hours, IV mean: 15 hours</p> <p><b>Use of hyaluronidase:</b> No data</p>
<b>Outcomes</b>	<p><b><u>Adverse effects</u></b></p> <p><b>Outcome definition:</b> An insufficient description of adverse effects observed for. Study description of adverse effects observed for: “Administration monitoring form had several sections. One section collected data on edema, redness, bleeding and agitation that could develop during or after infusion practices.”</p> <p><b>How was the outcome assessed:</b> Nurse from a different institute.</p> <p><b><u>Time requirement of initiation:</u></b></p> <p><b>Outcome definition:</b> Clearly defined</p> <p><b>Unit of measurement:</b> Minutes</p> <p><b>How was the outcome assessed:</b> Study assessor</p>
<b>Notes</b>	<p>The study reports a very high frequency of patients with Redness and Bleeding (74% and 73% respectively) in the IV group. This high frequency is not mentioned in the discussion. Giving us reason to believe that it is either a reporting error or doublet entry for the same adverse effect. We have treated data as doublet entry and removed half of the events from all analysis.</p> <p>Author contacted by email for missing data but no reply.</p>
Luk 2008 (27)	
<b>Methods</b>	<p><b>Publication type:</b> Letter to the editor</p> <p><b>Study design:</b> Open Randomized controlled trial</p> <p><b>Country of study:</b> China</p> <p><b>Language of publication:</b> English</p> <p><b>Year of study:</b> 2002-2005</p> <p><b>Source of funding:</b> Tung Wah Group Hospitals Research Fund</p> <p><b>Aim of study:</b> Safety and efficacy of subcutaneous hydration.</p> <p><b>Aim of intervention:</b> Clinical indication</p> <p><b>Sample size calculation:</b> No data</p>
<b>Participants</b>	<p><b>Recruitment:</b> No data</p> <p><b>Inclusion/exclusion criteria:</b> Elderly patients age &gt;65 years</p> <p><b>Type of patient:</b> Geriatric patients with “mild to moderate dehydration requiring parenteral fluid supplementation or were unsafe to feed orally.”</p> <p><b>Age:</b> Mean: 85, Range: 66-104</p> <p><b>Setting:</b> Hospital</p>

	<p><b>Sex:</b> Male: 34, Female: 23</p> <p><b>Number of participants:</b> SC: 29, IV: 28</p>
<b>Interventions</b>	<p><b>Intervention:</b> SC hydration (“Hypodermoclysis was performed using a 22-gauge butterfly needle inserted into the subcutaneous tissue at a 30° angle to the skin surface.”, “The lateral low aspect of the abdomen was chosen as the site for infusion.”)</p> <p><b>Comparator:</b> IV hydration (“For intravenous hydration, Angiocaths with 18 to 22 gauges were employed”)</p> <p><b>Fluid type infused:</b> NaCl, A combination of NaCl and glucose</p> <p><b>Duration of intervention:</b> Up to 3 days</p> <p><b>Number of infusions:</b> Unable to calculate</p> <p><b>Infusion site duration:</b> No data</p> <p><b>Use of hyaluronidase:</b> No data</p>
<b>Outcomes</b>	<p><b><u>Adverse effects</u></b></p> <p><b>Outcome definition:</b> Clear description, with a list of adverse effects observed for and definitions of these.</p> <p>Study description of adverse effects observed for: “the infusion sites of both groups were carefully inspected for local complications such as redness, cellulitis, large localized collections of oedema (&gt;10- cm diameter), pain, and haematoma.”</p> <p><b>How was the outcome assessed:</b> No data</p>
<b>Notes</b>	Author contacted by email for missing data but no reply.
Noriega 2014 (30)	
<b>Methods</b>	<p><b>Publication type:</b> Journal article</p> <p><b>Study design:</b> Randomized controlled trial</p> <p><b>Country of study:</b> Spain</p> <p><b>Language of publication:</b> Spanish</p> <p><b>Year of study:</b> 2012-2013 §</p> <p><b>Source of funding:</b> No external funding §</p> <p><b>Aim of study:</b> Efficacy of subcutaneous hydration</p> <p><b>Aim of intervention:</b> Clinical indication (Translation from Spanish: “The intervention consisted of the administration of up to 1.5 l per day per route with the objective of rehydration via SC vs. IV.”)</p> <p><b>Sample size calculation:</b> Yes*</p>
<b>Participants</b>	<p><b>Recruitment:</b> All patients admitted to acute geriatric unit was assessed for eligibility.</p> <p><b>Inclusion/exclusion criteria:</b> Inclusion: Clinical dehydration based on biochemical markers, need for parenteral fluid.</p> <p>Exclusion: Hemodynamic unstable, need for more than 2 L of fluid per day.</p> <p><b>Type of patient:</b> Geriatric patients, dehydrated (mean s-osmolality 327 mOsm/kg, mean s-urea 108 mg/dl, mean s-creatinine 1.9 mg/dl at baseline).</p> <p><b>Age:</b> Mean: 85.4, SD: 7.6</p> <p><b>Setting:</b> Hospital, Unit of Acute Geriatrics at Hospital General de Granollers, Spain</p> <p><b>Sex:</b> Male: 35, Female: 32</p> <p><b>Number of participants:</b> 34 (SC), 33 (IV)</p>
<b>Interventions</b>	<p>Up to 1.5 liters of fluid per 24 hours.</p> <p><b>Intervention:</b> SC hydration (Translation from Spanish: “The sites authorized for subcutaneous infusion were the inner thighs, the lateral abdominal wall and the scapular region (supra and interscapular)”, “...21 to 25 gauge (G) gauge needle needles were used...”)</p> <p><b>Comparator:</b> IV hydration (Translation from Spanish: “The authorized sites for IV infusion were the back of the hand, forearm and elbow flexion, avoiding damaged and / or irradiated areas of the skin as much as possible. Abbocath® 20-24 G caliber catheters were used”)</p> <p><b>Fluid type infused:</b> NaCl, 5% dextrose, a combination of NaCl and dextrose</p> <p><b>Duration of intervention:</b> 3 days, Predetermined duration</p> <p><b>Number of infusions:</b> ** 102 in SC group, 99 in IV group</p>

<b>Outcomes</b>	<p><b>Infusion site duration:</b> No data, Numbers of catheters use: SC: <math>1.21 \pm 0.41</math>; IV: <math>1.48 \pm 0.62</math>.</p> <p><b>Use of hyaluronidase:</b> No use of hyaluronidase §</p> <p><b><u>Adverse effects</u></b></p> <p><b>Outcome definition:</b> An insufficient description of adverse effects observed for. Study description of adverse effects observed for: Translation from Spanish: “Daily observations were made by researchers...the presence of adverse effects (extravasation, edema and local infection), the need for replacement catheter...”</p> <p><b>How was the outcome assessed:</b> Study Assessor</p> <p><b><u>Serum osmolality</u></b></p> <p><b>Outcome definition:</b> Clearly defined</p> <p><b>Unit of measurement:</b> mOsm/kg</p> <p><b>How was the outcome assessed:</b> Blood sample analysis</p> <p><b><u>Urea</u></b></p> <p><b>Outcome definition:</b> Clearly defined</p> <p><b>Unit of measurement:</b> mg/dl</p> <p><b>How was the outcome assessed:</b> Blood sample analysis</p> <p><b><u>Creatinine</u></b></p> <p><b>Outcome definition:</b> Clearly defined</p> <p><b>Unit of measurement:</b> mg/dl</p> <p><b>How was the outcome assessed:</b> Blood sample analysis</p> <p><b><u>Death</u></b></p> <p><b>Outcome definition:</b> Clearly defined</p> <p><b>How was the outcome assessed:</b> Death was not listed as a secondary outcome, but only listed as a reason for lost to follow up.</p>
<b>Notes</b>	<p>*They describe a non-inferior intention but not a non-inferior sample size calculation.</p> <p>Further, we cannot reproduce the sample size calculation due to lack of variance on data.</p> <p>**Calculated based on number of participants per group x mean duration of intervention</p> <p>§Author able to supply some of the missing data.</p>
O’Keeffe 1996 (28)	
<b>Methods</b>	<p><b>Publication type:</b> Journal article</p> <p><b>Study design:</b> Randomized controlled trial</p> <p><b>Country of study:</b> UK</p> <p><b>Language of publication:</b> English</p> <p><b>Year of study:</b> No data</p> <p><b>Source of funding:</b> No data</p> <p><b>Aim of study:</b> Safety and Efficacy of hypodermoclysis (“The aim of this study was to compare the effectiveness and tolerance of the two methods of administering fluids in elderly patients with cognitive impairment”)</p> <p><b>Aim of intervention:</b> Clinical indication (“Up to 2 litres of fluid was permitted in any 24-hour period”)</p> <p><b>Sample size calculation:</b> Yes</p>
<b>Participants</b>	<p><b>Recruitment:</b> Patients admitted to an acute geriatric unit</p> <p><b>Inclusion/exclusion criteria:</b> Inclusion: Require parenteral fluids due to dehydration or poor intake and cognitive impairment. Exclusion: Require I.V. medication, more than 2L of fluid required per 24 hours, poor tissue perfusion.</p> <p><b>Type of patient:</b> Geriatric patient with cognitive impairment (Mini-Mental Status Examination score of <math>\leq 20</math>). Mild dehydration or poor oral intake (mean s-urea 28 mg/dl, mean s-creatinine 1.2 mg/dl at baseline)</p> <p><b>Age:</b> Mean: 82.5, SD: 6.52</p> <p><b>Setting:</b> Hospital, acute geriatric unit.</p> <p><b>Sex:</b> Male: 23, Female: 37</p> <p><b>Number of participants:</b> 60</p>
<b>Interventions</b>	Up to 2 liters of fluid per 24 hours.



	<p><b>Intervention:</b> SC (“Subcutaneous fluids were administered in the infraclavicular, scapular, abdominal or thigh areas through a 21-gauge ‘butterfly’ cannula sited by a doctor”)</p> <p><b>Comparator:</b> IV (“Intravenous fluid were administred through and 18-20-gauge cannula in the forearm veins”)</p> <p><b>Fluid type infused:</b> NaCl, 5% dextrose, a combination of NaCl and dextrose. These was acceptable fluids, no data on administered fluids.</p> <p><b>Duration of intervention:</b> 48 hours (predetermined)</p> <p><b>Number of infusions:</b> SC: 90, IV: 90**</p> <p><b>Use of hyaluronidase:</b> No use of hyaluronidase</p>
<b>Outcomes</b>	<p><u><b>Adverse effects</b></u></p> <p><b>Outcome definition:</b> No list of adverse effects observed for.</p> <p><b>How was the outcome assessed:</b> Nursing staff</p> <p><u><b>Agitation</b></u></p> <p><b>Outcome definition:</b> “Presence of agitated bahaviour (using a modification of the Cohen-Mansfield Agitation Inventory.)”</p> <p><b>How was the outcome assessed:</b> Nursing staff</p> <p><u><b>Death</b></u></p> <p><b>Outcome definition:</b> Cleary defined</p> <p><b>How was the outcome assessed:</b> Death was not listed as a secondary outcome, but only listes as a reason for lost to follow up.</p>
<b>Notes</b>	<p>One patient was switched to SC because of difficulties with venous access. This patient is excluded in the article but included in the meta-analysis as "Need of resetting of infusion needle".</p> <p>**Number of infusions calculated by number of participants x 1.5 per day (base on the volume of infused fluid) per group.</p> <p>Author contacted by email for missing data but no reply.</p>
Slesak 2003 (29)	
<b>Methods</b>	<p><b>Publication type:</b> Journal article</p> <p><b>Study design:</b> Randomized controlled trial</p> <p><b>Country of study:</b> Germany</p> <p><b>Language of publication:</b> English</p> <p><b>Year of study:</b> 2001-2002</p> <p><b>Source of funding:</b> No external funding. §</p> <p><b>Aim of study:</b> Safety and efficacy of hypodermoclysis, patient’s acceptance.</p> <p><b>Aim of intervention:</b> Clinical indication. Volume of fluid therapy depended on the medical necessity (maximum volume given was 1.5 l per day in both groups.)</p> <p><b>Sample size calculation:</b> Yes, based on patients, nurses and doctor’s assessment of score.</p>
<b>Participants</b>	<p><b>Recruitment:</b> Admitted to geriatric department</p> <p><b>Inclusion/exclusion criteria:</b> Inclusion: Receiving parenteral fluid. Exclusion: &gt;60 years of age, General edema, skin disease, fluid regime inappropriate, IV drug administration.</p> <p><b>Type of patient:</b> Geriatric patients, with signs of mild to moderate dehydration (median s-creatinine 1.0 mg/dl; 88). (“Patients aged 60 and older presenting with signs of mild to moderate dehydration needing parenteral fluids on admission or during their stay in the geriatric department were enrolled in the study.”)</p> <p><b>Age:</b> Mean: 85.3 years, SD: 6,7</p> <p><b>Setting:</b> Hospital, geriatric wards in the Geriatric Department</p> <p><b>Sex:</b> Male: 29, Female: 67</p> <p><b>Number of participants:</b> SC: 48, IV: 48</p>
<b>Interventions</b>	<p>Up to 1.5 liters of fluid per 24 hours.</p> <p><b>Intervention:</b> SC (“Nurses followed the hospital’s standard guidelines for SC infusions (butterfly 21 gauge (G)), in SC tissue of thigh, abdomen, or thorax.”)</p> <p><b>Comparator:</b> IV (“Doctors put in place peripheral IV catheters (size 22 G to 18 G”)</p>

	<p><b>Fluid type infused:</b> A combination of NaCl and glucose, Ringer lactate., “Fluids were given by bolus infusion of 500 mL within 2 to 6 hours. The amount and duration of fluid therapy depended on the medical necessity.”</p> <p><b>Duration of intervention:</b> SC: Median: 6, range 1;36 days. IV: Median: 6, range 1;32 days.</p> <p><b>Number of infusions:</b> SC: 288, IV: 288**</p> <p><b>Infusion site duration:</b> SC: median 2.0 range: 0.5;9, IV median: 2.8, range: 0.3-8.8 days</p> <p><b>Use of hyaluronidase:</b> Hyaluronidase used when deemed necessary</p>
<b>Outcomes</b>	<p><b><u>Adverse effects</u></b></p> <p><b>Outcome definition:</b> Clear description.</p> <p>Study description of adverse effects observed for: “Nursing staff and doctors thoroughly observed adverse reactions and wrote them down in a standardized form. Localized adverse effects were categorized into two groups: measuring more or less than 10 cm in diameter” Listed adverse effects: Acute cardiac failure, Hyponatremia, Large edema, Large erythema, Cellulitis, Large phlebitis, severe pain, Leakage/paravesal, Minor erythema, Minor edema, Slight pain, Minor hematoma, Cannula plugged, Minor phlebitis, Itching.</p> <p><b>How was the outcome assessed:</b> “Nursing staff and doctors thoroughly observed adverse reactions and wrote them down in a standardized form.”</p> <p><b><u>Time requirement of initiation</u></b></p> <p><b>Outcome definition:</b> Clearly defined</p> <p><b>Unit of measurement:</b> Minutes. Reported as median and range.</p> <p><b>How was the outcome assessed:</b> Study assessor</p> <p><b><u>Creatinine</u></b></p> <p><b>Outcome definition:</b> Clearly defined</p> <p><b>Unit of measurement:</b> mg/dl. Reported as median and quantile. Missing data on some patients. No reason listed.</p> <p><b>How was the outcome assessed:</b> Blood sample analysis</p> <p><b><u>Volume infused</u></b></p> <p><b>Outcome definition:</b> Clearly defined</p> <p><b>Unit of measurement:</b> ml per day***</p>
<b>Notes</b>	<p>**Calculated based on number of participants per group x mean duration of intervention.</p> <p>*** Reported as median and range. In meta-analysis data have been converted to mean and sd by median = mean and sd = range / 4</p> <p>§ Additional information requested and supplied from author.</p>

### 3.2 Non-randomized studies

Arinzon 2004 (33)

<b>Methods</b>	<p><b>Publication type:</b> Journal article</p> <p><b>Study design:</b> Cross sectional prospective</p> <p><b>Country of study:</b> No data</p> <p><b>Language of publication:</b> English</p> <p><b>Year of study:</b> 2001-2002</p> <p><b>Source of funding:</b> No data</p> <p><b>Aim of study:</b> Safety and efficacy of hypodermoclysis</p> <p><b>Aim of intervention:</b> Clinical indication</p> <p><b>Sample size calculation:</b> No data</p>
<b>Participants</b>	<p><b>Recruitment:</b> Patients in three long term wards</p> <p><b>Inclusion/exclusion criteria:</b> Received hypodermoclysis</p> <p><b>Type of patient:</b> Geriatric patients</p> <p><b>Age:</b> Mean: 78.2, SD: 7.2</p> <p><b>Setting:</b> Long-term care</p>

	<p><b>Sex:</b> Male: 6, Female: 51</p> <p><b>Number of participants:</b> 57</p>
<b>Interventions</b>	<p><b>Intervention:</b> Subcutaneous hydration</p> <p><b>Comparator:</b> None</p> <p><b>Fluid type infused:</b> NaCl + a combination of NaCl and dextrose</p> <p><b>Duration of intervention:</b> No data</p> <p><b>Number of infusions:</b> 180</p> <p><b>Infusion site duration:</b> No data</p> <p><b>Use of hyaluronidase:</b> No use of hyaluronidase</p>
<b>Outcomes</b>	<p><b><u>Adverse effects</u></b></p> <p><b>Outcome definition:</b> Clear description.</p> <p>Study description of adverse effects observed for: “The adverse effects of fluid administration were also evaluated. These included: local reactions (e.g. swelling, obstruction, redness or inflammation), complaints of discomfort or pain and fluid overload (such as signs of exacerbation of congestive heart failure).”</p> <p><b>How was the outcome assessed:</b> No data</p>
<b>Notes</b>	Unable to find active email of corresponding author.
Bigot 2013 (32)	
<b>Methods</b>	<p><b>Publication type:</b> Abstract</p> <p><b>Study design:</b> Cross sectional prospective</p> <p><b>Country of study:</b> France</p> <p><b>Language of publication:</b> English</p> <p><b>Year of study:</b> No data</p> <p><b>Source of funding:</b> No data</p> <p><b>Aim of study:</b> Safety of hypodermoclysis</p> <p><b>Aim of intervention:</b> No data</p> <p><b>Sample size calculation:</b> No data</p>
<b>Participants</b>	<p><b>Recruitment:</b> No data</p> <p><b>Inclusion/exclusion criteria:</b> No data</p> <p><b>Type of patient:</b> Geriatric patient</p> <p><b>Age:</b> No data</p> <p><b>Setting:</b> Hospital</p> <p><b>Sex:</b> No data</p> <p><b>Number of participants:</b> 115</p>
<b>Interventions</b>	<p><b>Intervention:</b> SC</p> <p><b>Comparator:</b> None</p> <p><b>Fluid type infused:</b> No data, Drugs was added to the infusion in 14.7% of cases.</p> <p><b>Duration of intervention:</b> No data</p> <p><b>Total number of infusions:</b> Unable to calculate total number of infusions.</p> <p><b>Infusion site duration:</b> No data</p> <p><b>Use of hyaluronidase:</b> No data</p>
<b>Outcomes</b>	<p><b><u>Adverse effects</u></b></p> <p><b>Outcome definition:</b> No list of adverse effects observed for.</p> <p><b>How was the outcome assessed:</b> No data</p>
<b>Notes</b>	Author contacted by email for missing data and possible full text article but no reply.
Bruera 1990 (44)	
<b>Methods</b>	<p><b>Publication type:</b> Journal article</p> <p><b>Study design:</b> Cross sectional retrospective</p> <p><b>Country of study:</b> Canada</p> <p><b>Language of publication:</b> English</p> <p><b>Year of study:</b> 1988</p> <p><b>Source of funding:</b> No external funding\$</p>

<b>Participants</b>	<b>Aim of study:</b> Safety of hypodermoclysis
	<b>Aim of intervention:</b> Clinical indication
	<b>Sample size calculation:</b> No data
	<b>Recruitment:</b> Consecutive patients admitted to palliative care unit
	<b>Inclusion/exclusion criteria:</b> Require parenteral hydration
	<b>Type of patient:</b> Terminal patients
	<b>Age:</b> Mean age: 62, SD: 14
	<b>Setting:</b> Hospital
	<b>Sex:</b> Male: 21, Female: 37
	<b>Number of participants:</b> 58
<b>Interventions</b>	<b>Intervention:</b> Subcutaneous hydration
	<b>Comparator:</b> None
	<b>Fluid type infused:</b> A combination of NaCl and dextrose, KCl was added to all infusions, mean daily dose of KCl was 25 ±8 mEq, Morphine and hydromorphone was added to some of the infusions.
	<b>Duration of intervention:</b> Mean: 14 days, SD 9
	<b>Number of infusions:</b> 812**
	<b>Infusion site duration:</b> Mean: 4, SD: 3
	<b>Use of hyaluronidase:</b> All interventions with hyaluronidase
	<b>Adverse effects</b>
<b>Outcomes</b>	<b>Outcome definition:</b> No list of adverse effects observed for.
	The paper does not describe adverse effects during infusion, but only reason for discontinuation.
	<b>How was the outcome assessed:</b> No data
	§ Additional information requested and supplied from author.
<b>Notes</b>	**Calculated based on number of participants x mean duration of intervention

Bruera 1996 (43)

<b>Methods</b>	<b>Publication type:</b> Journal Article
	<b>Study design:</b> Cross sectional retrospective
	<b>Country of study:</b> Canada
	<b>Language of publication:</b> English
	<b>Year of study:</b> 1991 and 1993
	<b>Source of funding:</b> No external funding§
	<b>Aim of study:</b> Volume of fluid infused
	<b>Aim of intervention:</b> Clinical indication
	<b>Sample size calculation:</b> No data
	<b>Recruitment:</b> Consecutive patients
<b>Participants</b>	<b>Inclusion/exclusion criteria:</b> All patients receiving SC hydration
	<b>Type of patient:</b> Terminal patients
	<b>Age:</b> Mean: 63, SD 14
	<b>Setting:</b> Hospital
	<b>Sex:</b> Male: 85, Female: 118
	<b>Number of participants:</b> 203
<b>Interventions</b>	<b>Intervention:</b> Subcutaneous hydration
	<b>Comparator:</b> None*
	<b>Fluid type infused:</b> NaCl, A combination of NaCl and dextrose
	<b>Duration of intervention:</b> Mean: 12, SD: 8
	<b>Number of infusions:</b> 2436**
	<b>Infusion site duration:</b> Mean: 5.2, SD: 2.8
	<b>Use of hyaluronidase:</b> All interventions with hyaluronidase
	<b>Adverse effects</b>
<b>Outcomes</b>	<b>Outcome definition:</b> No list of adverse effects observed for.

The study describes 62 patients needed to have the rate of infusions decreased because of site problems or the development of complete renal failure, but no further description. Data from this study is therefore not included in data syntheses.

**How was the outcome assessed:** Chart review

## Notes

Only patients from the Palliative care unit is included in this review as the authors could not determine if there was any complication in the patients in the cancer unit.

\*This study is a case-control comparing the volume of infused fluid between SC and IV.

We have only included data from the SC group, as data on adverse effects was not available in the IV group.

§ Additional information requested and supplied from author.

\*\*Calculated based on number of participants x mean duration of intervention

Centeno 1999 (35)

## Methods

**Publication type:** Letter to the editor

**Study design:** Cross sectional prospective

**Country of study:** Canada

**Language of publication:** English

**Year of study:** 1998

**Source of funding:** No external funding§

**Aim of study:** Efficacy without hyaluronidase

**Aim of intervention:** Clinical indication

**Sample size calculation:** No data

## Participants

**Recruitment:** Consecutive patients admitted

**Inclusion/exclusion criteria:** Requiring hypodermoclysis

**Type of patient:** Terminal patients

**Age:** No data

**Setting:** Palliative care unit

**Sex:** No data

**Number of participants:** 24

## Interventions

**Intervention:** Subcutaneous hydration

**Comparator:** None

**Fluid type infused:** NaCl + a combination of NaCl and dextrose

**Duration of intervention:** Mean: 12 days, SD: 9

**Number of infusions:** 288\*\*

**Infusion site duration:** Mean: 3.3 days, SD: 5.4

**Use of hyaluronidase:** Hyaluronidase was use when deemed necessary. In 2/26 patients was it necessary to add hyaluronidase

## Outcomes

**Adverse effects**

**Outcome definition:** No list of adverse effects observed for.

**How was the outcome assessed:** No data

## Notes

\*\*Calculated based on number of participants x mean duration of intervention

§ Additional information requested and supplied from author.

Author able to supply some of the missing data.

Chalany 2015 (45)

## Methods

**Publication type:** Journal article

**Study design:** Cross sectional

**Country of study:** Czech Republic

**Language of publication:** Czech

**Year of study:** 2012-2012

**Source of funding:** No data

**Aim of study:** Safety of hypodermoclysis

<b>Participants</b>	<b>Aim of intervention:</b> Clinical indication
	<b>Sample size calculation:</b> N/A
<b>Interventions</b>	<b>Recruitment:</b> Patients was recruited from a nursing home for patients with terminal dementia
	<b>Inclusion/exclusion criteria:</b> Terminal dementia
	<b>Type of patient:</b> Terminal dementia
	<b>Age:</b> Mean age: 78.8, SD 6.4
	<b>Setting:</b> Geronto-psychiatric ward
	<b>Sex:</b> Male: 0, Female: 60
<b>Interventions</b>	<b>Number of participants:</b> 60
	<b>Intervention:</b> Subcutaneous hydration
	<b>Comparator:</b> None
	<b>Fluid type infused:</b> NaCl
	<b>Duration of intervention:</b> Mean: 4.2 days, SD 2.6
	<b>Number of infusions:</b> 252**
<b>Outcomes</b>	<b>Infusion site duration:</b> No data
	<b>Use of hyaluronidase:</b> No data
	<b>Adverse effects</b>
	<b>Outcome definition:</b> Clear description.
	Study description of adverse effects observed for: Translation from Czech: “Complication of subcutaneous rehydration were defined as the presence of local edema, local redness or symptoms of local infection at the site of needle puncture...”
	<b>How was the outcome assessed:</b> Nurse chart
<b>Notes</b>	**Calculated based on number of participants x mean duration of intervention
	Unable to find active email of corresponding author.

Dasgupta 2000 (31)

<b>Methods</b>	<b>Publication type:</b> Journal article
	<b>Study design:</b> Prospective Case-control
<b>Methods</b>	<b>Country of study:</b> Canada
	<b>Language of publication:</b> English
	<b>Year of study:</b> 1998
	<b>Source of funding:</b> No external funding§
	<b>Aim of study:</b> Safety and efficacy of subcutaneous hydration
	<b>Aim of intervention:</b> Clinical indication
<b>Participants</b>	<b>Sample size calculation:</b> No data
	<b>Recruitment:</b> All patients matching inclusion during the study period.
	<b>Inclusion/exclusion criteria:</b> Inclusion: Received either SC or IV hydration.
	Exclusion: Received SC medication, only one SC infusion, received blood products, life-threatening conditions.
	<b>Type of patient:</b> Geriatric and cancer patients
	<b>Age:</b> Mean: 83.7, SD: 10.5
<b>Interventions</b>	<b>Setting:</b> Long-term care
	<b>Sex:</b> Male: 15, Female: 40
	<b>Number of participants:</b> 55
	<b>Intervention:</b> SC hydration
	<b>Comparator:</b> IV hydration
	<b>Fluid type infused:</b> A combination of NaCl and dextrose
<b>Interventions</b>	<b>Duration of intervention:</b> Mean: SC: 11.4, IV: 5.3, SD: SC: 9.8, IV: 2.6
	<b>Number of infusions:</b> 807 in SC group, 106 in IV group
	<b>Infusion site duration:</b> No data
	<b>Use of hyaluronidase:</b> No use of hyaluronidase§
<b>Outcomes</b>	<b>Adverse effects</b>

**Outcome definition:** Clear description.

Study description of adverse effects observed for: “Adverse effects of fluid administration were evaluated. These included local catheter reactions (e.g., redness, obstruction, or swelling), patient discomfort (e.g., attempts by the resident to remove the catheter), and possible episodes of fluid overload (e.g., symptoms suggesting congestive heart failure for which furosemide therapy was prescribed, or for which the fluid infusion rate was decreased).”

**How was the outcome assessed:** Study assessor

**Notes**

§ Additional information requested and supplied from author.

Fainsinger 1994 (36)

**Methods**

**Publication type:** Journal Article

**Study design:** Cross sectional Prospective

**Country of study:** Canada

**Language of publication:** English

**Year of study:** 1990-1991

**Source of funding:** No data

**Aim of study:** To assess indication for SC

**Aim of intervention:** Clinical indication

**Sample size calculation:** N/A

**Participants**

**Recruitment:** Consecutive patients who died while admitted.

**Inclusion/exclusion criteria:** Transferred or discharged were excluded.

**Type of patient:** Terminal patients

**Age:** Mean age: 66, SD: 13

**Setting:** Palliative care unit

**Sex:** Male: 37, Female: 32

**Number of participants:** 69 patients received SC hydration

**Interventions**

**Intervention:** SC

**Comparator:** None

**Fluid type infused:** NaCl, A combination of NaCl and dextrose

**Duration of intervention:** Mean: 14 days, SD:18

**Number of infusions:** 966\*\*

**Infusion site duration:** Mean: 4.7 days, SD: 5.4 days.

**Use of hyaluronidase:** All interventions with hyaluronidase

**Outcomes**

**Adverse effects**

**Outcome definition:** No list of adverse effects observed for.

**How was the outcome assessed:** Study assessor

**Notes**

\*\*Calculated based on number of participants x mean duration of intervention

Author contacted by email for missing data but no reply.

Hussain 1996 (46)

**Methods**

**Publication type:** Journal article

**Study design:** Cross sectional retrospective

**Country of study:** USA

**Language of publication:** English

**Year of study:** 1992-1994

**Source of funding:** No data

**Aim of study:** Safety and efficacy of hypodermoclysis

**Aim of intervention:** Clinical indication

**Sample size calculation:** No data

**Participants**

**Recruitment:** All patients that received SC during the observation period

**Inclusion/exclusion criteria:** Received SC

	<p><b>Type of patient:</b> Geriatric patients</p> <p><b>Age:</b> Mean age: 85, SD: No data</p> <p><b>Setting:</b> Long-term care</p> <p><b>Sex:</b> Male: 10, Female: 26</p> <p><b>Number of participants:</b> 36</p>
<b>Interventions</b>	<p><b>Intervention:</b> SC</p> <p><b>Comparator:</b> None</p> <p><b>Fluid type infused:</b> NaCl, A combination of NaCl and dextrose</p> <p><b>Duration of intervention:</b> Mean: 4 days, SD: No data</p> <p><b>Number of infusions:</b> 144**</p> <p><b>Infusion site duration:</b> "Sites were rotated after administration of each liter"</p> <p><b>Use of hyaluronidase:</b> Hyaluronidase when deemed necessary (used in 78% of patients)</p>
<b>Outcomes</b>	<p><u><b>Adverse effects</b></u></p> <p><b>Outcome definition:</b> No list of adverse effects observed for.</p> <p><b>How was the outcome assessed:</b> Study assessor</p>
<b>Notes</b>	<p>**Calculated based on number of participants x mean duration of intervention.</p> <p>Unable to find active email of corresponding author.</p>
Justino 2013 (37)	
<b>Methods</b>	<p><b>Publication type:</b> Journal article</p> <p><b>Study design:</b> Cross sectional prospective</p> <p><b>Country of study:</b> Brazil</p> <p><b>Language of publication:</b> Portuguese</p> <p><b>Year of study:</b> 2008-2009</p> <p><b>Source of funding:</b> No data</p> <p><b>Aim of study:</b> Applicability of hypodermoclysis</p> <p><b>Aim of intervention:</b> Clinical indication</p> <p><b>Sample size calculation:</b> No data</p>
<b>Participants</b>	<p><b>Recruitment:</b> All patients connected with the Pain Care Department</p> <p><b>Inclusion/exclusion criteria:</b> Received SC</p> <p><b>Type of patient:</b> Cancer patients</p> <p><b>Age:</b> Mean age: 61, Range: 22-95</p> <p><b>Setting:</b> Hospital, outpatient, patient home</p> <p><b>Sex:</b> Male: 6, Female: 10</p> <p><b>Number of participants:</b> 16 patients included in study, only 5 received SC hydration the rest received subcutaneous medication.</p>
<b>Interventions</b>	<p><b>Intervention:</b> SC</p> <p><b>Comparator:</b> None</p> <p><b>Fluid type infused:</b> NaCl, A combination of NaCl and dextrose</p> <p><b>Duration of intervention:</b> Mean: 10.16 days, Range: 1-55, data for all 16 patients</p> <p><b>Number of infusions:</b> Unknown number of hydration infusions</p> <p><b>Infusion site duration:</b> No data</p> <p><b>Use of hyaluronidase:</b> No data</p>
<b>Outcomes</b>	<p><u><b>Adverse effects</b></u></p> <p><b>Outcome definition:</b> No list of adverse effects observed for.</p> <p><b>How was the outcome assessed:</b> Study assessor</p>
<b>Notes</b>	<p>Author contacted by email for missing data but no reply.</p>
Kackielo 2000 (52)	
<b>Methods</b>	<p><b>Publication type:</b> Abstract</p> <p><b>Study design:</b> Case report</p> <p><b>Country of study:</b> USA</p> <p><b>Language of publication:</b> English</p> <p><b>Year of study:</b> No data</p>



	<b>Source of funding:</b> No data <b>Aim of study:</b> Safety of hypodermoclysis <b>Aim of intervention:</b> N/A <b>Sample size calculation:</b> N/A
<b>Participants</b>	<b>Recruitment:</b> N/A <b>Inclusion/exclusion criteria:</b> N/A <b>Type of patient:</b> Terminal patient <b>Age:</b> 78 <b>Setting:</b> Hospital <b>Sex:</b> Male <b>Number of participants:</b> 1
<b>Interventions</b>	<b>Intervention:</b> SC <b>Comparator:</b> None <b>Fluid type infused:</b> No data <b>Duration of intervention:</b> N/A <b>Infusion site duration:</b> 3 days treatment prior to admission <b>Use of hyaluronidase:</b> No data
<b>Outcomes</b>	<b><u>Adverse effects</u></b> <b>Outcome definition:</b> N/A <b>How was the outcome assessed:</b> Assessor
<b>Notes</b>	Unable to find email address of corresponding author.

LAMANDÉ 2004 (38)

<b>Methods</b>	<b>Publication type:</b> Journal article <b>Study design:</b> Cross sectional prospective <b>Country of study:</b> France <b>Language of publication:</b> French <b>Year of study:</b> 2002 <b>Source of funding:</b> No data <b>Aim of study:</b> Safety of hypodermoclysis <b>Aim of intervention:</b> Clinical indication <b>Sample size calculation:</b> No data
<b>Participants</b>	<b>Recruitment:</b> All patients receiving SC in the unit was included. <b>Inclusion/exclusion criteria:</b> All patients were included <b>Type of patient:</b> Geriatric patients <b>Age:</b> Mean: 85, SD: 7 <b>Setting:</b> Short-term and Long-term care <b>Sex:</b> Male: 22, Female: 28 <b>Number of participants:</b> 50
<b>Interventions</b>	<b>Intervention:</b> SC <b>Comparator:</b> None <b>Fluid type infused:</b> NaCl, a combination of NaCl and glucose <b>Duration of intervention:</b> Mean: 20 days, SD: 26 <b>Number of infusions:</b> 1426 <b>Infusion site duration:</b> Daily site change <b>Use of hyaluronidase:</b> No data
<b>Outcomes</b>	<b><u>Adverse effects</u></b> <b>Outcome definition:</b> An incomplete list of adverse effects observed for, but no definition of these. Study description of adverse effects observed for: Translation from French: "...The following parameters were collected daily throughout the duration of the HDC: ...and local tolerance (pain, hematoma, infection, edema, other). ... For local tolerance, the collection was done through the patient interview and inspection of the injection site. The phenomena of intolerance could also be reported to the doctor by the caregiver."

	<b>How was the outcome assessed:</b> Patient interview and Assessor reported
<b>Notes</b>	Unable to find active email of corresponding author.
Lemeray 2012 (54)	
<b>Methods</b>	<b>Publication type:</b> Journal article <b>Study design:</b> Case report <b>Country of study:</b> France <b>Language of publication:</b> French <b>Year of study:</b> 2012 <b>Source of funding:</b> No external funding§ <b>Aim of intervention:</b> Clinical indication <b>Aim of study:</b> Safety of hypodermoclysis <b>Sample size calculation:</b> N/A
<b>Participants</b>	<b>Type of patient:</b> Geriatric patient <b>Age: Mean age:</b> 90 <b>Setting:</b> Hospital <b>Sex:</b> 1 female
<b>Interventions</b>	<b>Intervention:</b> Subcutaneous hydration <b>Comparator:</b> None <b>Fluid type infused:</b> A combination of NaCl and glucose <b>Duration of intervention:</b> 3 hours <b>Infusion site duration:</b> N/A <b>Use of hyaluronidase:</b> No use of hyaluronidase§
<b>Outcomes</b>	<b><u>Adverse effects</u></b> <b>Outcome definition:</b> N/A <b>How was the outcome assessed:</b> No data
<b>Notes</b>	§ Additional information requested and supplied from author.
Martinez-Riquelme 2005 (39)	
<b>Methods</b>	<b>Publication type:</b> Journal article <b>Study design:</b> Cross sectional prospective <b>Country of study:</b> England <b>Language of publication:</b> English <b>Year of study:</b> 2005 <b>Source of funding:</b> No data <b>Aim of study:</b> Efficacy of hypodermoclysis <b>Aim of intervention:</b> Clinical indication <b>Sample size calculation:</b> No data
<b>Participants</b>	<b>Recruitment:</b> No data <b>Inclusion/exclusion criteria:</b> Short bowel and GI failure causing excessive fluid loss, No effect of conventional treatment, Adequate macronutrient status, <b>Type of patient:</b> GI failure patients <b>Age:</b> Mean age: 65.3, SD: 13.5 <b>Setting:</b> Home based treatment <b>Sex:</b> Male: 4, Female: 6 <b>Number of participants:</b> 10
<b>Interventions</b>	<b>Intervention:</b> SC <b>Comparator:</b> None <b>Fluid type infused:</b> NaCl, A combination of NaCl and dextrose, 2-4 mmol Mg was added if Mg depletion was confirmed. <b>Duration of intervention:</b> Total duration was 3 months with 3-7 days treatment per week <b>Number of infusions:</b> Unable to calculate total number of infusions.

<b>Outcomes</b>	<b>Infusion site duration:</b> No data
	<b>Use of hyaluronidase:</b> No data
	<b><u>Adverse effects</u></b>
	<b>Outcome definition:</b> No list of adverse effects observed for.
<b>Notes</b>	<b>How was the outcome assessed:</b> No data
	Author contacted by email for missing data but no reply.

Mongardon 2008 (51)

<b>Methods</b>	<b>Publication type:</b> Letter to the editor
	<b>Study design:</b> Case report
	<b>Country of study:</b> France
	<b>Language of publication:</b> English
	<b>Year of study:</b> No data
	<b>Source of funding:</b> No data
	<b>Aim of study:</b> Safety of hypodermoclysis
	<b>Aim of intervention:</b> Clinical indication
	<b>Sample size calculation:</b> N/A
	<b>Recruitment:</b> N/A
<b>Participants</b>	<b>Inclusion/exclusion criteria:</b> N/A
	<b>Type of patient:</b> Geriatric patient
	<b>Age:</b> 86
	<b>Setting:</b> Hospital
	<b>Sex:</b> Female: 1
<b>Interventions</b>	<b>Number of participants:</b> 1
	<b>Intervention:</b> SC
	<b>Comparator:</b> None
	<b>Fluid type infused:</b> NaCl
	<b>Duration of intervention:</b> Few hours
	<b>Infusion site duration:</b> N/A
	<b>Use of hyaluronidase:</b> No data
	<b><u>Adverse effects</u></b>
	<b>Outcome definition:</b> N/A
	<b>How was the outcome assessed:</b> Assessor
<b>Notes</b>	Unable to find active email of corresponding author.

Sato 2008 (53)

<b>Methods</b>	<b>Publication type:</b> Journal Article
	<b>Study design:</b> Case report
	<b>Country of study:</b> Japan
	<b>Language of publication:</b> Japanese
	<b>Year of study:</b> 2007-2008
	<b>Source of funding:</b> No data
	<b>Aim of study:</b> Efficacy of SC hydration
	<b>Aim of intervention:</b> Clinical indication
	<b>Sample size calculation:</b> No data
	<b>Recruitment:</b> N/A
<b>Participants</b>	<b>Inclusion/exclusion criteria:</b> N/A
	<b>Type of patient:</b> Geriatric patient
	<b>Age:</b> Mean: 85, range 78-90
	<b>Setting:</b> Home care
	<b>Sex:</b> Male: 1, Female: 2
	<b>Number of participants:</b> 3

<b>Interventions</b>	<b>Intervention:</b> SC hydration <b>Comparator:</b> None <b>Fluid type infused:</b> 5% glucose <b>Duration of intervention:</b> No data <b>Infusion site duration:</b> No data <b>Use of hyaluronidase:</b> No data
<b>Outcomes</b>	<b><u>Adverse effects</u></b> <b>Outcome definition:</b> N/A <b>How was the outcome assessed:</b> No data
<b>Notes</b>	Unable to find active email of corresponding author.

Schen 1981 (47)

<b>Methods</b>	<b>Publication type:</b> Journal article <b>Study design:</b> Cross sectional retrospective <b>Country of study:</b> Israel <b>Language of publication:</b> English <b>Year of study:</b> No data <b>Source of funding:</b> No data <b>Aim of study:</b> Safety of hypodermoclysis <b>Aim of intervention:</b> Clinical indication <b>Sample size calculation:</b> No data
<b>Participants</b>	<b>Recruitment:</b> No data <b>Inclusion/exclusion criteria:</b> No data <b>Type of patient:</b> Geriatric patients <b>Age:</b> Mean: 82, SD: No data <b>Setting:</b> Hospital, long-term care <b>Sex:</b> No data <b>Number of participants:</b> 634
<b>Interventions</b>	<b>Intervention:</b> SC <b>Comparator:</b> None <b>Fluid type infused:</b> NaCl, 5% dextrose <b>Duration of intervention:</b> No data <b>Number of infusions:</b> 4500 <b>Infusion site duration:</b> No data <b>Use of hyaluronidase:</b> All infusions in hospital was with hyaluronidase, all infusions in long-term care was without.
<b>Outcomes</b>	<b><u>Adverse effects</u></b> <b>Outcome definition:</b> No list of adverse effects observed for. <b>How was the outcome assessed:</b> No data
<b>Notes</b>	Data from Schen 1981 Schen 1982 and Schen 1983 is expected to be from the same observational study and data is combined. Unable to find active email of corresponding author.

Schen 1982 (50)

<b>Methods</b>	<b>Publication type:</b> Letter to the editor <b>Study design:</b> Cross sectional retrospective <b>Country of study:</b> Israel <b>Language of publication:</b> English <b>Year of study:</b> No data <b>Source of funding:</b> No data <b>Aim of study:</b> Safety of hypodermoclysis <b>Aim of intervention:</b> Clinical indication <b>Sample size calculation:</b> No data
<b>Participants</b>	<b>Recruitment:</b> No data

	<p><b>Inclusion/exclusion criteria:</b> No data</p> <p><b>Type of patient:</b> Geriatric patients</p> <p><b>Age:</b> Mean: 82, SD: no data</p> <p><b>Setting:</b> Hospital</p> <p><b>Sex:</b> No data</p> <p><b>Number of participants:</b> 67 (350 infusions)</p>
<b>Interventions</b>	<p><b>Intervention:</b> SC</p> <p><b>Comparator:</b> None</p> <p><b>Fluid type infused:</b> NaCl, 5% dextrose, up to 34 mmol/l of potassium was added if needed.</p> <p><b>Duration of intervention:</b> No data</p> <p><b>Infusion site duration:</b> No data</p> <p><b>Use of hyaluronidase:</b> All interventions with hyaluronidase</p>
<b>Outcomes</b>	
<b>Notes</b>	This article is an update/continuation of Schen 1981
Schen 1983 (48)	
<b>Methods</b>	<p><b>Publication type:</b> Letter to the editor</p> <p><b>Study design:</b> Cross sectional retrospective</p> <p><b>Country of study:</b> Israel</p> <p><b>Language of publication:</b> English</p> <p><b>Year of study:</b> No data</p> <p><b>Source of funding:</b> No data</p> <p><b>Aim of study:</b> Safety of hypodermoclysis</p> <p><b>Aim of intervention:</b> Clinical indication</p> <p><b>Sample size calculation:</b> No data</p>
<b>Participants</b>	<p><b>Recruitment:</b> No data</p> <p><b>Inclusion/exclusion criteria:</b> No data</p> <p><b>Type of patient:</b> Geriatric patient</p> <p><b>Age:</b> No data</p> <p><b>Setting:</b> Hospital and long-term care</p> <p><b>Sex:</b> No data</p> <p><b>Number of participants:</b> 634</p>
<b>Interventions</b>	<p><b>Intervention:</b> SC</p> <p><b>Comparator:</b> None</p> <p><b>Fluid type infused:</b> NaCl, 5% dextrose</p> <p><b>Duration of intervention:</b> No data</p> <p><b>Infusion site duration:</b> No data</p> <p><b>Use of hyaluronidase:</b> All infusions in hospital was with hyaluronidase, all infusions in long-term care was without.</p>
<b>Outcomes</b>	
<b>Notes</b>	This article is an update/continuation of Schen 1981
Torsheim 1999 (40)	
<b>Methods</b>	<p><b>Publication type:</b> Journal article</p> <p><b>Study design:</b> Cross sectional prospective</p> <p><b>Country of study:</b> Norway</p> <p><b>Language of publication:</b> Norwegian</p> <p><b>Year of study:</b> No data</p> <p><b>Source of funding:</b> No data</p> <p><b>Aim of study:</b> Efficacy of hypodermoclysis</p> <p><b>Aim of intervention:</b> Clinical indication</p> <p><b>Sample size calculation:</b> No data</p>

<b>Participants</b>	<p><b>Recruitment:</b> Patients admitted to palliation care unit was assessed for eligibility. No data on if all admitted patients was assess for eligibility.</p> <p><b>Inclusion/exclusion criteria:</b> Inclusion: Dehydrated, ability to give consent. Exclusion: edema.</p> <p><b>Type of patient:</b> Cancer patients</p> <p><b>Age:</b> Mean: 73, SD: 7.5</p> <p><b>Setting:</b> Hospital, patient home</p> <p><b>Sex:</b> Male: 5, Female: 4</p> <p><b>Number of participants:</b> 9</p>
<b>Interventions</b>	<p><b>Intervention:</b> SC</p> <p><b>Comparator:</b> None</p> <p><b>Fluid type infused:</b> NaCl, 5% glucose</p> <p><b>Duration of intervention:</b> 17 infusion in total, no data on duration</p> <p><b>Infusion site duration:</b> No data</p> <p><b>Use of hyaluronidase:</b> No use.</p>
<b>Outcomes</b>	<p><b><u>Adverse effects</u></b></p> <p><b>Outcome definition:</b> Clearly described.</p> <p>Study description of adverse effects observed for. Translation from Norwegian: "Observations were recorded in a standardized observation form completed by the nurse. Any swelling in the subcutis was evaluated by measuring the diameter or circumferential increase of the stomach and thigh. Inflammation signs in cutis / subcutis were evaluated and documented with polaroid photo. Pain or other discomfort is recorded, with a description of location and character. If the infusion was interrupted, the cause should be stated in the form."</p> <p><b>How was the outcome assessed:</b> Study assessor</p>
<b>Notes</b>	Unable to find active email of corresponding author.
Vidal 2016 (41)	
<b>Methods</b>	<p><b>Publication type:</b> Journal article</p> <p><b>Study design:</b> Cross sectional prospective</p> <p><b>Country of study:</b> USA</p> <p><b>Language of publication:</b> English</p> <p><b>Year of study:</b> No data</p> <p><b>Source of funding:</b> No funding</p> <p><b>Aim of study:</b> Safety and efficacy of hypodermoclysis, "To determine if caregivers were capable of administering SC"</p> <p><b>Aim of intervention:</b> Predefined volume (1000 ml/day)</p> <p><b>Sample size calculation:</b> No data</p>
<b>Participants</b>	<p><b>Recruitment:</b> Patients included in a previous study on the relevance of hydration in the terminal patient could continue in this study.</p> <p><b>Inclusion/exclusion criteria:</b> Having a caregiver that could administer SC fluid.</p> <p><b>Type of patient:</b> Cancer patient</p> <p><b>Age:</b> Median: 67, Range 60;78</p> <p><b>Setting:</b> Home based intervention</p> <p><b>Sex:</b> Male: 11, Female: 10</p> <p><b>Number of participants:</b> 21</p>
<b>Interventions</b>	<p><b>Intervention:</b> SC</p> <p><b>Comparator:</b> None</p> <p><b>Fluid type infused:</b> NaCl</p> <p><b>Duration of intervention:</b> Up to 7 days</p> <p><b>Infusion site duration:</b> No data</p> <p><b>Number of infusions.</b> 120</p> <p><b>Use of hyaluronidase:</b> No data</p>
<b>Outcomes</b>	<b><u>Adverse effects</u></b>

	<p><b>Outcome definition:</b> Clearly described.</p> <p>Study description of adverse effects observed for: “Caregivers received daily phone calls from research nurses to assess the following: ...related issues including needle displacement, leakage, swelling, pain, discomfort, itching, bruising or any other problems, and the need for a research nurse visit. The caregiver rates the symptoms of swelling, discomfort, pain, redness, itch, bruising and others on a scale of 0 to 10, with 10 being the worst possible symptom and 0 no symptoms. For needle displacement and leakage, the answer was yes/no.”</p> <p><b>How was the outcome assessed:</b> Caregiver report / assessor observed</p>
<b>Notes</b>	Author contacted by email for missing data but no reply.
Worobec 1997 (42)	
<b>Methods</b>	<p><b>Publication type:</b> Journal article</p> <p><b>Study design:</b> Cross sectional prospective</p> <p><b>Country of study:</b> Canada</p> <p><b>Language of publication:</b> English</p> <p><b>Year of study:</b> 1995</p> <p><b>Source of funding:</b> No data</p> <p><b>Aim of study:</b> Efficacy of hypodermoclysis</p> <p><b>Aim of intervention:</b> Clinical indication</p> <p><b>Sample size calculation:</b> No data</p>
<b>Participants</b>	<p><b>Recruitment:</b> Patients of a chronic care setting</p> <p><b>Inclusion/exclusion criteria:</b> All patients receiving SC in the setting.</p> <p><b>Type of patient:</b> Geriatric patient</p> <p><b>Age:</b> Mean: 78, SD: 6.86</p> <p><b>Setting:</b> Long term-care</p> <p><b>Sex:</b> Male: 4, Female: 8</p> <p><b>Number of participants:</b> 12</p>
<b>Interventions</b>	<p><b>Intervention:</b> SC</p> <p><b>Comparator:</b> None</p> <p><b>Fluid type infused:</b> No data</p> <p><b>Duration of intervention:</b> No data</p> <p><b>Infusion site duration:</b> No data</p> <p><b>Use of hyaluronidase:</b> All interventions with hyaluronidase</p>
<b>Outcomes</b>	<p><u><b>Adverse effects</b></u></p> <p><b>Outcome definition:</b> No list of adverse effects observed for.</p> <p><b>How was the outcome assessed:</b> Patient file by assessor</p>
<b>Notes</b>	Unable to find active email of corresponding author.
Yap 2001(49)	
<b>Methods</b>	<p><b>Publication type:</b> Journal article</p> <p><b>Study design:</b> Cross sectional retrospective</p> <p><b>Country of study:</b> Singapore</p> <p><b>Language of publication:</b> English</p> <p><b>Year of study:</b> 2000</p> <p><b>Source of funding:</b> No data</p> <p><b>Aim of study:</b> Safety of hypodermoclysis</p> <p><b>Aim of intervention:</b> Clinical indication</p> <p><b>Sample size calculation:</b> No data</p>
<b>Participants</b>	<p><b>Recruitment:</b> All patients admitted was review</p> <p><b>Inclusion/exclusion criteria:</b> All patients who received subcutaneous hydration</p> <p><b>Type of patient:</b> Terminal patients</p> <p><b>Age:</b> No data</p> <p><b>Setting:</b> Hospice</p>

	<p><b>Sex:</b> No data</p> <p><b>Number of participants:</b> 51</p>
<b>Interventions</b>	<p><b>Intervention:</b> Subcutaneous hydration</p> <p><b>Comparator:</b> None</p> <p><b>Fluid type infused:</b> 5% dextrose, A combination of NaCl and glucose/dextrose</p> <p><b>Duration of intervention:</b> 5.49 days (mean), SD: 4.43 days,*</p> <p><b>Number of infusions:</b> 290**</p> <p><b>Infusion site duration:</b> 3.7 days*</p> <p><b>Use of hyaluronidase:</b> No data</p> <p>*Calculated from information in article</p>
<b>Outcomes</b>	<p><b><u>Adverse effects</u></b></p> <p><b>Outcome definition:</b> No list of adverse effects observed for.</p> <p><b>How was the outcome assessed:</b> No data</p>
<b>Notes</b>	<p>*A total of 79 needles was inserted giving and mean infusion site duration of 3.7 days.</p> <p>**Calculated as one infusion per day</p> <p>Unable to find active email of corresponding author.</p>
ŠŤASTNÁ 2009 (34)	
<b>Methods</b>	<p><b>Publication type:</b> Journal article</p> <p><b>Study design:</b> Cross sectional prospective</p> <p><b>Country of study:</b> Czech Republic</p> <p><b>Language of publication:</b> Czech</p> <p><b>Year of study:</b> 2008</p> <p><b>Source of funding:</b> No data</p> <p><b>Aim of study:</b> Safety of hypodermoclysis</p> <p><b>Aim of intervention:</b> Clinical indication</p> <p><b>Sample size calculation:</b> No data</p>
<b>Participants</b>	<p><b>Recruitment:</b> Patients from a geriatric unit</p> <p><b>Inclusion/exclusion criteria:</b> Requiring parenteral hydration with a difficult venous access</p> <p><b>Type of patient:</b> Geriatric patient</p> <p><b>Age:</b> Median: 83, Range: 56-96</p> <p><b>Setting:</b> Hospital</p> <p><b>Sex:</b> Male: 20, Female: 41</p> <p><b>Number of participants:</b> 61</p>
<b>Interventions</b>	<p><b>Intervention:</b> SC</p> <p><b>Comparator:</b> None</p> <p><b>Fluid type infused:</b> Plasma-Lyte</p> <p><b>Duration of intervention:</b> Median: 4 days, range: 1-39 days</p> <p><b>Number of infusions:</b> 425</p> <p><b>Infusion site duration:</b> No data</p> <p><b>Use of hyaluronidase:</b> No data</p>
<b>Outcomes</b>	<p><b><u>Adverse effects</u></b></p> <p><b>Outcome definition:</b> No list of adverse effects observed for.</p> <p><b>How was the outcome assessed:</b> No data</p>
<b>Notes</b>	<p>Author contacted by email for missing data but no reply.</p>



## Supplementary Text S4. Risk of Bias 2. Judgement of individual domains.

### 4.1 Outcome: Adverse effects

Study & year	Experimental	Comparator	Randomization process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall
Delamaire 1992	SC infusion	IV infusion	?	+	?	?	?	—
Challiner 1994	SC infusion	IV infusion	+	+	+	?	?	!
O'Keeffe 1995	SC infusion	IV infusion	?	+	+	?	?	!
Noriega 2014	SC infusion	IV infusion	?	+	+	?	?	!
Luk 2008*	SC infusion	IV infusion	?	—	?	?	?	—
Slesak 2003	SC infusion	IV infusion	+	+	+	?	?	!
Esmeray 2018	SC infusion	IV infusion	?	?	+	—	?	—

\* Not included in the meta-analysis as data was not provided in a way so it could be included.

For response to signaling questions see Supplementary Text 4.7.



## 4.2 Outcome: Death

Study & year	Experimental	Comparator	Randomization process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall
Delamaire 1992	SC infusion	IV infusion	?	+	+	+	+	!
Challiner 1994	SC infusion	IV infusion	+	+	+	+	+	+
O'Keeffa 1995	SC infusion	IV infusion	+	+	+	+	+	+
Slesak 2003	SC infusion	IV infusion	+	+	+	+	+	+
Noriega 2014	SC infusion	IV infusion	?	+	+	+	+	!
Esmeray 2018	SC infusion	IV infusion	?	+	+	+	+	!

For response to signaling questions see Supplementary Text 4.8



4.3 Outcome: Catherter insertion time

Study & year	Experimental	Comparator	Randomization process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall
Slesak 2003	SC infusion	IV infusion	+	+	+	?	?	!
Esmeray 2018	SC infusion	IV infusion	?	+	+	?	?	!

For response to signaling questions see Supplementary Text 4.9.

-  Low risk
-  Some concerns
-  High risk

4.4 Outcome: Osmolality

Study & year	Experimental	Comparator	Randomization process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall
Challiner 1994	SC infusion	IV infusion	+	+	+	+	—	—
Noriega 2014	SC infusion	IV infusion	?	+	+	+	?	!

For response to signaling questions see Supplementary Text 4.10.

-  Low risk
-  Some concerns
-  High risk

### 4.5 Outcome: Volume of fluid infused

Study & year	Experimental	Comparator	Randomization process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall
O'Keeffa 1995	SC infusion	IV infusion	?	+	+	?	?	!
Slesak 2003	SC infusion	IV infusion	+	+	+	?	?	!
Noriega 2014	SC infusion	IV infusion	?	+	+	?	?	!

For response to signaling questions see Supplementary Text 4.11.

-  Low risk
-  Some concerns
-  High risk

#### 4.6 Outcome: Agitation

Study & year	Experimental	Comparator	Randomization process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall
Noriega 2014	SC infusion	IV infusion	?	+	+	?	?	!
O'Keeffe 1995	SC infusion	IV infusion	?	+	+	?	?	!
Esmeray 2018	SC infusion	IV infusion	?	?	+	?	?	!

For response to signaling questions see Supplementary Text 4.12.



#### 4.7 Signaling questions for the outcome: Adverse effects

<b>Unique ID</b>	Challiner 1994	<b>Study ID</b>		<b>Assessor</b>	
<b>Ref or Label</b>	Challiner 1994	<b>Aim</b>	assignment to intervention (the 'intention-to-treat' effect)		
<b>Experimental</b>	SC	<b>Comparator</b>	IV	<b>Source</b>	Journal article(s) with results of the trial
<b>Outcome</b>	Adverse effects	<b>Results</b>		<b>Weight</b>	
<b>Domain</b>	<b>Signalling question</b>			<b>Response</b>	<b>Comments</b>
<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?			Y	"Random treatment allocation was generated by computer, such that within each block of eight patients there were four patients on each treatment.  These treatment allocations were transferred to sequentially numbered sealed envelopes which were opened by the junior doctor on call once he or she had decided the patient was eligible for the trial and consent had been obtained."
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?			Y	
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?			N	
	<b>Risk of bias judgement</b>			<b>Low</b>	
<b>Bias due to deviations from intended interventions</b>	2.1. Were participants aware of their assigned intervention during the trial?			PY	No description of blinding and therefore very unlikely.
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?			PY	
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?			PN	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?			NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?			NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?			Y	The paper does not perform statistical test on adverse effects. Signaling question answered as data are included in the meta-analysis.

	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	PY	No data on how many patients were observed for adverse effects, but as the patients were in-patients we expect they were observed. From method section: "Any complication of the fluid therapy were noted."
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	NA	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	Two patients excluded during the study but are re-included in our analysis
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	PN	No description of which adverse effects were observed but probably ok as it is described that it was trained health care staff observing patients.
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	PN	Both were interventions that required similar degree of observation
	4.3 Were outcome assessors aware of the intervention received by study participants?	PY	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	PY	Subjective outcome. Assessors conscious or unconscious preference for either method could influence the result.
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	PN	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	No statistical analysis plan or protocol is described in the paper.
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	
	5.3 ... multiple eligible analyses of the data?	N	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	



Overall bias	Risk of bias judgement			Some concerns	
Unique ID	Delamaire 1992	Study ID		Assessor	
Ref or Label		Aim	assignment to intervention (the 'intention-to-treat' effect)		
Experimental	SC	Comparator	IV	Source	Conference abstract(s) about the trial
Outcome	Adverse effects	Results		Weight	
Domain	Signalling question			Response	Comments
Bias arising from the randomization process	1.1 Was the allocation sequence random?			NI	The paper only describes patients being randomized but no additional informations is given.
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?			NI	
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?			NI	No baseline data reported.
	Risk of bias judgement			Some concerns	
Bias due to deviations from intended interventions	2.1. Were participants aware of their assigned intervention during the trial?			PY	No description of blinding for patients or caregivers
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?			PY	
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?			PN	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?			NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?			NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?			Y	The paper does not perform statistical test on adverse effects. Signaling question is answered as data are included in the meta-analysis.
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?			NA	
	Risk of bias judgement			Low	
Bias due to missing outcome data	3.1 Were data for this outcome available for all, or nearly all, participants randomized?			NI	No information on number of patients randomized.

	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	PY	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	We don't know if patients were excluded after randomizations.
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	PN	The methods section state that tolerance and complications are in focus as outcomes.
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
	4.3 Were outcome assessors aware of the intervention received by study participants?	Y	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	PY	Subjective outcome. Assessors conscious or unconscious preference for either method could influence the result.
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	PN	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	No statistical analysis plan or protocol is described in the paper.
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	
	5.3 ... multiple eligible analyses of the data?	N	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Overall bias</b>	<b>Risk of bias judgement</b>	<b>High</b>	As only sparse data is available we have judged the study to have some concerns in multiple domains in a way that substantially lowers confidence in the result.

<b>Unique ID</b>	Noriega 2014	<b>Study ID</b>		<b>Assessor</b>	
<b>Ref or Label</b>		<b>Aim</b>	assignment to intervention (the 'intention-to-treat' effect)		
<b>Experimental</b>	SC	<b>Comparator</b>	IV	<b>Source</b>	Journal article(s) with results of the trial

Outcome	Adverse effects	Results		Weight	
Domain	Signalling question			Response	Comments
<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?			PY	Translations from spanish: "Randomization of treatment was performed by mixed blocks 6 sealed envelopes. Each block consisted of 3 cards with treatment 'IV' and 3 'SC'. The envelopes were opened after the patient's inclusion in the study and after obtaining informed consent."  It might be possible to guess the allocation of the later envelopes depending on the previous allocations (page 104).
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?			PY	
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?			N	Table 1
	<b>Risk of bias judgement</b>			<b>Some concerns</b>	Based on 1.2
<b>Bias due to deviations from intended interventions</b>	2.1. Were participants aware of their assigned intervention during the trial?			PY	No description of blinding and therefore very unlikely.
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?			PY	
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?			PN	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?			NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?			NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?			Y	The paper does not perform statistical test on adverse effects. Signaling question answered as data is included in the meta-analysis.
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?			NA	

	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	Y	Numbers in tables is equal to randomized numbers, excluding those who died. Three patients died during the study. One 1 SC group and 2 in IV group. This is a sufficiently small fraction not to induce potential relevant bias.
	3.2 If N/PN/Ni to 3.1: Is there evidence that result was not biased by missing outcome data?	NA	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/Ni to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	N	Study description of adverse effects observed for: Translation from Spanish: "Daily observations were made by researchers...the presence of adverse effects (extravasation, edema and local infection), the need for replacement catheter..."
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
	4.3 Were outcome assessors aware of the intervention received by study participants?	Y	
	4.4 If Y/PY/Ni to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	PY	Subjective outcome. Assessors conscious or unconscious preference for either method could influence the result.
	4.5 If Y/PY/Ni to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	PN	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	No statistical analysis plan or protocol is described in the paper.
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	
	5.3 ... multiple eligible analyses of the data?	N	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	

Overall bias	Risk of bias judgement			Some concerns	
Unique ID	O'Keeffe 1995	Study ID		Assessor	
Ref or Label		Aim	assignment to intervention (the 'intention-to-treat' effect)		
Experimental	SC	Comparator	IV	Source	Journal article(s) with results of the trial
Outcome	Adverse effects	Results		Weight	
Domain	Signalling question			Response	Comments
Bias arising from the randomization process	1.1 Was the allocation sequence random?			Y	Allocation sequence generated by table of random numbers.
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?			PY	Block randomization and sealed envelope.  It might be possible to guess the allocation of the later envelopes depending on the previous allocations.
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?			N	
	Risk of bias judgement			Some concerns	Based 1.2
Bias due to deviations from intended interventions	2.1. Were participants aware of their assigned intervention during the trial?			PY	No description of blinding and therefore very unlikely.
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?			PY	Caregivers described as assessors.
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?			PN	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?			NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?			NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?			Y	The paper does not perform statistical test on adverse effects. Signaling question answered as data is included in the meta-analysis.

	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	Y	One patient in i.v.-group excluded because of adverse effect (p.37). This event is re-included in our meta-analysis.
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	NA	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	PN	No list of adverse effects described, but "nursing staff also note the presence of any ... disturbance directly related to the infusion." (p.37)
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
	4.3 Were outcome assessors aware of the intervention received by study participants?	Y	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	PY	Subjective outcome. Assessors conscious or unconscious preference for either method could influence the result.
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	PN	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	No statistical analysis plan or protocol is described in the paper.
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	
	5.3 ... multiple eligible analyses of the data?	N	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Overall bias</b>	<b>Risk of bias judgement</b>	<b>Some concerns</b>	

<b>Unique ID</b>	Slesak 2003	<b>Study ID</b>		<b>Assessor</b>	
<b>Ref or Label</b>		<b>Aim</b>	assignment to intervention (the 'intention-to-treat' effect)		
<b>Experimental</b>	SC	<b>Comparator</b>	IV	<b>Source</b>	Journal article(s) with results of the trial
<b>Outcome</b>	Adverse effects	<b>Results</b>		<b>Weight</b>	
<b>Domain</b>	<b>Signalling question</b>			<b>Response</b>	<b>Comments</b>
<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?			Y	Random treatment allocation was generated by mixing blocks of six sealed envelopes. Block size unknown to staff.
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?			Y	
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?			N	
	<b>Risk of bias judgement</b>			<b>Low</b>	
<b>Bias due to deviations from intended interventions</b>	2.1. Were participants aware of their assigned intervention during the trial?			Y	Described as an open trial.
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?			Y	
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?			N	A total of 31% of patients switched intervention: 13/48 SC -> IV; 17/48 IV -> SC. This is according to protocol: "A switch of therapies was possible if medically or ethically indicated." (p.156, 2nd column, first two lines).
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?			NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?			NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?			Y	Signaling question answered as data is included in the meta-analysis.
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?			NA	
	<b>Risk of bias judgement</b>			<b>Low</b>	

<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	PY	Although the paper does not describe specifically how many patients were observed for adverse effects we do not suspect a large number of missing data. The method section writes: "Nursing staff and doctors thoroughly observed adverse reactions and wrote them down in a standardized form." This had been designed and tested in a pilot phase.  Data in table 2 and first paragraph on page 158 support complete reporting.
	3.2 If N/PN/Ni to 3.1: Is there evidence that result was not biased by missing outcome data?	NA	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/Ni to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	N	"Nursing staff and doctors thoroughly observed adverse reactions and wrote them down in a standardized form."
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
	4.3 Were outcome assessors aware of the intervention received by study participants?	Y	
	4.4 If Y/PY/Ni to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	PY	Subjective outcome. Assessors conscious or unconscious preference for either method could influence the result.
	4.5 If Y/PY/Ni to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	PN	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	No statistical analysis plan or protocol is described in the paper.



	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	
	5.3 ... multiple eligible analyses of the data?	N	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Overall bias</b>	<b>Risk of bias judgement</b>	<b>Some concerns</b>	

<b>Unique ID</b>	Esmeray 2018	<b>Study ID</b>		<b>Assessor</b>	
<b>Ref or Label</b>		<b>Aim</b>	assignment to intervention (the 'intention-to-treat' effect)		
<b>Experimental</b>	SC	<b>Comparator</b>	IV	<b>Source</b>	Journal article(s) with results of the trial
<b>Outcome</b>	Adverse effects	<b>Results</b>		<b>Weight</b>	
<b>Domain</b>	<b>Signalling question</b>			<b>Response</b>	<b>Comments</b>
<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?		PY	Allocation sequence generated by "Random drawing method".  No information on allocation concealment when including patients.	
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?		NI		
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?		N		
	1.4 Is a roughly equal proportion of participants allocated to each of the two groups?		Y		15 in each group.
	1.5 If N/PN/NI to 1.4: Are period effects included in the analysis?		NA		
	<b>Risk of bias judgement</b>		<b>Some concerns</b>		
<b>Bias due to deviations from intended interventions</b>	2.1. Were participants aware of their assigned intervention during the trial?		Y	No description of blinding and therefore very unlikely. However, 67% of patients had dementia and were bedridden.	
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?		Y		
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?		N		
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?		NA		

	2.5 Was there sufficient time for any carry-over effects to have disappeared before outcome assessment in the second period?	NI	No information on time between the two groups (wash-out period).
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	PY	Although the paper does not describe specifically how many patients were observed for adverse effects we have no grounds for suspecting a large number of missing data.
	3.2 If N/PN/NI to 3.1: Are the proportions of missing outcome data and reasons for missing outcome data similar across interventions?	NA	
	3.3. If N/PN/NI to 3.1: Is there evidence that results were robust to the presence of missing outcome data?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	N	"Administration monitoring form had several sections. One section collected data on edema, redness, bleeding and agitation that could develop during or after infusion practices."  "All administrations were performed on abdomen by the researcher, whereas the side effects were evaluated by a nurse, who came from a different institution, which connected of the institution."
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
	4.3 Were outcome assessors aware of the intervention received by study participants?	Y	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	PY	Subjective outcome. Assessors conscious or unconscious preference for either method could influence the result.
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	PN	
	<b>Risk of bias judgement</b>	<b>High</b>	Very high number of minor adverse effects in IV group compared to all other studies

			without any comment from the authors. We have treated some of the data as doublet entry and removed half of the events from all analysis. This will introduce bias in favor of the comparator (IV).
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	No statistical analysis plan or protocol is described in the paper.
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	
	5.3 ... multiple eligible analyses of the data?	N	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Overall bias</b>	<b>Risk of bias judgement</b>	<b>High</b>	

<b>Unique ID</b>	Luk 2008	<b>Study ID</b>		<b>Assessor</b>	
<b>Ref or Label</b>		<b>Aim</b>	assignment to intervention (the 'intention-to-treat' effect)		
<b>Experimental</b>	SC	<b>Comparator</b>	IV	<b>Source</b>	Journal article(s) with results of the trial
<b>Outcome</b>	Adverse effects	<b>Results</b>		<b>Weight</b>	
<b>Domain</b>	<b>Signalling question</b>			<b>Response</b>	<b>Comments</b>
<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?			NI	"We carried out an open randomised controlled study".
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?			NI	
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?			NI	Insufficient information to evaluate quality of randomization.
	<b>Risk of bias judgement</b>			<b>Some concerns</b>	No baseline information is reported.
<b>Bias due to deviations from intended interventions</b>	2.1. Were participants aware of their assigned intervention during the trial?			Y	Study is described as an open trial. "We carried out an open randomised controlled study"
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?			Y	

	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?	NI	No information on how many patients did or did not received the assigned intervention.
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?	NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?	NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	NI	It is not described what analysis were used. "Between the hypodermoclysis and intravenous groups, there were no significant differences in terms of percentage of patients with complications, catheter dislodgement and death."
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NI	
	<b>Risk of bias judgement</b>	<b>High</b>	
<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	NI	It is not described how many patients were observed for adverse effects. They state that "In some of the other patients the infusion was stopped prior to day 3" but not how many or from what group.
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	PN	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	PY	Adverse effects could be a reason to stop the hydration treatment.
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	PN	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	N	"For secondary outcomes, the infusion sites of both groups were carefully inspected" (p.49)
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	PN	
	4.3 Were outcome assessors aware of the intervention received by study participants?	Y	Described as an open trial.

	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	PY	Subjective outcome. Assessors conscious or unconscious preference for either method could influence the result.
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	PN	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	No statistical analysis plan or protocol is described in the paper.
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	PN	Adequate number of what the authors consider adverse effects.
	5.3 ... multiple eligible analyses of the data?	NI	It is not described which analysis is used.
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	Results report percentages while actual numbers are not provided.
<b>Overall bias</b>	<b>Risk of bias judgement</b>	<b>High</b>	

#### 4.8 Signalling questions for the outcome: Death

<b>Unique ID</b>	Challiner 1994	<b>Study ID</b>		<b>Assessor</b>	
<b>Ref or Label</b>		<b>Aim</b>	assignment to intervention (the 'intention-to-treat' effect)		
<b>Experimental</b>	SC	<b>Comparator</b>	IV	<b>Source</b>	Journal article(s) with results of the trial
<b>Outcome</b>	Deaths	<b>Results</b>		<b>Weight</b>	
<b>Domain</b>	<b>Signalling question</b>		<b>Response</b>		<b>Comments</b>
<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?		Y		"Random treatment allocation was generated by computer, such that within each block of eight patients there were four patients on each treatment.
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?		Y		
					These treatment allocations were transferred to sequentially numbered sealed envelopes which were opened by the junior doctor on call once he or she had decided the patient was eligible for the trial and consent had been obtained."
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?		N		
	<b>Risk of bias judgement</b>		<b>Low</b>		
<b>Bias due to deviations from intended interventions</b>	2.1. Were participants aware of their assigned intervention during the trial?		PY		Blinding not described.
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?		PY		
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?		PN		
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?		NA		
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?		NA		
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?		Y		The paper does not present statistical test on death.

	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	PY	
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	NA	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	N	Very likely that death was noticed as inpatients were observed repeatedly for clinical and biochemical outcomes.
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
	4.3 Were outcome assessors aware of the intervention received by study participants?	Y	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	N	
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	
	5.3 ... multiple eligible analyses of the data?	N	
	<b>Risk of bias judgement</b>	<b>Low</b>	Low number of observations (n=1) with accurate reporting.
<b>Overall bias</b>	<b>Risk of bias judgement</b>	<b>Low</b>	

<b>Unique ID</b>	Delamaire 1992	<b>Study ID</b>		<b>Assessor</b>	
<b>Ref or Label</b>		<b>Aim</b>	assignment to intervention (the 'intention-to-treat' effect)		
<b>Experimental</b>	SC	<b>Comparator</b>	IV	<b>Source</b>	Conference abstract(s) about the trial
<b>Outcome</b>	Deaths	<b>Results</b>		<b>Weight</b>	
<b>Domain</b>	<b>Signalling question</b>			<b>Response</b>	<b>Comments</b>
<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?			NI	The paper only describes patients being randomized but no additional informations is given.
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?			NI	
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?			NI	No baseline data reported.
	<b>Risk of bias judgement</b>			<b>Some concerns</b>	
<b>Bias due to deviations from intended interventions</b>	2.1. Were participants aware of their assigned intervention during the trial?			PY	There is no information on concealment for patients or caregivers.
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?			PY	
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?			PN	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?			NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?			NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?			PY	
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?			NA	
	<b>Risk of bias judgement</b>			<b>Low</b>	The very limited description of methods causes some uncertainty.
<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?			PY	There is no information on missing data but there is no indication of lacking data and full reporting on this outcome is very likely.
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?			NA	



	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	N	
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
	4.3 Were outcome assessors aware of the intervention received by study participants?	PY	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	N	
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	A very distinct outcome that cannot be misunderstood or neglected knowingly or unknowingly.
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	
	5.3 ... multiple eligible analyses of the data?	N	
	<b>Risk of bias judgement</b>	<b>Low</b>	This outcome is solid.
<b>Overall bias</b>	<b>Risk of bias judgement</b>	<b>Some concerns</b>	Limited description of methods is an overall concern though the aims and outcomes are stated fairly well and this outcome cannot be neglected.

<b>Unique ID</b>	Noriega 2014	<b>Study ID</b>		<b>Assessor</b>	
<b>Ref or Label</b>		<b>Aim</b>	assignment to intervention (the 'intention-to-treat' effect)		
<b>Experimental</b>	SC	<b>Comparator</b>	IV	<b>Source</b>	Journal article(s) with results of the trial
<b>Outcome</b>	Deaths	<b>Results</b>		<b>Weight</b>	

Domain	Signalling question	Response	Comments
<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?	N	Translations from spanish: "Randomization of treatment was performed by mixed blocks 6 sealed envelopes. Each block consisted of 3 cards with treatment 'IV' and 3 'SC'. The envelopes were opened after the patient's inclusion in the study and after obtaining informed consent."
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?	Y	
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?	N	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Bias due to deviations from intended interventions</b>	2.1. Were participants aware of their assigned intervention during the trial?	Y	
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?	Y	
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?	PN	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?	NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?	NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	Y	
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	Y	Death is not reported as an outcome. It is listed that 3 patients died. Translated from spanish: "In the end, a total of 70 did not complete the follow-up due to death in the first 72 hours (one in the SC group and 2 in the IV group)."
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	NA	

	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	N	Outcome distinct.
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	Outcome detailed for both groups.
	4.3 Were outcome assessors aware of the intervention received by study participants?	Y	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	N	
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	The data are provided in actual numbers.
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	
	5.3 ... multiple eligible analyses of the data?	N	
	<b>Risk of bias judgement</b>	<b>Low</b>	The raw data are available.
<b>Overall bias</b>	<b>Risk of bias judgement</b>	<b>Some concerns</b>	

<b>Unique ID</b>	O'Keeffe 1995	<b>Study ID</b>		<b>Assessor</b>	
<b>Ref or Label</b>		<b>Aim</b>	assignment to intervention (the 'intention-to-treat' effect)		
<b>Experimental</b>	SC	<b>Comparator</b>	IV	<b>Source</b>	Journal article(s) with results of the trial
<b>Outcome</b>	Number of Deaths	<b>Results</b>		<b>Weight</b>	
<b>Domain</b>	<b>Signalling question</b>			<b>Response</b>	<b>Comments</b>
<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?			Y	Allocation sequence generated by table of random numbers.
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?			Y	

			Block randomization. Sealed envelope.
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?	N	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias due to deviations from intended interventions</b>	2.1. Were participants aware of their assigned intervention during the trial?	Y	No description of concealment or sham.
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?	Y	
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?	PN	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?	NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?	NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	PY	
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	Y	Death is not reported as an outcome. It is only listed that 1 patient died: "...and 1 patient in the s.c. group died".
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	NA	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	Death cannot be overlooked as confirmed by reporting of this outcome.
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	N	This outcome cannot be overlooked.
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
	4.3 Were outcome assessors aware of the intervention received by study participants?	Y	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	N	

	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	
	5.3 ... multiple eligible analyses of the data?	N	
	<b>Risk of bias judgement</b>	<b>Low</b>	Crude data are reported and very few. No analysis deemed necessary.
<b>Overall bias</b>	<b>Risk of bias judgement</b>	<b>Low</b>	

<b>Unique ID</b>	Slesak 2003	<b>Study ID</b>		<b>Assessor</b>	
<b>Ref or Label</b>		<b>Aim</b>	assignment to intervention (the 'intention-to-treat' effect)		
<b>Experimental</b>	SC	<b>Comparator</b>	IV	<b>Source</b>	Journal article(s) with results of the trial
<b>Outcome</b>	Deaths	<b>Results</b>		<b>Weight</b>	
<b>Domain</b>	<b>Signalling question</b>			<b>Response</b>	<b>Comments</b>
<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?			Y	Random treatment allocation was generated by mixing blocks of six sealed envelopes. Block size unknown to staff.
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?			Y	
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?			N	
	<b>Risk of bias judgement</b>			<b>Low</b>	
<b>Bias due to deviations from intended interventions</b>	2.1. Were participants aware of their assigned intervention during the trial?			Y	Described as an open trial.
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?			Y	
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?			N	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?			NA	

	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?	NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	Y	
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	PY	Missing data for other outcomes are described in detail.  Death is not reported probably due to survival of all participants.
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	NA	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	N	
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
	4.3 Were outcome assessors aware of the intervention received by study participants?	PY	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	N	
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	
	5.3 ... multiple eligible analyses of the data?	N	
	<b>Risk of bias judgement</b>	<b>Low</b>	No deaths reported - all patients probably lived through the intervention.

<b>Overall bias</b>	<b>Risk of bias judgement</b>	<b>Low</b>	
---------------------	-------------------------------	------------	--

<b>Unique ID</b>	Esmeray 2018	<b>Study ID</b>		<b>Assessor</b>	
<b>Ref or Label</b>		<b>Aim</b>	assignment to intervention (the 'intention-to-treat' effect)		
<b>Experimental</b>	SC	<b>Comparator</b>	IV	<b>Source</b>	Journal article(s) with results of the trial
<b>Outcome</b>	Deaths	<b>Results</b>		<b>Weight</b>	

<b>Domain</b>	<b>Signalling question</b>	<b>Response</b>	<b>Comments</b>
<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?	PY	Allocation sequence generated by "Random drawing method".
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?	NI	
			No information on allocation concealment when including patients.
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?	N	
	1.4 Is a roughly equal proportion of participants allocated to each of the two groups?	Y	15 in each group.
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Bias due to deviations from intended interventions</b>	2.1. Were participants aware of their assigned intervention during the trial?	PY	No concealment described, but patients had dementia with 67% bedridden.
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?	PY	
			Assessor came from a different institution but still no concealment of intervention described.
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?	N	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?	NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?	NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	PY	

	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	PY	
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	NA	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	N	We expect death to be reported.
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
	4.3 Were outcome assessors aware of the intervention received by study participants?	PY	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	N	
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	
	5.3 ... multiple eligible analyses of the data?	N	
	<b>Risk of bias judgement</b>	<b>Low</b>	No events.
<b>Overall bias</b>	<b>Risk of bias judgement</b>	<b>Some concerns</b>	



#### 4.9 Signalling questions for the outcome: Catheter insertion time

<b>Unique ID</b>	Slesak 2003	<b>Study ID</b>		<b>Assessor</b>	
<b>Ref or Label</b>		<b>Aim</b>	assignment to intervention (the 'intention-to-treat' effect)		
<b>Experimental</b>	SC	<b>Comparator</b>	IV	<b>Source</b>	Journal article(s) with results of the trial
<b>Outcome</b>	Catheter insertions time	<b>Results</b>		<b>Weight</b>	1
<b>Domain</b>	<b>Signalling question</b>			<b>Response</b>	<b>Comments</b>
<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?			Y	Random treatment allocation was generated by mixing blocks of six sealed envelopes. Block size unknown to staff.
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?			Y	
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?			N	
	<b>Risk of bias judgement</b>			<b>Low</b>	
<b>Bias due to deviations from intended interventions</b>	2.1. Were participants aware of their assigned intervention during the trial?			Y	Described as an open trial.
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?			Y	
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?			N	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?			NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?			NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?			Y	
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?			NA	
	<b>Risk of bias judgement</b>			<b>Low</b>	
<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?			PY	Although the paper does not describe specifically how many patients data on insertion time is based on we do not suspect a

			large number of missing data.
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	NA	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	PN	There is no description in the method section on how this outcome is collected. But "The ... time needed per cannula" sounds reasonable.
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	PN	
	4.3 Were outcome assessors aware of the intervention received by study participants?	Y	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	PY	
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	PN	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	No description of statistical analysis plan or protocol is provided in the paper.
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	
	5.3 ... multiple eligible analyses of the data?	N	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Overall bias</b>	<b>Risk of bias judgement</b>	<b>Some concerns</b>	

<b>Unique ID</b>	Esmeray 2018	<b>Study ID</b>		<b>Assessor</b>	
<b>Ref or Label</b>		<b>Aim</b>	assignment to intervention (the 'intention-to-treat' effect)		
<b>Experimental</b>	SC	<b>Comparator</b>	IV	<b>Source</b>	Journal article(s) with results of the trial
<b>Outcome</b>	Catheter insertions time	<b>Results</b>		<b>Weight</b>	
<b>Domain</b>	<b>Signalling question</b>			<b>Response</b>	<b>Comments</b>
<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?			PY	Allocation sequence generated by "Random drawing method".  No information on allocation concealment when including patients.
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?			NI	
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?			N	
	1.4 Is a roughly equal proportion of participants allocated to each of the two groups?			Y	15 in each group.
	<b>Risk of bias judgement</b>			<b>Some concerns</b>	
<b>Bias due to deviations from intended interventions</b>	2.1. Were participants aware of their assigned intervention during the trial?			Y	
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?			Y	
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?			N	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?			NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?			NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?			Y	
	2.7 Was there sufficient time for any carry-over effects to have disappeared before outcome assessment in the second period?			Y	No information on time between the two groups (wash-out period), but no wash-out is needed for this outcome.
	<b>Risk of bias judgement</b>			<b>Low</b>	

<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	PY	Although the paper does not describe specifically how many patients were observed for this outcome we do not suspect a large number of missing data. Data are provided for mean time spent on insertion of catheter, but lacking for number of insertions included in the calculation.
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	NA	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	N	There is no description in the method section on how this outcome is collected. But "Time spend for catheter insertion (minute)" sounds reasonable.
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
	4.3 Were outcome assessors aware of the intervention received by study participants?	Y	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	PY	
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	PN	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	No description of statistical analysis plan or protocol is provided in the paper.
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	

	5.3 ... multiple eligible analyses of the data?	N	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Overall bias</b>	<b>Risk of bias judgement</b>	<b>Some concerns</b>	

#### 4.10 Signalling questions for the outcome: Osmolality

<b>Unique ID</b>	Challiner 1994	<b>Study ID</b>		<b>Assessor</b>	
<b>Ref or Label</b>		<b>Aim</b>	assignment to intervention (the 'intention-to-treat' effect)		
<b>Experimental</b>	SC	<b>Comparator</b>	IV	<b>Source</b>	Journal article(s) with results of the trial
<b>Outcome</b>	Osmolality / blood samples	<b>Results</b>		<b>Weight</b>	
<b>Domain</b>	<b>Signalling question</b>		<b>Response</b>		<b>Comments</b>
<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?		Y		"Random treatment allocation was generated by computer, such that within each block of eight patients there were four patients on each treatment.
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?		Y		
					These treatment allocations were transferred to sequentially numbered sealed envelopes which were opened by the junior doctor on call once he or she had decided the patient was eligible for the trial and consent had been obtained."
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?		N		
	<b>Risk of bias judgement</b>		<b>Low</b>		
<b>Bias due to deviations from intended interventions</b>	2.1. Were participants aware of their assigned intervention during the trial?		PY		No description of blinding.
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?		PY		
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?		PN		
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?		NA		
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?		NA		
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?		Y		"An analysis of covariance was performed to allow for differences in

			baselines between the two groups. No statistical difference between the osmolalities of the two treatment groups was found (P = 0.12)."
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	Y	"Not included in the analysis are two patients allocated to the subcutaneous group who dropped out of the study on Day 2: one died and one developed local oedema."
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	NA	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	N	"Venous blood samples were collected into plain 'Vacutainer' tubes for measurement of serum urea, electrolytes, glucose and osmolality, on admission, prior to starting parenteral fluids (Day 1), and on Days 2 and 3 between 9 and 10 a.m. Osmolality was measured using the Osmomat 030 (Clandon, UK)." This is described as a standard laboratory procedure.
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
	4.3 Were outcome assessors aware of the intervention received by study participants?	PY	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	N	It is unlikely that serum values can be

	4.5 If Y/PY/Ni to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	NA	influenced by knowledge of treatment assignment.
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	No statistical analysis plan or protocol is described in the paper.
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	PY	The method section the paper describes serum urea, electrolytes were also collected, but despite these also are an indication for hydration status no description or analyses of this data is reported.
	5.3 ... multiple eligible analyses of the data?	N	
	<b>Risk of bias judgement</b>	<b>High</b>	The paper states the following: "The aim of our study was to find out if subcutaneous fluids are effective in restoring hydration in elderly stroke patients when used in routine clinical practice. Serum osmolality was chosen as the biochemical marker of hydration." Despite this statement, we judge the study to have a high risk of selective reporting bias.
<b>Overall bias</b>	<b>Risk of bias judgement</b>	<b>High</b>	

<b>Unique ID</b>	Noriega 2014	<b>Study ID</b>		<b>Assessor</b>	
<b>Ref or Label</b>		<b>Aim</b>	assignment to intervention (the 'intention-to-treat' effect)		
<b>Experimental</b>	SC	<b>Comparator</b>	IV	<b>Source</b>	Journal article(s) with results of the trial
<b>Outcome</b>	Osmolality / blood samples	<b>Results</b>		<b>Weight</b>	
<b>Domain</b>	<b>Signalling question</b>		<b>Response</b>		<b>Comments</b>



<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?	PY	Translations from spanish: "Randomization of treatment was performed by mixed blocks 6 sealed envelopes. Each block consisted of 3 cards with treatment 'IV' and 3 'SC'. The envelopes were opened after the patient's inclusion in the study and after obtaining informed consent."  It might be possible to guess the allocation of the later envelopes depending on the previous allocations (page 104).
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?	PY	
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?	N	Table 1
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	Based on 1.2
<b>Bias due to deviations from intended interventions</b>	2.1. Were participants aware of their assigned intervention during the trial?	PY	No description of blinding/concealment.
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?	PY	
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?	PN	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?	NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?	NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	Y	
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	PN	Three patients died during the study. One 1 SC group and 2 in IV group. This is a sufficiently small fraction not to induce potentially relevant bias.

			It is not described how many patients had data on Osmolality / blood samples available.
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	PN	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	PN	No reason to suspect that data from patients were removed based on the value of the data.
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	N	Translation from Spanish: “The main efficacy variables of the hydration treatment were those established in previous studies as useful in hydration status monitoring: variations in urea, creatinine and serum osmolality levels in serial measurements (in our study they were obtained 24 hours prior to inclusion and after 24, 48 and 72 h the start of treatment).”
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
	4.3 Were outcome assessors aware of the intervention received by study participants?	Y	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	PN	It is unlikely that serum values can be influenced by knowledge of treatment assignment.
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	No statistical analysis plan or protocol is described in the paper.
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	
	5.3 ... multiple eligible analyses of the data?	N	

	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Overall bias</b>	<b>Risk of bias judgement</b>	<b>Some concerns</b>	

#### 4.11 Signalling questions for the outcome: Volume of fluid infused

<b>Unique ID</b>	Noriega 2014	<b>Study ID</b>		<b>Assessor</b>	
<b>Ref or Label</b>		<b>Aim</b>	assignment to intervention (the 'intention-to-treat' effect)		
<b>Experimental</b>	SC	<b>Comparator</b>	IV	<b>Source</b>	Journal article(s) with results of the trial
<b>Outcome</b>	Volume of fluid infused	<b>Results</b>		<b>Weight</b>	
<b>Domain</b>	<b>Signalling question</b>			<b>Response</b>	<b>Comments</b>
<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?			PY	Translations from spanish: "Randomization of treatment was performed by mixed blocks 6 sealed envelopes. Each block consisted of 3 cards with treatment 'IV' and 3 'SC'. The envelopes were opened after the patient's inclusion in the study and after obtaining informed consent."  It might be possible to guess the allocation of the later envelopes depending on the previous allocations (page 104).
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?			PY	
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?			N	Table 1
	<b>Risk of bias judgement</b>			<b>Some concerns</b>	Based on 1.2
<b>Bias due to deviations from intended interventions</b>	2.1. Were participants aware of their assigned intervention during the trial?			PY	
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?			PY	
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?			PN	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?			NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?			NA	

	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	Y	
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	Y	Three patients died during the study. One 1 SC group and 2 in IV group. This is a sufficiently small fraction not to introduce potentially relevant bias.
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	NA	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	N	Translation from Spanish: "Daily observations were made by researchers which stated the type of solution, the volume administered, ...."
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
	4.3 Were outcome assessors aware of the intervention received by study participants?	Y	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	PY	Fluid volume prescription and assessment may be unknowingly influenced by knowledge of the intervention.
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	PN	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	No statistical analysis plan or protocol is described in the paper.
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	
	5.3 ... multiple eligible analyses of the data?	N	

	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Overall bias</b>	<b>Risk of bias judgement</b>	<b>Some concerns</b>	

<b>Unique ID</b>	O'Keeffe 1995	<b>Study ID</b>		<b>Assessor</b>	
<b>Ref or Label</b>		<b>Aim</b>	assignment to intervention (the 'intention-to-treat' effect)		
<b>Experimental</b>	SC	<b>Comparator</b>	IV	<b>Source</b>	Journal article(s) with results of the trial
<b>Outcome</b>	Volume of fluid infused	<b>Results</b>		<b>Weight</b>	
<b>Domain</b>	<b>Signalling question</b>			<b>Response</b>	<b>Comments</b>
<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?			Y	Allocation sequence generated by table of random numbers.
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?			PY	Block randomization and sealed envelope.  It might be possible to guess the allocation of the later envelopes depending on the previous allocations.
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?			N	
	<b>Risk of bias judgement</b>			<b>Some concerns</b>	Based 1.2
<b>Bias due to deviations from intended interventions</b>	2.1. Were participants aware of their assigned intervention during the trial?			PY	No description of blinding/concealment
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?			PY	
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?			PN	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?			NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?			NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?			Y	

	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	Y	One patient in each group excluded. This is insufficient to change the result.
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	NA	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	PN	"Nursing staff noted the amount of fluid prescribed and the actual amount of fluid administered". No information on the accuracy of measuring method.
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	
	4.3 Were outcome assessors aware of the intervention received by study participants?	Y	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	PY	Fluid volume prescription and assessment may be unknowingly influenced by knowledge of the intervention.
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	PN	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	No statistical analysis plan or protocol is described in the paper.
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	
	5.3 ... multiple eligible analyses of the data?	N	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Overall bias</b>	<b>Risk of bias judgement</b>	<b>Some concerns</b>	

<b>Unique ID</b>	Slesak 2003	<b>Study ID</b>		<b>Assessor</b>	
<b>Ref or Label</b>		<b>Aim</b>	assignment to intervention (the 'intention-to-treat' effect)		
<b>Experimental</b>	SC	<b>Comparator</b>	IV	<b>Source</b>	Journal article(s) with results of the trial
<b>Outcome</b>	Volume of fluid infused	<b>Results</b>		<b>Weight</b>	
<b>Domain</b>	<b>Signalling question</b>			<b>Response</b>	<b>Comments</b>
<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?			Y	Random treatment allocation was generated by mixing blocks of six sealed envelopes. Block size unknown to staff.
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?			Y	
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?			N	
	<b>Risk of bias judgement</b>			<b>Low</b>	
<b>Bias due to deviations from intended interventions</b>	2.1. Were participants aware of their assigned intervention during the trial?			Y	Described as an open trial.
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?			Y	
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?			N	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?			NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?			NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?			Y	
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?			NA	
	<b>Risk of bias judgement</b>			<b>Low</b>	From method section: "A switch of therapies was possible if medically or ethically indicated."  From results section: "The SC infusion was switched 13 times to IV... A switch from the IV method to the SC arm was made 17 times."



			A large number of switches but all according to protocol.
<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	NI	Although the paper does not describe specifically how many patients provided data for volumen of fluid infused there is no reason to suspect missing data of a magnitude that would markedly influence the results.
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	PN	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	PN	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	PN	No description on how this outcome was assessed, but it is reported as a volume per day as is appropriate.
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	PN	
	4.3 Were outcome assessors aware of the intervention received by study participants?	Y	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	PY	Fluid volume prescription and assessment may be unknowingly influenced by knowledge of the intervention.
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	PN	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	No statistical analysis plan or protocol is described in the paper.
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	
	5.3 ... multiple eligible analyses of the data?	N	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	

Overall bias	Risk of bias judgement	Some concerns	
--------------	------------------------	---------------	--

#### 4.12 Signalling questions for the outcome: Agitation

<b>Unique ID</b>	Noriega 2014	<b>Study ID</b>		<b>Assessor</b>	
<b>Ref or Label</b>		<b>Aim</b>	assignment to intervention (the 'intention-to-treat' effect)		
<b>Experimental</b>	SC	<b>Comparator</b>	IV	<b>Source</b>	Journal article(s) with results of the trial
<b>Outcome</b>	Agitation	<b>Results</b>		<b>Weight</b>	
<b>Domain</b>	<b>Signalling question</b>			<b>Response</b>	<b>Comments</b>
<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?			PY	Translations from spanish: "Randomization of treatment was performed by mixed blocks 6 sealed envelopes. Each block consisted of 3 cards with treatment 'IV' and 3 'SC'. The envelopes were opened after the patient's inclusion in the study and after obtaining informed consent."
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?			PY	
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?			N	Table 1
	<b>Risk of bias judgement</b>			<b>Some concerns</b>	Based on 1.2
<b>Bias due to deviations from intended interventions</b>	2.1. Were participants aware of their assigned intervention during the trial?			PY	
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?			PY	
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?			PN	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?			NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?			NA	

	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	Y	Signalling question answered as data are included in the metaanalysis.
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	Y	Percentages in analysis on p.106 match the number of included
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	NA	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	N	Evaluation of clinical status, pharmacological and physical restraints. Translation from spanish: "The presence of psychomotor agitation was documented by regular monitoring of physical and / or pharmacological restraint."
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	PN	
	4.3 Were outcome assessors aware of the intervention received by study participants?	Y	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	PY	Assessors evaluation could have been influenced by a preference knowingly or unknowingly
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	PN	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	No description of a prespecified analysis plan
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	
	5.3 ... multiple eligible analyses of the data?	N	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	

Overall bias	Risk of bias judgement	Some concerns	
--------------	------------------------	---------------	--

Unique ID	O'Keeffe 1995	Study ID		Assessor	
Ref or Label		Aim	assignment to intervention (the 'intention-to-treat' effect)		
Experimental	SC	Comparator	IV	Source	Journal article(s) with results of the trial
Outcome	Agitation	Results		Weight	

Domain	Signalling question	Response	Comments
<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?	Y	Allocation sequence generated by table of random numbers.
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?	PY	Block randomization and sealed envelope.  It might be possible to guess the allocation of the later envelopes depending on the previous allocations.
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?	N	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	Based 1.2
<b>Bias due to deviations from intended interventions</b>	2.1. Were participants aware of their assigned intervention during the trial?	PY	No description of blinding. Caregivers = assessors
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?	PY	
	2.3. If Y/PY/Ni to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?	PN	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?	NA	
	2.5. If Y/PY/Ni to 2.4: Were these deviations from intended intervention balanced between groups?	NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	Y	As evaluated from table 1
	2.7 If N/PN/Ni to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	

<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	Y	p. 38, as evaluated from calculations. One patient from each group was excluded from the analysis, but this is too limited to alter the results.
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	NA	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	N	Citing from page37, first column: "Before randomization, the doctor recorded the presence of absence of agitated behaviour (using a modification of the Cohan-Mansfield Agitation Inventory) based on his own observations and on discussions with nurses or carers regarding the behaviour of the subject during the previous 48 h."  Citing from page37, second column: "Nursing staff also noted the presence of any agitation or disturbance directly related to the infusion."
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	PN	
	4.3 Were outcome assessors aware of the intervention received by study participants?	PY	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	PY	Subjective evaluation with the inherent risk in an open label trial of unknowingly favouring one intervention.
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	PN	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	No prespecified analysis plan described.

	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	
	5.3 ... multiple eligible analyses of the data?	N	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Overall bias</b>	<b>Risk of bias judgement</b>	<b>Some concerns</b>	

<b>Unique ID</b>	Esmeray 2018	<b>Study ID</b>		<b>Assessor</b>	
<b>Ref or Label</b>		<b>Aim</b>	assignment to intervention (the 'intention-to-treat' effect)		
<b>Experimental</b>	SC	<b>Comparator</b>	IV	<b>Source</b>	Journal article(s) with results of the trial
<b>Outcome</b>	Agitation	<b>Results</b>		<b>Weight</b>	
<b>Domain</b>	<b>Signalling question</b>			<b>Response</b>	<b>Comments</b>
<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?			PY	Allocation sequence generated by "Random drawing method".
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?			NI	
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?			N	No information on allocation concealment when including patients.
	1.4 Is a roughly equal proportion of participants allocated to each of the two groups?			Y	15 in each group.
	<b>Risk of bias judgement</b>			<b>Some concerns</b>	
<b>Bias due to deviations from intended interventions</b>	2.1. Were participants aware of their assigned intervention during the trial?			Y	No description of blinding but 67% were demented and bedridden
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?			Y	
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?			N	
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?			NA	
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?			NA	
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?			Y	

	2.7 Was there sufficient time for any carry-over effects to have disappeared before outcome assessment in the second period?	NI	No information on the time between the two groups (wash-out period).
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	PY	No reason to suspect missing of a marked number of data
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	NA	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	N	"Administration monitoring form had several section. One section collected data on edema, redness, bleeding and agitation that could develop during or after infusion practices." No further definition of agitation is provided, but assessors were trained staff with recordings on the monitoring form.
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	PN	
	4.3 Were outcome assessors aware of the intervention received by study participants?	Y	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	PY	Knowingly or unknowingly preference for either method could influence evaluation.
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	PN	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	NI	The paper proves no description of protocol or analysis plan.
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	
	5.3 ... multiple eligible analyses of the data?	N	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	




Overall bias	Risk of bias judgement	Some concerns	
--------------	------------------------	---------------	--

**Supplementary Table S2. Risk of bias of cross-sectional studies for the outcome of adverse effects**

Study (Overall risk of bias)	Appropriate eligibility criteria and recruitment of patients	Lost to follow up	Outcome measure <sup>a</sup>
<b>Prospective studies</b>			
Fainsinger 1994 ( <i>High risk of bias</i> )	<i>Inadequate</i>	<i>Adequate</i>	<i>Inadequate</i>
Worobec 1997 ( <i>High risk of bias</i> )	<i>Adequate</i>	<i>Unclear</i>	<i>Inadequate</i>
Centeno 1999 ( <i>High risk of bias</i> )	<i>Adequate</i>	<i>Unclear</i>	<i>Inadequate</i>
Torsheim 1999 ( <i>Low risk of bias</i> )	<i>Adequate</i>	<i>Adequate</i>	<i>Adequate</i>
Dasgupta 2000 ( <i>Low risk of bias</i> )	<i>Adequate</i>	<i>Adequate</i>	<i>Adequate</i>
Arinzon 2004 ( <i>Low risk of bias</i> )	<i>Adequate</i>	<i>Adequate</i>	<i>Adequate</i>
Lamandé 2004 ( <i>Low risk of bias</i> )	<i>Adequate</i>	<i>Adequate</i>	<i>Unclear</i>
Martinez-Riquelme 2005 ( <i>High risk of bias</i> )	<i>Unclear</i>	<i>Unclear</i>	<i>Inadequate</i>
Stastna 2009 ( <i>High risk of bias</i> )	<i>Adequate</i>	<i>Adequate</i>	<i>Inadequate</i>
Bigot 2013 ( <i>High risk of bias</i> )	<i>Unclear</i>	<i>Unclear</i>	<i>Inadequate</i>
Justino 2013 ( <i>High risk of bias</i> )	<i>Adequate</i>	<i>Adequate</i>	<i>Inadequate</i>
Vidal 2016 ( <i>High risk of bias</i> )	<i>Adequate</i>	<i>Inadequate</i>	<i>Unclear</i>
<b>Retrospective studies<sup>b</sup></b>			
Schen 1981 Schen 1982 Schen 1983 ( <i>High risk of bias</i> )	<i>Unclear</i>	<i>Adequate</i>	<i>Inadequate</i>
Bruera 1990 ( <i>High risk of bias</i> )	<i>Adequate</i>	<i>Adequate</i>	<i>Inadequate</i>
Bruera 1996 ( <i>High risk of bias</i> )	<i>Adequate</i>	<i>Adequate</i>	<i>Inadequate</i>
Hussain 1996 ( <i>High risk of bias</i> )	<i>Adequate</i>	<i>Adequate</i>	<i>Inadequate</i>
Yap 2001 ( <i>High risk of bias</i> )	<i>Adequate</i>	<i>Adequate</i>	<i>Inadequate</i>
Chalany 2015 ( <i>High risk of bias</i> )	<i>Unclear</i>	<i>Adequate</i>	<i>Adequate</i>
<sup>a</sup> Further information on adverse effects description of included studies can be found in Supplementary Text S3. Extracted study characteristics.			
<sup>b</sup> Retrospective studies are judged to have a higher baseline risk of bias by design.			

## Supplementary Figure S1. Subgroup meta-analysis by setting of study on number adverse effects comparing subcutaneous vs intravenous hydration

Meta-analysis pooling of Risk Ratios using the random-effects inverse-variance model with DerSimonian-Laird estimate of tau<sup>2</sup>.



Tests of effect size = 1:


No data on setting	z = -2.344	p = 0.019
Hospital	z = -2.950	p = 0.003
Short, -longterm facility	z = -5.504	p > 0.00001
Overall	z = -6.417	p > 0.00001

Mantel-Haenszel Q statistics for heterogeneity

	Value	df	p-value
No data on setting	0.00	0	.
Hospital	1.02	3	0.795
Short, -longterm facility	0.00	0	.
Overall	4.36	5	0.499
Between	3.33	2	0.189
Between:Within (F)	4.88	2, 3	0.114

## Supplementary Figure S2. Subgroup meta-analysis by use of hyaluronidase on number adverse effects comparing subcutaneous vs intravenous hydration

Meta-analysis pooling of Risk Ratios using the random-effects inverse-variance model with DerSimonian-Laird estimate of tau<sup>2</sup>.



Tests of effect size = 1:


No data on the use of hyaluronidase	z = -1.858	p = 0.063
No use of hyaluronidase	z = -2.245	p = 0.025
Hyaluronidase when deemed necessary	z = -2.084	p = 0.037
Overall	z = -6.417	p > 0.00001

Mantel-Haenszel Q statistics for heterogeneity

	Value	df	p-value
No data on the use of hyaluronidase	2.67	1	0.102
No use of hyaluronidase	0.33	1	0.567
Hyaluronidase when deemed necessary	0.02	1	0.886
Overall	4.36	5	0.499
Between	1.34	2	0.511
Between:Within (F)	0.67	2, 3	0.576

**Supplementary Figure S3. Meta-analysis on serious adverse effects comparing subcutaneous vs intravenous hydration**

Meta-analysis pooling of Risk Ratios using the random-effects inverse-variance model with DerSimonian-Laird estimate of tau<sup>2</sup>. All studies in this analysis have Some Concern of bias.




Both-armed zero-event (BA0E) excluded due to the choice of DerSimonian-Laird random effects model.

Test of overall effect = 1: z = -1.525 p = 0.127

Heterogeneity Measures

		Value	df	p-value
Mantel-Haenszel Q		0.00	2	1.000
I <sup>2</sup> (%)		0.0%		
Modified H <sup>2</sup>		0.000		
tau <sup>2</sup>		0.0000		


**Supplementary Figure S4. Meta-analysis on all the different types of adverse effects comparing subcutaneous vs intravenous hydration**



<sup>a</sup> Continuity correction of 0.50 applied to studies with zero cells.  
n/N: Number of adverse effects / Number of infusions, CI: Confidence Interval, SC: Subcutaneous, IV: Intravenous.

Supplementary Figure S5. Meta-analysis on reduction of serum osmolality comparing subcutaneous vs intravenous hydration

Meta-analysis pooling of Mean Differences using the random-effects inverse-variance model with DerSimonian-Laird estimate of tau<sup>2</sup>.



Tests of effect size = 0:


Some concern            z = 1.265   p = 0.206  
High risk of bias        z = 1.563   p = 0.118  
Overall                    z = 2.005   p = 0.045

Cochran Q statistics for heterogeneity

	Value	df	p-value
Some concern	0.00	0	.
High risk of bias	0.00	0	.
Overall	0.02	1	0.876
Between	0.02	1	0.876
Between:Within (F)	.	1, 0	.

## Supplementary Figure S6. Meta-analysis on death comparing subcutaneous vs intravenous hydration

Meta-analysis pooling of Risk Ratios using the random-effects inverse-variance model with DerSimonian-Laird estimate of tau<sup>2</sup>.



Both-armed zero-event (BA0E) excluded due to choice of DerSimonian-Laird for estimating tau-squared. Continuity correction of 0.50 applied to studies with zero cells.

Tests of effect size = 1:

Low risk of bias	z = 0.929	p = 0.353
Some concern	z = -0.577	p = 0.564
Overall	z = 0.279	p = 0.780


Mantel-Haenszel Q statistics for heterogeneity

	Value	df	p-value
Low risk of bias	0.00	1	0.992
Some concern	0.00	0	.
Overall	1.12	2	0.571
Between	1.12	1	0.290
Between:Within (F)	11611.40	1, 1	0.006



**Supplementary Figure S7. Meta-analysis on volume of fluid infused comparing subcutaneous vs intravenous hydration**

Meta-analysis pooling of Standardised Mean Differences by the method of Cohen using the random-effects inverse-variance model with DerSimonian-Laird estimate of tau<sup>2</sup>.  
All studies in this analysis have Some Concern of bias.




Test of overall effect = 0: z = 3.163 p = 0.002

Heterogeneity Measures

	Value	df	p-value
Cochran's Q	3.99	2	0.136
I <sup>2</sup> (%)	49.8%		
Modified H <sup>2</sup>	0.993		
tau <sup>2</sup>	0.0582		

**Supplementary Figure S8. Meta-analysis on agitation comparing subcutaneous vs intravenous hydration**

Meta-analysis pooling of Risk Ratios using the random-effects inverse-variance model with DerSimonian-Laird estimate of tau<sup>2</sup>. All studies in this analysis have Some Concern of bias.




Test of overall effect = 1: z = -2.689 p = 0.007

Heterogeneity Measures

	Value	df	p-value
Mantel-Haenszel Q	6.03	2	0.049
I <sup>2</sup> (%)	64.7%		
Modified H <sup>2</sup>	1.831		
tau <sup>2</sup>	0.1996		

**Supplementary Figure S9. Meta-analyses on time spend on catheter insertion comparing subcutaneous vs intravenous hydration**

Meta-analysis pooling of Mean Differences using the random-effects inverse-variance model with DerSimonian-Laird estimate of tau<sup>2</sup>. All studies in this analysis have Some Concern of bias.




Test of overall effect = 0: z = -3.678 p = 0.00012

Heterogeneity Measures

	Value	df	p-value
Cochran's Q	2.58	1	0.108
I <sup>2</sup> (%)	61.2%		
Modified H <sup>2</sup>	1.577		
tau <sup>2</sup>	1.0024		

**Supplementary Figure S10. Funnel plot for adverse effects from 6 RCTs of subcutaneous vs intravenous hydration**



### Supplementary Table S3. GRADE Evidence profile: subcutaneous hydration

Quality assessment						Summary of findings					
						Adverse effects / number of infusions		Risk Ratio (95% CI)	Absolute risk per 1000 infusions		Quality
						SC	IV		Incidence of adverse effects with SC hydration	Incidence of adverse effects with SC hydration	
No of studies (design)	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias						
Risk of adverse effects											
Lowest risk of bias subgroup (4 RCTs)	Serious limitations <sup>a</sup>	No inconsistency	No serious indirectness	Serious imprecision <sup>b</sup>	Undetected	82/548	119/545	RR 0.69 (0.53: 0.88)	90 <sup>c</sup>	130 with IV (95% CI 102-169) <sup>d</sup>	⊕⊕⊕○ Moderate
						n (SC)	n (IV)	Effect measure (95% CI)	Absolute effect		
Effect of treating the problem (dehydration), inferred from the surrogate outcome “Effect on serum osmolality” (2 RCTs)	Serious limitations <sup>e</sup>	No serious inconsistency	Very serious indirectness	Serious imprecision	Undetected	51	50	MD 5.75 (0.13: 11.37)	IV hydration will lower serum osmolality by 5.75 mmol/kg (95% CI 0.13 more to 11.4 more) compared with SC hydration.		⊕○○○ Very low
Effect of hydration treatment, “Death” (3 RCTs)	No serious limitations	No serious inconsistency	No indirectness	Very serious imprecision	Undetected	3/84	2/82	RR 1.3 (0.25: 6.34)	Unable to calculate meaningful absolute values due to a very large confidence interval.		⊕○○○ Very low
Effect of the hydration treatment, inferred from the surrogate outcome “Volume of fluid infused” (3 RCTs)	Serious limitations <sup>a</sup>	No serious inconsistency	Very serious indirectness	No serious imprecision	Undetected	110	111	SMD: 0.62 (0.24: 1.01) <sup>f</sup>	IV hydration will infuse 155 ml more fluid per day (95% CI 60 ml more to 253 ml more) compared to SC hydration when infusing 1000 ml/day. <sup>g</sup>		⊕○○○ Very low
Effect of the hydration treatment, inferred from the surrogate outcome “Agitation” (3 RCTs) <sup>h</sup>	Serious limitations <sup>a</sup>	No serious inconsistency	Serious indirectness	No serious imprecision	Undetected	26/93	63/93	RR 0.42 (0.22: 0.79)	68% of patients with some cognitive impairment treated with IV hydration experience agitation vs 28% treated with SC hydration (95% CI 15-54).		⊕⊕○○ Low
Time spent on catheter insertion (2 RCTs)	Serious limitations <sup>a</sup>	Serious inconsistency	No serious indirectness	No serious imprecision	Undetected	138	138	MD 3.2 (1.48: 4.87)	Setting up SC hydration takes 3.2 fewer minutes (1.5 to 4.9 less) than setting up IV hydration.		⊕○○○ Very low

RCT: Randomized controlled trial, SC: Subcutaneous, IV: Intravenous, CI: Confidence interval, RR: risk ratio, MD: Mean difference, SDM, Standardized Mean Difference.

<sup>a</sup> All studies at Some Concern of bias.

<sup>b</sup> Optimal information size not reached (740 infusions needed in both groups).

<sup>c</sup> Based on incidence of adverse effects from SC hydration from the studies with the lowest risk of bias (4 RCTs and 4 observational studies.)

<sup>d</sup> Calculated by multiplying the incidence with SC hydration with the inverse risk ratio from the meta-analysis.

<sup>e</sup> One study with some concern and one with high risk of bias.

<sup>f</sup> We have use standard mean difference (SMD) as included studies reported either volume per day or volume overall.

<sup>g</sup> Based on numbers from Slesak 2003<sup>29</sup> with 1000 ml ± 250 being infused per day in IV group.

<sup>h</sup> All studies included mostly patients with cognitive impairment or dementia.

## Reference

1. El-Sharkawy AM, Watson P, Neal KR, et al. Hydration and outcome in older patients admitted to hospital (The HOOP prospective cohort study). *Age Ageing*. 2015;44(6):943-947.  
doi:10.1093/ageing/afv119
2. Thomas DR, Cote TR, Lawhorne L, et al. Understanding Clinical Dehydration and Its Treatment. *J Am Med Dir Assoc*. 2008;9(5):292-301. doi:10.1016/j.jamda.2008.03.006
3. Lipschitz S, Campbell AJ, Roberts MS, et al. Subcutaneous fluid administration in elderly subjects: validation of an under-used technique. *J Am Geriatr Soc*. 1991;39(1):6-9.
4. Turner T, Cassano A-M. Subcutaneous dextrose for rehydration of elderly patients--an evidence-based review. *BMC Geriatr*. 2004;4:2. doi:10.1186/1471-2318-4-2
5. Remington R, Hultman T. Hypodermoclysis to treat dehydration: A review of the evidence. *J Am Geriatr Soc*. 2007;55(12):2051-2055. doi:10.1111/j.1532-5415.2007.01437.x
6. Caccialanza R, Constans T, Cotogni P, Zaloga GP, Pontes-Arruda A. Subcutaneous Infusion of Fluids for Hydration or Nutrition: A Review. *J Parenter Enter Nutr*. 2018;42(2):296-307.  
doi:10.1177/0148607116676593
7. Lowe E, Gillon S. ARE SUBCUTANEOUS FLUIDS UNDERUSED IN THE HOSPICE SETTING? *BMJ Support Palliat Care*. 2014;4(Suppl 1):A101.3-A102. doi:10.1136/bmjspcare-2014-000654.292
8. Yurkofsky M, Ouslander JG. Medical care in skilled nursing facilities (SNFs) in the United States. <https://www.uptodate.com>. Published 2019. Accessed May 9, 2019.
9. Barua P, Bhowmick BK. Hypodermoclysis - A victim of historical prejudice. *Age Ageing*. 2005;34(3):215-217. doi:10.1093/ageing/afi077
10. Zorzela L, Loke YK, Ioannidis JP, et al. PRISMA harms checklist: Improving harms reporting in systematic reviews. *BMJ*. 2016;352:i157. doi:10.1136/bmj.i157
11. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction—GRADE evidence

profiles and summary of findings tables. *J Clin Epidemiol*. 2011;64(4):383-394.

doi:10.1016/J.JCLINEPI.2010.04.026

12. Higgins J, Green S, (editors), eds. *Cochrane Handbook for Systematic Reviews of Interventions*. Version 5. The Cochrane Collaboration, 2011. Available from [www.handbook.cochrane.org](http://www.handbook.cochrane.org).
13. Google Translate. <https://translate.google.com/>.
14. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. *Lancet (London, England)*. 2000;356(9237):1255-1259. doi:10.1016/S0140-6736(00)02799-9
15. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;366:l4898. doi:10.1136/bmj.l4898
16. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). *J Clin Epidemiol*. 2011;64(4):407-415.  
doi:10.1016/J.JCLINEPI.2010.07.017
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7(3):177-188.  
doi:10.1016/0197-2456(86)90046-2
18. Fisher D. ADMETAN: Stata module to provide comprehensive meta-analysis. 2018;(S458561).  
doi:DOI:
19. Guyatt GH, Oxman AD, Santesso N, et al. GRADE guidelines: 12. Preparing Summary of Findings tables—binary outcomes. *J Clin Epidemiol*. 2013;66(2):158-172.  
doi:10.1016/J.JCLINEPI.2012.01.012
20. El-Sharkawy AM, Sahota O, Maughan RJ, Lobo DN. The pathophysiology of fluid and electrolyte balance in the older adult surgical patient. *Clin Nutr*. 2014;33(1):6-13.  
doi:10.1016/j.clnu.2013.11.010
21. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred Reporting Items for

Systematic Reviews and Meta-Analyses: The PRISMA Statement. *Ann Intern Med*.

2009;151(4):264. doi:10.7326/0003-4819-151-4-200908180-00135

22. NCT03710408. Adverse Effects of Subcutaneous vs Intravenous Hydration on Older Acutely Admitted Patients: an Assessor-blinded, Non-inferiority RCT.

<https://clinicaltrials.gov/show/nct03710408>. doi:10.1002/CENTRAL/CN-01664216

23. TCTR20140506002. Satisfaction in Hypodermoclysis and Intravenous Hydration in Palliative Care Patients. <http://apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20140506002>. doi:10.1002/CENTRAL/CN-01825225

24. Challiner YC, Jarrett D, Hayward MJ, Al-Jubouri MA, Julious SA. A comparison of intravenous and subcutaneous hydration in elderly acute stroke patients. *Postgrad Med J*. 1994;70(821):195-197. doi:10.1136/pgmj.70.821.195

25. Delamaire D, Meigne B, Lecoq A, Cattenoz C, Michel M, Michel O. Un essai contrôlé d'hydratation en faveur d'une actualisation de l'hypodermoclyse chez le sujet âgé. *La Rev Médecine Interne*. 1992;13(7):S321. doi:10.1016/S0248-8663%2805%2980908-7

26. Esmeray G, Şenturan L, Döventaş A. A Study on Efficacy of Hydration Administered by Subcutaneous Infusion in Geriatric Patients. *Turkish J Geriatr Geriatr Derg*. 2018;21(3):438-445. doi:10.31086/tjgeri.2018344059

27. Luk J, Chan F, Chu L. Is hypodermoclysis suitable for frail Chinese elderly. *Asian J Gerontol Geriatr*. 2008;3(1):49-50.

28. O'Keeffe ST, Lavan JN. Subcutaneous fluids in elderly hospital patients with cognitive impairment. *Gerontology*. 1996;42(1):36-39.  
<http://www.ncbi.nlm.nih.gov/pubmed/8641599>. Accessed April 26, 2016.

29. Slesak G, Schnürle JW, Kinzel E, Jakob J, Dietz K. Comparison of subcutaneous and intravenous rehydration in geriatric patients: A randomized trial. *J Am Geriatr Soc*.



2003;51(2):155-160. doi:10.1046/j.1532-5415.2003.51052.x

30. Noriega OD, Blasco SA. Eficacia de la vía subcutánea frente a la hidratación intravenosa en el paciente anciano hospitalizado: estudio controlado aleatorizado. *Rev Esp Geriatr Gerontol*. 2014;49(3):103-107. doi:10.1016/j.regg.2013.12.003
31. Dasgupta M, Binns MA, Rochon PA. Subcutaneous fluid infusion in a long-term care setting. *J Am Geriatr Soc*. 2000;48(7):795-799.
32. Bigot A, Boccanfuso L, Rouch L, Lebaudy C, Gérard S, Cestac P. Investigation into the usage of hypodermoclysis in the geriatric units. *Int J Clin Pharm*. 2013;35(6):1298.
33. Arinzon Z, Feldman J, Fidelman Z, Gepstein R, Berner YN. Hypodermoclysis (subcutaneous infusion) effective mode of treatment of dehydration in long-term care patients. *Arch Gerontol Geriatr*. 2004;38(2):167-173. doi:10.1016/j.archger.2003.09.003
34. Centeno C, Bruera E. Subcutaneous hydration with no hyaluronidase in patients with advanced cancer. *J Pain Symptom Manag*. 1999;17(5):305-306.
35. Fainsinger RL, MacEachern T, Miller MJ, et al. The use of hypodermoclysis for rehydration in terminally ill cancer patients. *J Pain Symptom Manage*. 1994;9(5):298-302.
36. Justino ET, Tuoto FS, Kalinke LP, Mantovani M de F. HYPODERMOCLYSIS IN ONCOLOGY PATIENTS RECEIVING PALLIATIVE CARE. *Cogitare Enferm*. 2013;18(1):84-89.
37. Lamande M, Dardaine-Giraud V, Ripault H, Chavanne D, Constans T. Utilisation de l'hypodermoclyse en gériatrie : Étude prospective sur 6 mois. *L'Année gériatologique*. 2004;18(1):121-130.
38. Martínez-Riquelme A, Rawlings J, Morley S, Kendall J, Hosking D, Allison S. Self-administered subcutaneous fluid infusion at home in the management of fluid depletion and hypomagnesaemia in gastro-intestinal disease. *Clin Nutr*. 2005;24(1):158-163.  
doi:10.1016/J.CLNU.2004.09.016

39. Torsheim AK, Falkmer U, Kaasa S. [Hydration of patients with advanced cancer--is subcutaneous infusion a good solution?]. *Tidsskr den Nor lægeforening*. 1999;119(19):2815-2817.
40. Vidal M, Hui D, Williams J, Bruera E. A Prospective Study of Hypodermoclysis Performed by Caregivers in the Home Setting. *J Pain Symptom Manage*. 2016;52(4):570-574.e9.  
doi:10.1016/j.jpainsymman.2016.04.009
41. Worobec G, Brown MK. Hypodermoclysis therapy. In a chronic care hospital setting. *J Gerontol Nurs*. 1997;23(6):23-28.
42. ŠŤASTNÁ V, SOUKUPOVÁ K, KUČEROVÁ H. NAŠE ZKUŠENOSTI SE SUBKUTÁNNÍ REHYDRATACÍ. *Ces Geriatr Rev*. 2009;7(1):46-48.
43. Bruera E, Belzile M, Watanabe S, Fainsinger RL. Volume of hydration in terminal cancer patients. *Support Care Cancer*. 1996;4(2):147-150.
44. Bruera E, Legris MA, Kuehn N, Miller MJ. Hypodermoclysis for the administration of fluids and narcotic analgesics in patients with advanced cancer. *J Pain Symptom Manag*. 1990;5(4):218-220.
45. Chalany J. [Subcutaneous rehydration in patients in terminal phase of dementia]. *Casopis lékařů českých*. 2015;154(1):14-18.
46. Hussain NA, Warshaw G. Utility of clysis for hydration in nursing home residents. *J Am Geriatr Soc*. 1996;44(8):969-973.
47. Schen RJ, Singer-Edelstein M. Subcutaneous infusions in the elderly. *J Am Geriatr Soc*. 1981;29(12):583-585. doi:10.1111/j.1532-5415.1981.tb01265.x
48. Schen RJ, Singer-Edelstein M. Hypodermoclysis. *Jama*. 1983;250(13):1694-1694.  
doi:10.1001/jama.1983.03340130024016
49. Yap LK, Tan SH, Koo WH. Hypodermoclysis or subcutaneous infusion revisited. *Singapore*

*Med J*. 2001;42(11):526-529.

50. Schen RJ, Ariely S. Administration of potassium by subcutaneous infusion in elderly patient. *Br Med J*. 1982;285(6349):1167-1168. doi:10.1136/bmj.285.6349.1167
51. Mongardon N, Le Manach Y, Tresallet C, Lescot T, Langeron O. Subcutaneous hydration: a potentially hazardous route. *Eur J Anaesthesiol*. 2008;25(9):771-772.  
doi:10.1017/S0265021508004158 [doi]
52. Kackielo H, Carney M. Hypodermoclysis associated with rhabdomyolysis leading to acute renal failure and death. *J Am Geriatr Soc*. 2000;48(8):S129-S129.
53. Sato K, Karino M, Nishi T, et al. Three elderly patient cases maintained by home hypodermoclysis--a practical hydrating method performed by family members. *Gan To Kagaku Ryoho*. 2008;35:85-87.
54. Lemeray J, Kluger N, Girard C. Adverse effect of hypodermoclysis: an unusual clinical presentation. *Ann Dermatol Venereol*. 2012;139(1):77-78. doi:10.1016/j.annder.2011.06.001 [doi]
55. Delamaire D, Meigne B, Lecoq A, Cattenoz C, Michel M, Michel O. A rehydration randomized trial favoring the subcutaneous route in the elderly. *Rev Med interne*. 1992;13(7):S321.  
doi:10.1016/S0248-8663(05)80908-7
56. Lima Ribeiro SM, Morley JE. Dehydration is Difficult to Detect and Prevent in Nursing Homes. *J Am Med Dir Assoc*. 2015;16(3):175-176. doi:10.1016/j.jamda.2014.12.012
57. Dychter SS, Gold DA, Carson D, Haller M. Intravenous therapy: a review of complications and economic considerations of peripheral access. *J Infus Nurs*. 2012;35(2):84-91.  
doi:10.1097/NAN.0b013e31824237ce
58. Gumińska I, Lisiak W, Gembicki M. Rate of distribution of Na<sup>131</sup>I and of <sup>131</sup>I labelled albumin injected subcutaneously. *Pol Med J*. 1967;6(2):303-310.

59. Witlox J, Eurelings LSM, de Jonghe JFM, Kalisvaart KJ, Eikelenboom P, van Gool WA. Delirium in Elderly Patients and the Risk of Postdischarge Mortality, Institutionalization, and Dementia. *JAMA*. 2010;304(4):443-451. doi:10.1001/jama.2010.1013